Regulation of extrafollicular immunoglobulin class switch recombination by George, Laura
i 
 
 
 
 
Regulation of Extrafollicular Immunoglobulin 
Class Switch Recombination 
Laura George 
 
 
 
 
 
 
A thesis submitted to 
 
The University of Birmingham 
for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
School of Immunity and Infection 
College of Medicine and Dental Science 
University of Birmingham 
September 2013 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
ii  
 
 
 
 
DEDICATION 
 
 
 
 
 
 
 
For my father 
iii  
 
 
ACKNOWLEDGMENTS 
 
 
 
Thanks to my excellent supervisor Dr Kai-Michael Toellner for his advice and guidance 
during this project. I would also like to thank him for allowing me the opportunity to work on 
this project and for all his support over the last few years. 
 
 
I would like to acknowledge Dr Yang Zhang for her help and practical tips in the lab. 
Mahmood Khan for his help with the immunohistochemistry. Dr Saeeda Bobat and Sarah 
Cook for proof reading the drafts. Dr Jennifer Marshall for the groundwork for the project. 
Members of the Cunningham group: Jessica Hitchcock, Dr Adrianna Flores-Garcia and 
Charlie Cook (now part of the Toellner group) who have helped me one way or another over 
the course of my PhD. All the members of BMSU and members of the IBR 4
th 
floor who have 
made the last few years an enjoyable experience. 
 
 
Thanks to Dr Kyoko Nakamura who produced the miR-125b overexpressing mice and helped 
with much of the experimental work and Professor Peter Lane for his suggestions for this 
aspect of the project. 
 
 
Lastly thanks to my family for their support and love, specifically my mum and brothers. 
Finally thanks to Richard. 
iv  
 
 
 
ABSTRACT 
 
 
 
The humoral immune response is characterised by the production of antibody secreting B 
cells. Some of these cells have cycled through the germinal centre, diversifying and 
optimising their antigen receptors to produce affinity-matured, class switched antibody. As 
this is a relatively slow process, the first class switched antibody is produced by non-mutated 
B blasts that have differentiated independently of the germinal centre reaction outside B-cell 
follicles. Extrafollicular foci of plasmablasts provide the first line of defence within the 
adaptive antibody response. 
 
 
IRF4 has been shown to be essential for Ig class switching and plasma-cell differentiation. 
Two expression levels of IRF4 were reported, with intermediate levels proposed to regulate 
CSR in the GC, while high levels regulate plasma-cell differentiation. We have correlated the 
two phases of IRF4 induction with specific stages of B-cell differentiation. Following 
immunisation of quasi-monoclonal mice with NP-Ficoll, intermediate levels of IRF4 protein 
are expressed by all B blasts as they move to the outer T zone and before the formation of 
germinal centres or plasma cells. This is followed by expression of AID and CSR. In contrast, 
plasma-cell differentiation occurs with high level expression of IRF4, expression of Blimp1 
and complete suppression of AID and CSR. The NFκB family signalling molecules C-REL 
and NFκB1 have been shown to be required for the induction of IRF4 protein in B cells 
following stimulation. We show that these signalling molecules are not necessary to induce 
the early rapid intermediate level expression of IRF4, and extrafollicular expression of AID 
and CSR occur normally when they are absent. IRF4-high expression and plasma-cell 
differentiation, however, are blocked in the absence of these molecules. 
v  
Using overexpression of the micro-RNA miR-125b we show that all phases of IRF4 protein 
expression can be blocked. This leads to inhibition of AID protein induction and CSR , 
indicating that extrafollicular intermediate level IRF4 expression is related to AID expression 
and CSR. Further, we show that AID in the GC is expressed normally when IRF4 is 
repressed, leading to normal affinity maturation This shows that AID expression is regulated 
differently in extrafollicular B blasts and in the germinal centre. 
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1.INTRODUCTION 
 
 
 
1.1 Overview 
 
The adaptive immune response consists of cellular and humoral immunity. Whilst cellular 
immunity is provided by T cells, humoral immunity is provided by antibody producing B 
cells. Antibody elicits its protective function mainly in two ways. The first of these is via 
opsonisation, antibody coated pathogens are recognised and destroyed by phagocytes such as 
macrophages and neutrophils. The second method is via neutralisation, antibody binding to 
specific epitopes on a pathogen blocks the interactions required for bacteria or virus to enter 
host cells. In addition, antibody is protective via the process of antibody dependent cell- 
mediated cytotoxicity (ADCC). Infected cells express viral proteins on their surface that are 
bound by antibody. Natural killer cells recognise antibody bound to infected cells via their Fc 
receptors and destroy the infected cell. This section will briefly, without references, introduce 
the project in the context of the immune response. 
Antibody affinity increases over the course of an immune response, however this process is 
relatively slow. Affinity matured antibodies are produced by B cells that have differentiated 
via the germinal centre (GC) pathway. The GC is a specialised structure within the B-cell 
follicle where B cells mutate their immunoglobulin genes. Classically, these structures can 
start to form within four days of antigen exposure. In contrast, during the first days after 
infection, protection is provided by the rapid extrafollicular response. This occurs 
independently of the GC reaction and does not produce affinity matured B cells, however 
some of these antibody-producing cells do undergo class switch recombination (CSR). In the 
latter process, B cells change their heavy chain gene, but do not alter the affinity of their B- 
cell receptor (membrane bound Immunoglobulin (Ig)). This produces an antibody with a 
different heavy chain, but unaltered specificity. The antibody class induced is dependent upon 
the type of pathogen or antigen, and the route of delivery.  This thesis is primarily concerned 
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with the extrafollicular B-cell response and the role of IRF4 for CSR. IRF4 is a transcription 
factor that is differentially expressed during B-cell activation and differentiation. By altering 
the two phases of IRF4 induction, this thesis aimed to test its role in the process of CSR. 
1.2 Overview of the murine spleen 
 
The B-cell responses detailed in this thesis are primarily studied in the spleen, this is a highly 
vascularised organ which lacks afferent lymphatic vessels. The main functions of the spleen 
are blood filtration, haematopoiesis and defence against blood-borne pathogens. It should be 
noted that splenic haematopoiesis is a process that occurs in rodents (Cesta, 2006) but not 
humans. 
Together the spleen, lymph nodes and gut associated lymphoid tissue (GALT) comprise 
the peripheral lymphoid organs. Here, mature naive lymphocytes re--‐circulate and are 
able to encounter antigen that has entered the spleen via the blood, or the lymph nodes 
via the lymphatics. The spleen is comprised of white pulp and red pulp areas, the latter 
making up the bulk of the organ (Fig 1.1). One function of the spleen is to remove 
senescent red blood cells; this is performed by macrophages within the red pulp. The 
white pulp is comprised of the periarteriolar lymphoid sheath (PALS) surrounding the 
central arterioles. The latter is the site where antigen and lymphocytes enter the white 
pulp. The PALS is comprised of T--‐cell areas and B-‐‐cell follicles. The B-‐‐cell follicle is 
surrounded by the marginal zone which contains macrophages and non-‐‐recirculating 
marginal zone B cells (Martin and Kearney, 2001; Muppidi et al., 2011). 
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Figure 1 1 The structure of the spleen (A) Blood enters via the afferent splenic artery which 
branches into a network of central arterioles. These central arterioles end in cords in the red 
pulp which feed into venous sinuses. These then feed into the efferent splenic vein.   (B) 
The structure of the white pulp in the mouse. The central arteriole is surrounded by the white 
pulp known as the PALS. This consists of a central T-cell area with an adjacent B-cell 
follicle. The PALS is then surrounded by the marginal zone containing marginal zone B cells 
and macrophages (Mebius and Kraal, 2005). 
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The Red Pulp 
 
The red pulp is perfused by a rich blood supply. Blood enters the spleen via the afferent 
splenic artery and branches into central arterioles that terminate in cords in the red pulp. The 
cords are composed of reticular fibres, reticular cells and macrophages (Cesta, 2006; Mebius 
and Kraal, 2005). The structure of the cords traps ageing erythrocytes between endothelial 
cells which facilitates easier phagocytosis by red pulp macrophages. This is important for 
iron recycling, a process that will not be discussed here. Red pulp macrophages also perform 
a second important function by performing phagocytosis of blood borne particulate matter. 
The second role of the spleen is also carried out in the red pulp, as it is here that 
haematopoiesis occurs. This is the developmental site of erythroid, myeloid and 
megakaryocytic cells and also will not be discussed further (Cesta, 2006). 
Most importantly in the context of this thesis, the red pulp is the site in which plasmablasts 
and plasma cells produce antibody, following antigen-specific differentiation in the follicles. 
From this location in the red pulp, antibody can enter the blood stream rapidly. Migration of 
plasmablasts to the red pulp is dependent upon the network of chemokines expressed and may 
be mediated by upregulation of CXCR4 and downregulation of CXCR5 and CCR7. CXCR4 
binds CXCL12 expressed in the red pulp, whereas CXCR5 and CCR7 bind chemokines in the 
follicular and T-cell areas of the white pulp respectively (Hargreaves et al., 2001). 
The White Pulp 
 
In contrast to the red pulp, the white pulp is the site where B cells are initially activated and T 
cells are primed on dendritic cells. Activated B cells can then interact with these primed T 
cells. This area is also the site of B-cell receptor hypermutation that occurs within GC. The 
white pulp can be further divided into the B-cell follicles− these are surrounded by the 
marginal zone− and the T-cell area. These separate areas are described in the following 
sections. 
5  
B-cell follicles 
 
Naïve recirculating B cells are attracted to the follicles via the gradient of CXCL13. This 
chemokine is produced by follicular stromal cells such as follicular dendritic cells 
(FDC)(Cyster et al., 2000) and marginal reticular cells (MRC) (Katakai et al., 2008). The 
receptor for CXCL13 is CXCR5, this is expressed on all mature B cells. Activated B cells 
migrate within the follicles in order to access antigen and T-cell help. In addition, migration 
to specialised microenvironments is required to support production of antibodies. 
B cells can respond in a T-dependent or T-independent manner to antigen. These two types of 
responses will be discussed in more detail later. The first event which occurs within two hours 
of B-cell activation in the T-dependent response, is migration to the outer follicle (Gatto and 
Brink, 2013) (Figure 1.2). This migration is controlled by B-cell expression of EBI2, a G- 
protein coupled receptor, whose ligand is 7α,25-dihydroxycholesterol (Hannedouche et al., 
2011; Liu et al., 2011). Upregulation of EBI2 on B cells occurs within one hour of B-cell 
activation (Kelly et al., 2011). Concentrations of 7α,25-dihydroxycholesterol are highest in 
the outer follicle, whilst degradation of this ligand is highest in the T zone, creating a gradient 
(Gatto and Brink, 2013). The reason for B-cell migration to the outer follicle so early after 
activation is currently unknown, but may occur in order to allow B cells to capture antigen 
from the marginal sinus and interact with the resident macrophages present there. 
The second migration event after B-cell activation is to the border with the T zone. This 
occurs within six hours of activation. At this time, B cells downregulate EBI2 (Kelly et al., 
2011) and upregulate CCR7 (Reif et al., 2002). The ligands for the CCR7 receptor, CCL21 
and CCL19, are highest in the T zone and a decreasing gradient of CCL21 extends into the B- 
cell follicle (Okada et al., 2005). Although EBI2 transcripts are lower at this stage, the 
receptor is still required for even distribution of B cells along the T-B boundary (Kelly et al., 
2011). Following interactions with T cells, B cells can differentiate via one of two pathways. 
They can move to the follicles to become GC B cells, or migrate to the red pulp, to form 
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extrafollicular plasmablast foci. Deficiency of EBI2 leads to a failure of B cells to locate to 
the outer follicle two days after activation, and leads to decreased GC and plasmablast 
responses to TD antigens (Pereira et al., 2009) (Gatto et al., 2009). 
 
 
 
 
 
Figure 1. 2 B-cell migration in the first hours post-activation. 
Within one hour of activation, B cells upregulate their expression of EBI2 which allows them 
to migrate to the outer follicle along a gradient of 7α,25-dihydroxycholesterol. Within four 
hours of activation B cells down-regulate their expression of EBI2, upregulate their 
expression of CCR7 and migrate to the border with the T zone following the gradient of 
CCL19 and CCL21. Four days after activation B cells have differentiated into GC B cells or 
extra-follicular plasmablasts. 
 
 
 
B-cell follicles are the location of GC and FDC. The former will be discussed in more detail 
later. In terms of FDC: these stromal cells capture and display opsonised antigens for long 
periods of time (Sukumar et al., 2008) and may have a role in secondary responses (Tew et 
al., 1997). They also act as a reservoir for infectious agents such as HIV (Smith et al., 2001). 
FDC express complement receptors CD21 and CD35 and the low affinity receptor for IgG 
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FcγRIIb (Allen and Cyster, 2008). Expression of these receptors allows FDC to retain 
opsonised antigen for presentation to B cells. 
T Zone 
 
The T zone is sandwiched between the follicles and only contacts the red pulp at specific 
points, known as marginal zone bridging channels. At these points, a break in the marginal 
sinus and B-cell follicles allows the T zone to directly contact the red pulp. 
Antigen and lymphocytes can enter the white pulp of the spleen via the central arterioles, 
located in the T zone. This allows T cells to become activated by antigen bearing 
interdigitating DCs that have migrated from the periphery.  These T cells are largely CD4
+
, 
although some CD8
+  
cells may also be present. CCL19 and CCL21, produced by T zone 
 
fibroblastic reticular cells (FRC) (Siegert and Luther, 2012), attract DCs and T cells 
expressing CCR7 to the T zone. T cells also enter the spleen via the marginal zone bridging 
channel (MZBC) (Bajénoff et al., 2008) and are again guided by a gradient of CCL21 on 
FRC. FRC are a type of stromal cell unique to the TZ and MZBC and these stromal cells 
drive T-cell migration along their fibres. Expression of CCL19 and CCL21 by FRC requires 
the expression of LTαβ and TNF on stromal cells. Engagement of these receptors with the 
ligands, expressed on haematopoietic cells during neonatal development, stimulates signalling 
via NFκB and production of the chemokines (Mebius and Kraal, 2005; Ngo et al., 2001). 
Following antigen activation, T cells can differentiate into T follicular helper cells   (T
FH
). 
 
This differentiation requires the transcription factors BCL6, c-Maf and BATF in T cells, with 
BATF upstream of BCL6 and c-Maf (Betz et al., 2010; Ise et al., 2011; Johnston et al., 2009). 
These T
FH 
cells downregulate CCR7 and upregulate CXCR5. This drives migration to the B- 
cell areas for T-B cell interactions. 
 
The marginal Zone 
 
The marginal zone is a transit area. Here, cells leaving the blood enter the spleen in an active 
G-protein coupled process (Cyster and Goodnow, 1995). Blood enters through the marginal 
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sinus− a vessel located between the marginal zone and the follicles− and travels in the 
direction of the red pulp. The marginal zone contains resident B cells and macrophages. MZ 
B cells will be discussed in more detail later. Macrophage types include marginal zone 
macrophages (MZM) expressing SIGNR1, and an inner ring of marginal zone metallophilic 
macrophages (MMM). This latter population express toll-like receptors and the macrophage 
receptor with collagenous structure (MARCO). B cells and marginal zone dendritic cells (DC) 
are sandwiched between these two types of macrophage. 
1.3 B-cell subtypes 
 
Five types of mature B-cell are found in the mouse spleen, these can first be divided into B-1 
and B-2 cells. B-1 cells are sub-divided into B-1a and B-1b, based upon their expression of 
CD5. B-2 cells include marginal zone and follicular B cells. In addition, regulatory B cells are 
present in the spleen. It is currently unknown whether these cells constitute a distinct B-cell 
subset, or are a component of the other subsets. 
B--‐1 Cells 
 
B-1 cells are so called as they are the first B cells to develop during embryonic development 
(Montecino-Rodriguez and Dorshkind, 2012). They differ from conventional B cells in a 
number of ways. They have limited diversity in their antigen receptors and are self-renewing 
outside of the central lymphoid organs, whereas B-2 cells are renewed from the bone marrow 
(Baumgarth, 2011). B-1 cells are also unique in that they do not form memory; repeated 
immunisations elicit similar or decreased responses. 
B-1 cells are the main B-cell type present in the peritoneal and pleural cavities in mice and are 
the main producers of natural antibody, however under certain circumstances they have the 
capacity to migrate to other sites. This natural antibody is cross-reactive for self-antigens and 
microbial products. In locations such as in the spleen and lymph nodes, B-1 cells are rare and 
can be difficult to identify. Within the peritoneal and pleural cavities B-1 cells can respond to 
polysaccharide antigens in a T-independent manner. This antibody response is crucial for 
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pathogen neutralisation, and inhibition of pathogen replication via the activation of 
complement. In addition, this natural antibody augments the response of B-2 cells, probably 
via the deposition of immune complex on FDC. B-1 cells in the peritoneal cavity secrete 
lower titres of natural IgM than B-1 cells in the spleen and bone marrow; whereas B-1 cells in 
the gut preferentially secrete IgA. These differences may occur because these cells migrate to 
the site of infection to become antibody-secreting cells. 
Microbial antigens recognised by these cells include LPS and phosphorylcholine of gram- 
positive bacteria as well as porins and Vi antigens (Marshall et al., 2012). Self-antigens 
recognised include oxidised lipids, annexin IV and phosphatidylcholine. As these molecules 
are expressed on apoptotic cells, B-1 cells may function in their clearance, this can occur in 
two ways. Firstly, secretion of antibodies against apoptotic markers promotes the 
phagocytosis of those cells by DCs. Secondly, B-1 cells can phagocytose apoptotic cells 
through BCR recognition or expression of TIM4, a receptor which binds phosphatidylserine 
on apoptotic cells. Interestingly, there is evidence that, rather than B-1 cells being cross- 
reactive for self-antigens or failing to be negatively selected during development, they are 
actually positively selected for self-reactivity. A proportion of B-1 cells in wild-type mice are 
specific for the Thy1 antigen (CD90) but mice lacking this antigen do not have Thy1 specific 
B-1 cells or anti-Thy1 antibody. (Hardy and Hayakawa, 2012). 
B-1 cells are divided into B-1a and B-1b based on their expression of CD5 which is not 
expressed by B1b cells. However, both types are slightly larger than B-2 cells and are 
IL5R
+
,CD9
+
,CD19
hi
, CD23
-
,CD43
+
, IgM
hi 
and IgD
low
. CD5 expression on B1a cells is, 
however, lower than the expression observed on T cells, and outside of the peritoneum, a 
sensitive detection method is required for their identification. In addition, many of  the 
markers used to identify B-1 cells are expressed on other B cells. B-1 cells can therefore be 
difficult to differentiate from activated, unswitched B-2 cells which can also upregulate CD43 
expression. CD5 is also expressed both on anergic B cells and B cells stimulated via their 
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BCR in vitro. IL5R can also be expressed by pre-plasmablasts and CD9 is also expressed on 
marginal zone B cells. 
Maintenance of B-1-cell numbers occurs via a ‘self-renewal’ process (Krop et al., 1996), 
whereby cell death is counterbalanced by proliferation. Natural antibody may provide a 
feedback mechanism for this process. 
B--‐2 B cells 
 
B-2 B cells are constantly renewed from cells produced in the bone marrow. Differentiation 
into follicular or marginal zone B cells then mainly occurs in the spleen. 
Marginal zone and follicular B cells are discussed in more detail below. 
 
 
Marginal Zone B cells 
These B cells respond strongly to T-independent antigens and are specialised to respond to 
blood borne pathogens, such as bacteria and viruses. Marginal zone B cells are IgM
hi
, CD21
hi
, 
IgD
low
, CD1d
hi
, CD23
− 
and recognise antigen presented by marginal zone macrophages. Loss 
of these macrophages leads to loss of the marginal zone B-cell compartment (Garraud et al., 
2012). Retention of marginal zone B cells is mediated by the integrins LFA-1 and α4β1 
(VLA-4), expressed on stromal cells (Lu and Cyster, 2002). These bind to ICAM-1 and 
 
VCAM-1 respectively. In addition, S1P1 and S1P3 are also involved in the localisation of 
marginal zone B cells (Cinamon et al., 2008). 
Marginal zone B cells are important for the early response to blood borne pathogens as upon 
activation, they rapidly secrete IgM. This class of antibody binds with low affinity but high 
avidity and is important for the neutralisation of pathogens. Additionally, marginal zone B 
cells can transport antigens into the follicles, in order to activate a TD response (Cinamon et 
al., 2008). This shuttling to the follicle is dependent upon the expression of the chemokine 
receptor CXCR5. 
Marginal zone B cells also express high levels of CD1d− a non-classical class I MHC 
 
molecule  that  can  present  glycolipid  antigens  to  iNKT  cells.  This  molecule  has  been 
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implicated in the formation of B-cell memory, with weaker stimulation through the CD1d 
receptor leading to greater B-cell memory (Lang et al., 2011), this appears to be due to more 
memory B cells emerging from the GC in this system. 
Follicular B cells 
 
Follicular B cells are mature naïve B cells that recirculate between the spleen and lymph 
nodes. These B cells are CD5-, CD19
mid
, CD1d
mid
, CD23
+
, CD43
-
, IgM
low
, IgD
hi 
and 
constitute more than 70% of the total B-cell population in the murine spleen. The decision 
over whether to become a follicular recirculating B-cell, or a marginal zone B-cell, has been 
proposed to be decided by the strength of signalling through the BCR. Signalling via BTK, 
which induces a strong signal, promotes the development of follicular B cells and BTK
-/- 
mice 
have a greater number of marginal zone B cells. Conversely, mice which lack the 
transcription factor Aiolos have a stronger BCR signal and produce more follicular cells 
(Cariappa et al., 2001). 
Furthermore, a number of transcription factors are thought to play a part in marginal zone 
versus follicular B-cell differentiation. NOTCH-2 signalling (Saito et al., 2003) in addition to 
RBP-J (Tanigaki et al., 2002), promotes the development of marginal zone B cells. MINT 
competes with RBP-J to bind and block notch signalling, and increased MINT levels lead to 
more follicular B cells. Moreover, E2A promotes the development of follicular B cells and is 
antagonised in turn by ID3 (Quong et al., 2004). 
Regulatory B cells 
 
Regulatory B cells are defined by their ability to produce IL-10 upon stimulation. IL-10 is 
known to supress both Th1- and Th2cell polarisation, pro-inflammatory cytokine production 
and antigen presentation by myeloid cells. IL-10 activated DCs also activate Treg cells (Soyer 
et al., 2013). B10 regulatory cells are a subset of the CD1d
hi 
CD5
+ 
Bcell population in the 
spleen (Ding et al., 2011). These cells express T-cell domain and mucin domain protein 
(TIM-1) and ligation of this receptor has been shown to induce B10 cells (Ding et al., 2011). 
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Regulatory B cells are also increased in number by BAFF signalling and their development in 
mice is known to require antigen and BCR stimulation (Kalampokis et al., 2013), as well as 
IL21 (Yoshizaki et al., 2012) and TLR4 or TLR9 stimulation (Kalampokis et al., 2013). IL10 
is dispensable for the development of these cells, as they are found in IL10
-/- 
mice (Maseda et 
al., 2012). Whether B10 cells really constitute a separate B-cell subset, or simply represent a 
B-cell differentiation state is unknown. There are no distinct markers for B10 cells, and they 
are defined simply by their ability to produce IL-10 upon stimulation with LPS or CpG, PMA 
and ionomycin. Whilst IFNα and TGFβ were found to inhibit formation of B10 cells by 
around 50% (Yoshizaki et al., 2012). Not all B cells become B10 cells after stimulation in 
B10 generating conditions however, with only around 1-3% of C57 splenic B cells becoming 
IL-10 producing B cells (Kalampokis et al., 2013). 
CD21low B cells 
 
A CD21
low/negative 
CD11c+ population has been reported in mice. These cells have an impaired 
response to CD40 and BCR stimulation but are responsive to TLR stimulation, particularly 
TLR7. This population may represent ‘exhausted’ B cells and are associated with 
autoimmunity, as they are capable of secreting autoantibodies following activation (Rubtsov 
et al., 2011). These cells were also found to express low levels of CD138 protein and 
transcripts for plasma-cell transcription factors Prdm1, Irf4 and Xbp1. Therefore these cells 
show a plasmablast phenotype (Rubtsov et al., 2011). Perforin, granzyme B and T-bet are also 
expressed. Similar CD21
low 
IgM
+
, CD27
+ 
cells have been identified in hepatitis C-related 
autoimmunity in humans (Terrier et al., 2011). These cells do not proliferate following BCR 
and CD40 stimulation, however they were responsive to TLR9 and were found to be more 
prone to apoptosis. 
 
1.4 B-cell activation and differentiation 
Naive B-cell responses to antigen can be classed into thymus dependent (TD) and thymus 
independent (TI) immune responses. In the former, B cells require help from an accessory 
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signal delivered by primed antigen specific T cells. In contrast, the latter requires a signal 
from antigen alone and strong responses can be induced in athymic mice. 
Thymus--‐independent antigens 
 
These are categorized into two types: TI-I and TI-II antigens. TI-I antigens stimulate B cells 
in the absence of T-cell help. These B-cell mitogens, such as LPS, do not elicit memory; yet 
can activate mature and immature B cells independently of co-stimulatory signals from T 
cells. This is because during BCR ligation they co-ligate co-receptors such as toll-like 
receptors (Lesinski and Westerink, 2001). In contrast, TI-II antigens extensively cross link B- 
cell receptors, thereby circumventing the requirement for T-cell help. This cross-linkage is 
achieved with repeating epitopes, such as those found on the capsulated bacteria such as 
pneumococci, meningococci and Haemophilus influenza b. These molecules are capable of 
activating complement, but not T cells, as they cannot be presented to T cells via MHC 
molecules. B cells which respond to these antigens are mainly marginal zone B cells (Vinuesa 
et al., 2003) and B-1 cells. As marginal zone B cells develop later in ontogeny: 1-2 weeks in 
mice and 1-2 years in humans, neonates tend to have poor responses to encapsulated bacteria 
(Adkins et al., 2004). TI responses normally are not capable of stimulating the formation of 
GC, however T-independent GC have been described in responses where there are pre- 
existing high frequencies of antigen-specific B cells. GC formed under these conditions 
involute when positive selection of centrocytes would normally occur, approximately five 
days after immunisation (Vinuesa et al., 2000). Although affinity maturation is absent due to 
GC being non-productive, TI-II responses can produce switched antibody. TI-II responses are 
important for the opsonisation of encapsulated bacteria. T cells cannot target these bacteria 
because they do not initially present protein antigen on their surface. 
Thymus Dependent antigens 
For this type of B-cell response, helper T cells specific for antigen must first be activated via 
interactions with DCs presenting peptide. When this occurs, T cells upregulate CXCR5 and 
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downregulate CCR7; this stimulates migration to the edge of the B-cell follicles (Ansel et al., 
1999). B cells in turn, bind antigen via their B-cell receptor (BCR), upregulate CCR7 and 
move to the edge of the B-cell follicle (Reif et al., 2002). BCR bound antigen is internalised, 
processed and presented on the B-cell surface in the form of peptide bound to MHC class II 
molecules. If this complex is recognised by a helper T-cell (TFH), activating signals such as 
CD40L and IL-4 are provided which induce the B-cell to proliferate and differentiate. In the 
absence of CD40L, GC do not develop after immunisation (Castigli et al., 1994; Chirmule et 
al., 2000; Kawabe et al., 1994),(Xu et al., 1994). Moreover, memory B-cell formation and 
affinity maturation to TD antigens are impaired (Renshaw et al., 1994), as is B-cell 
proliferation and immunoglobulin class switching. In response to CD40 ligation, B cells 
increase their expression of co-stimulatory molecules. After obtaining signals from TFH cells, 
differentiation can occur via one of two pathways. The B-cell can become an antibody 
forming plasma-cell via the extrafollicular response in the red pulp, or can become a GC B- 
cell. The former pathway rapidly produces low affinity plasma cells. The latter pathway 
produces antibody producing cells and memory cells. These are affinity matured and often 
class switched. Recently, antigen presented by DC inhibitory receptor 2 (DCIR2), which is 
found on marginal zone CD8α- DCs, has been found to stimulate class-switched antibody 
responses to TD antigen. This indicates a previously unknown role of marginal zone 
associated DCs in the TD response. This type of response does not produce GC, or affinity 
matured antibody however (Chappell et al., 2012). 
 
Antibody structure and function 
 
An antibody molecule is comprised of two heavy and two light chains which form a ‘Y’ 
shaped protein. In addition, there are two regions known as the constant and variable regions. 
Antigen specificity is encoded via the variable region; this is the site where point mutations 
are introduced in order to create antibodies with altered specificities. This is known as SHM. 
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Light chains can be either lambda (λ) or kappa (κ) and the C region of the light chain gene 
does not undergo CSR. 
There are several different classes of antibody that are defined by their expression of different 
constant region genes. Initially B cells express Cµ and Cδ, following CSR these genes can be 
exchanged in mice for Cγ3, Cγ1, Cγ2b, Cγ2a, Cε, or Cα (Chaudhuri and Alt, 2004). These 
classes of antibody are expressed as either membrane receptors, or secreted antibodies and 
altering the CH gene results in antibody molecules with differing effector functions. Antibody 
class determines whether multimeric units are formed in the serum, IgM forms pentamers 
resulting in a molecule with a high molecular weight whereas IgA can exist as a monomer or 
a dimer in sera. Altering the isotype of an antibody results in expression of a different Fc 
region. These regions interact with different Fc receptors on effector cells leading to altered 
function. IgM is the most effective class for complement activation followed by IgG 
subclasses. IgG is also capable of crossing the placenta to provide passive immunity to the 
foetus. IgA is capable of being secreted in milk, tears and mucous secretions. IgE in contrast 
binds to mast cells and basophils leading to the release of inflammatory mediators. 
1.5 BCR signalling 
 
The BCR is composed of heavy and light immunoglobulin chains that are specific for antigen. 
Signalling from an IgM or IgD BCR is mediated via two proteins which associate with the 
BCR to form the B-cell receptor complex. These are the Igβ and Igα subunits. These 
accessory proteins consist of a single chain with an amino terminal immunoglobulin-like 
domain, a transmembrane domain and a cytoplasmic tail. Each Igβ and Igα chain contains an 
ITAM motif. Tyrosine residues within these ITAMs become phosphorylated by associated 
kinases following ligand binding (Pierce and Liu, 2010). 
The first event after BCR ligation is oligomerisation and micro cluster formation. B cells are 
activated when their BCRs are cross-linked by a multivalent antigen and are capable of being 
activated  by  engagement  of  multiple  B-cell  receptors  (Metzger,  1992).  Engagement  of 
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multiple BCR leads to the formation of the immunological synapse. However, monovalent 
antigen are also capable of triggering BCR signalling (Pierce and Liu, 2010). Additionally, 
the BCR has a co-receptor which upon engagement strengthens signalling through the BCR. 
The co-receptor consists of CD19, CD21 and CD81. Engagement of CD21, the receptor for 
the complement component C3d, allows the cytoplasmic tail of CD19 to be phosphorylated 
by BCR associated tyrosine kinases. Three protein tyrosine kinases of the Src family are 
responsible for the phosphorylation of the ITAM sequences on Igβ and Igα. These are Fyn, 
Blk and Lyn and these protein kinases are activated by receptor cross-linking. The 
phosphorylated ITAM sequences then recruit Syk via its SH2 domain. Syk molecules 
transphosphorylate each other due to their close proximity after BCR cross-linking. Syk in 
turn, phosphorylates BLNK, this scaffold protein then recruits SH-2 containing proteins. Btk 
activates phospholipase-Cγ which hydrolyses PIP2 into DAG and IP3. Cross-linking of the 
BCR and activation of intracellular signalling pathways also stimulates BCR internalisation. 
This process is essential for antigen presentation to T cells. Receptor internalisation requires 
Vav and the GTPase dynamin (Malhotra et al., 2009). 
BCR signalling is in turn, negatively regulated by FcγRIIB. This is a low to medium affinity 
receptor for IgG1, IgG2a and IgG2b. Negative regulation is mediated via an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) within its cytoplasmic region. Cross-linking of the 
BCR in conjunction with FcγRIIB leads to phosphorylation of its ITIM by LYN. This recruits 
the lipid phosphatase SH2-domain-containing inositol polyphosphate 5’ phosphatase (SHIP). 
SHIP hydrolyses phosphoinositide intermediates and prevents recruitment of BTK and PLC-γ 
to the cell membrane, thereby preventing Ca
2+  
signalling. Isolated signalling through this 
 
receptor can lead to apoptosis via activation of BTK and JUN N-terminal kinase (JNK) 
(Nimmerjahn and Ravetch, 2008). 
Interestingly FcγRIIB is also expressed at high levels in plasma cells. This could be a 
mechanism by which plasma-cell numbers are regulated. During a new infection antigen- 
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specific B cells receive signals through both their BCR and FcγRIIB. In contrast non-specific 
plasma cells engage circulating IgG only. This occurs via their FcγRIIB and leads to 
apoptosis of the plasma-cell, thereby creating space in the bone marrow for new antigen- 
specific plasma cells (Nimmerjahn and Ravetch, 2008). 
1.6 Overview of the Germinal Centre 
 
GC develop in secondary lymphoid organs such as the spleen and lymph nodes during a T- 
cell dependent antibody response, usually within 6 days of primary immunisation. These 
structures give rise to high affinity antibody secreting plasma cells and memory cells, via the 
process of affinity maturation (Hauser et al., 2007). 
The GC is divided into a dark and light zone and surrounded by the follicular mantle (Figure 
 
1. 3). The follicular mantle is composed of predominantly naive IgD
+ 
B cells, whereas the 
dark zone contains rapidly dividing centroblasts. These have down-regulated surface 
immunoglobulin and are thought to be undergoing somatic hyper mutation (SHM) of the B- 
cell receptor (BCR) loci at the variable locus of the immunoglobulin gene. This is the process 
by which point mutations are introduced into the variable region locus of the IgH and IgL 
genes. Centroblasts have large nuclei and therefore stain darkly with haematoxylin and eosin. 
These cells are believed to give rise to centrocytes, present in the light zone. B cells which 
have undergone SHM may express receptors of low affinity, or alternatively receptors which 
recognise self-molecules  and must  therefore be  deleted from  the  B-cell repertoire.  This 
selection process is thought to occur in the light zone, as this area contains FDC, follicular 
helper T cells (TFH) and tingible body macrophages (Hauser et al., 2007). Whilst the latter are 
known to clear apoptotic cells (Baumann et al., 2002), FDC and TFH cells are thought to 
provide a survival signal to B cells which would otherwise become apoptotic (Vinuesa et al., 
2000). FDC are known to trap antigen in an unprocessed form for presentation to B cells 
(Sukumar et al., 2008). GCs are also the site of CSR, in which the antibody affinity is not 
altered but the IgH constant region (CH ) µ exon is replaced with the C region γ, α, ε or δ 
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exon, resulting in a different isotype antibody. Both CSR and affinity maturation require the 
enzyme activation-induced cytidine deaminase (AID) in an active form. Both processes occur 
in activated B cells in response to antigen stimulation and costimulatory signals. In Vitro CSR 
can be induced in response to LPS alone, or in combination with IL-4 or IFN-γ, as well as 
other cytokines (Chaudhuri and Alt, 2004). CSR involves a recombination event between two 
switch (S) regions of DNA. These are located upstream of each CH region gene except CHδ. 
AID has been shown to act as a DNA-cytidine deaminase and deaminates cytosines in the 
donor and acceptor S regions. The targeted bases are excised by uracil DNA glycosylase and 
the single stranded breaks converted to double stranded breaks (Stavnezer et al., 2008). The 
S-S regions are recombined, excising the DNA between the two sites (Stavnezer et al., 2008). 
The process of CSR will be discussed in more detail later. CSR has been shown to occur 
within 12 hours during a secondary response to antigen (Toellner et al., 1996) but can also 
occur in a T independent manner outside of GCs. GC classically persist for around three 
weeks, with involution beginning at 14 days, depending upon the model (Toellner et al., 
1996), and can be detected by the ability of the cells within this area to bind the lectin peanut 
agglutinin (PNA). They can also be detected by their expression of the transcription factor 
BCL-6. 
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Figure 1 3 :Overview of the germinal centre. 
GC form when antigen specific B cells interact with antigen specific T cells at the B-T zone 
boundary (Allen et al., 2007). B cells either move into extra follicular foci in the red pulp as 
short lived plasma cells, or move into follicles and form GC. These structures are the sites of 
somatic hypermutation which results in altered affinity B cells. The resulting B cells are 
screened for their ability to recognise antigen, after which they are either eliminated by 
apoptosis or selected to leave, either as memory or plasma cells (Reproduced from (Klein and 
Dalla-Favera, 2008). 
 
 
 
1.7 Transcription Factors in B-cell differentiation 
 
 
Cell fate decisions 
 
The cell fate decision between a GC B-cell or plasma-cell phenotype may be regulated in part 
by the transcription factor PAX5 (Singh and Sciammas, 2006). PAX5 represses the activation 
of genes associated with plasma-cell differentiation, such as Prdm1 (BLIMP1) Igj, cd28 and 
Ccr2, whilst positively regulating the transcription of Aicda (AID). Aicda is also positively 
regulated by E2A amongst other factors; these will be discussed in more detail later. In GC 
cells, repression of Blimp1 expression by BCL-6 (Shaffer et al., 2000) maintains the GC 
phenotype. As cells move towards plasma-cell differentiation, expression of PAX5 is reduced 
and BLIMP1 is up-regulated. The latter is a zinc finger transcription factor that represses the 
expression of BCL6 (Figure 1.4) and activates the expression of the chemokine receptor 
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CXCR4. This receptor is responsible for plasma-cell homing to the red pulp (Hargreaves et 
al., 2001) which is associated with an increase in the endoplasmic reticulum and protein 
synthesis. Moreover, de-repression of Xbp1 activates transcription of genes for chaperones 
and enzymes involved in the secretory apparatus of plasma cells. 
 
 
Figure 1 4: Transcription factors involved in cell fate decisions between plasma cells and 
GC cells. 
In the GC B-cell, PAX5 represses genes responsible for alternative lineage decisions. PAX5 
maintains expression of genes that maintain the GC-cell phenotype such as BCL6, which in 
turn represses Blimp-1. In plasma cells Blimp-1 acts to repress BCL6 and Pax5, leading to 
the loss of B-cell identity and the secretion of immunoglobulin. Reproduced with permission 
from (Singh and Sciammas, 2006). 
 
 
The positioning of B cells within the white pulp is also crucial for the differentiation of 
plasma cells. EBI2 deficient B cells do not migrate to the extrafollicular region and fail to 
form plasmablasts, although differentiation in vitro is not affected (Gatto et al., 2009). 
Positioning of B cells at the bridging channel and extrafollicular regions may be essential for 
interactions with other cell types such as DCs (García De Vinuesa et al., 1999) which are 
known to produce factors such as IL-6 and APRIL which promote plasma-cell differentiation 
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and survival (Mohr et al., 2009). In addition, strong stimulation via the BCR is required for 
extrafollicular plasma-cell differentiation. Interestingly the strength of the BCR signal, 
determined by the affinity of the BCR for the selected antigen, does not affect the size of the 
germinal centre response (Paus et al., 2006). Previous studies in the quasi-monoclonal mouse 
(QM) (Cascalho et al., 1996), which has a BCR with high affinity for the model antigen 4- 
Hydroxy-3-nitrophenylacetyl (NP), showed that smaller antigen doses induced mainly 
extrafollicular responses whereas high antigen doses induced both germinal centre and 
extrafollicular responses (Vinuesa et al., 2000). 
 
 
 
Extracellular signalling molecules responsible for Plasma--‐cell differentiation 
 
 
BAFF and APRIL 
 
Two members of the tumour necrosis factor family (TNF): B-cell activating factor (BAFF) 
and its homologue APRIL, are membrane associated proteins which have important roles in 
B-cell and plasmablast differentiation and survival (Mohr et al., 2009; Moisini and Davidson, 
2009). Proteolytic cleavage of the membrane proteins converts them to soluble cytokines. 
These proteins also have a role in FDC development and DC maturation (Moisini and 
Davidson, 2009). BAFF is capable of binding to three different receptors; these are BAFF- 
receptor (BAFF-R, BR3), TACI and B-cell maturation antigen (BCMA). APRIL, in contrast, 
binds only to TACI and BCMA. Plasma cells express TACI and/or BCMA, which are capable 
of binding BAFF or APRIL. BAFF or APRIL binding to TACI on plasma cells synergises 
with TLR signalling to activate MYD88 during the T-independent response. This initiates a 
signalling cascade involving IRAK1, IRAK4 and TRAF6. Downstream NFκB signalling is 
initiated (p50 and p65 heterodimers) for the induction of AID and CSR. TLR stimulation in 
turn leads to the upregulation of receptors for BAFF (Rawlings et al., 2012). 
Interactions between BAFF and BAFF-R are important for the survival of B2 cells past the T1 
 
stage of their development. The amount of BAFF signal is connected to the BCR signal 
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strength, as BCR signalling generates p100. This is cleaved to p52, a component of the NFκB 
signalling pathway that is also required for BAFF signalling. Generation of p100 leads to B- 
cell survival (Schiemann et al., 2001). Both BAFF and APRIL from trimers which can bind 
to three independent receptors simultaneously. Signalling is initiated through TRAF proteins. 
TRAF2 and TRAF6 bind to TACI to activate NFκB1, but only if at least six receptors are in 
close proximity. BAFFR in contrast recruits TRAF3 and therefore requires less receptor 
clustering, this leads to degradation of TRAF3 and indirectly leads to activation of the NFκB2 
pathway (Mackay and Schneider, 2009). 
Cells which are capable of producing BAFF include FDC, monocytes, macrophages, DCs 
neutrophils and iNKT (Shah et al., 2013) and the receptors for this molecule are upregulated 
by activated B cells. Expression of BAFF and APRIL can be increased by type I interferons 
IFN-γ, IL-10 and G-CSF. In addition, both BAFF and APRIL can be produced by plasma 
cells themselves, both in vitro and in vivo (Chu et al., 2007). Therefore, plasma cells may 
sustain their own survival in an autocrine manner. APRIL has also been shown to be required 
for the survival of class switched B cells in mice and APRIL and BAFF are involved in 
CD40-independent CSR to IgA. This occurs through TACI and BAFFR (Castigli, 2004). TI-II 
responses and TD IgM responses also require BAFF binding to TACI. 
CD40-CD40L Signalling 
 
Another member of the TNF family involved in plasma-cell differentiation is CD40L. CD40 
is a cell surface receptor that was first described on B cells, but is also expressed on 
monocytes, DCs, endothelial and epithelial cells. The ligand, CD40L, is also expressed on a 
wide range of cells including monocytes, DC, B cells, mast cells basophils and eosinophils. 
Expression of CD40L is tightly regulated. Some pre-formed CD40L is present in T cells 
before activation and can be rapidly expressed at the cell surface within minutes of activation. 
A second wave of CD40L is synthesised between 1-8h after activation, after this CD40L 
levels decrease again. Downregulation occurs via a number of mechanisms; release of soluble 
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CD40 which binds CD40L, cleavage of CD40L from the cell surface, downregulation of the 
mRNA for CD40L and finally, receptor mediated endocytosis and lysosomal degradation of 
CD40L. CD40 also has a second ligand− C4bp, this is a ligand which is expressed by FDC 
and is critical for TI, B-cell activation and B-cell proliferation (Brodeur et al., 2003). 
 
CD40 has been shown to be important for GC formation and plasma-cell survival and 
differentiation. CD40 receptor has been shown to associate with various TRAF proteins 
including TRAF3, TRAF2, TRAF5 and TRAF6 (Jabara et al., 2009; van Kooten and 
Banchereau, 2000). After engagement by CD40L on T cells, CD40 signals via NFκB1 to 
induce a high level of IRF4, this is required for plasma-cell differentiation (Klein et al., 2006). 
CD40L
KO 
mice do not form GC after immunisation (Castigli et al., 1994; Chirmule et al., 
2000; Kawabe et al., 1994; Xu et al., 1994), and have impaired memory B-cell formation and 
affinity maturation to TD antigens, although responses to TI antigens are maintained 
(Renshaw et al., 1994). B-cell memory can be restored by administration of CD28 AB 
(Chirmule et al., 2000). In addition, patients with hyper IgM syndrome, caused by a mutation 
in the CD40L gene, do not produce GC, although aggregates of centroblasts have been 
observed in lymph nodes (Facchetti et al., 1995). CD40 has been reported to drive B cells 
towards a memory cell phenotype, rather than a plasma-cell phenotype in vitro (Randall et al., 
1998). 
 
 
Interferon regulatory factor 4 in plasma--‐cell differentiation 
 
IRF4 is a member of the interferon regulatory factor (IRF) family of transcription 
factors. This family contains nine members: IRF1-‐‐9. Unlike other members of this family, 
IRF4 is not induced by interferon but rather by signalling via antigen-‐‐receptor, LPS or 
CD40 signalling (Paun and Pitha, 2007). Members of the IRF family are characterised by 
a DNA-‐‐binding domain containing five tryptophan repeats and, with the exception of 
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IRF-‐‐1 and IRF-‐‐2, all members contain the IRF associated domain (IAD). This domain is 
required for interactions with the 3' terminal part of the protein (Paun and Pitha, 2007). 
IRF4 is a crucial transcription factor for plasma-cell differentiation which is also induced in 
activated T cells (Huber et al., 2008) and macrophages (Satoh et al., 2010). IRF4 binds DNA 
closely when interacting with members of the Ets or helix-loop-helix family of transcription 
factors and has a redundant function with IRF8 in pre-B-cell development, but not in GC and 
plasma-cell development (Lu, 2008). Commitment to plasma or memory cell differentiation 
is thought to occur when centrocytes in the GC downregulate BCL-6, and activate BLIMP-1 
(Shapiro-Shelef et al., 2003; Turner et al., 1994), IRF4 and BMI-1. NFkB1 and STAT3 are 
also upregulated at this stage. However, BLIMP-1 alone does not appear to be sufficient for 
the development of plasma cells (Vinuesa et al., 2001) and premature upregulation of 
BLIMP-1 leads to apoptosis through downregulation of the anti-apoptotic protein Bfl-1/A1, a 
member of the bcl-2 family. BLIMP-1 acts upstream of XBP-1 and cannot drive plasma-cell 
differentiation in the absence of XBP-1 (Shapiro-Shelef et al., 2003). When IRF4 is 
conditionally knocked-out in GC B cells, GC development is unaffected whereas plasma cells 
lacking IRF4 are completely absent (Klein et al., 2006) (Sciammas et al., 2006). Additionally, 
XBP-1 expression is abrogated in B cells lacking IRF4 and CSR is deficient (Klein et al., 
2006), as is production of antibody (Sciammas et al., 2006). The latter effect is due to an 
inability to upregulate AID. IRF4 deficient mice also exhibit reduced numbers of memory B 
cells, indicating a requirement for IRF4 in the maintenance of the memory cell pool. In 
addition, memory cells developed from IRF4
-/- 
B cells are reported to be unable to 
differentiate into plasma cells (Klein et al., 2006). 
B cells lacking IRF4 are able to express BLIMP-1 mRNA at a similar level to wild-type B 
cells, however this is not sufficient for plasma-cell differentiation, indicating that BLIMP-1 
may act upstream of IRF4 (Klein et al., 2006) However IRF4 has also been reported to have 
contradictory roles in the induction of BLIMP-1 and AID expression. This appears to be due 
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to a dose-dependent effect. Transduction of wild type splenic B cells with IRF4 augments the 
generation of CD138 expressing cells, with high concentrations of IRF4 required for 
repression of the GC programme via the upregulation of Prdm1. Intermediate levels of IRF4, 
in contrast, induce AID expression and isotype switching (Sciammas et al., 2006). This action 
of IRF4 for the induction of AID expression has been suggested to be indirect, as AID has not 
as yet been shown to be a direct target of IRF4 (Sciammas et al., 2011). 
 
 
 
1.8 Regulation of AID 
 
AID is required for both SHM and Ig class switching. During SHM, point mutations are 
introduced to the variable region of antibody genes. During CSR, the antibody heavy chain is 
altered, whilst the affinity of the BCR remains the same. Both  processes require DNA 
cleavage facilitated by AID. This can potentially have dangerous consequences and must 
therefore be tightly regulated. 
The murine Ig locus contains eight CH genes. These are Cµ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε, 
and Cα. Located upstream of each IgH gene (except Cδ) is a switch (S) region of DNA; these 
sequences are where breaks are introduced. Switch regions are then joined, and the 
intervening DNA deleted (Figure 1.5). Characteristically, these regions are highly repetitive 
with the non-template strands being rich in guanines. Transcription through the specific CH S 
region is necessary for CSR to a specific CH gene, and transcription initiates at an upstream 
activator/cytokine responsive promoter (Chaudhuri and Alt, 2004). 
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Figure 1 5: Mechanism of Class Switch Recombination. A promoter, upstream of the VDJ 
segment drives transcription of the µ heavy chain. This associates with a light chain to form 
an IgM molecule. Following CSR the constant region of the heavy chain is exchanged for a 
downstream constant region gene. To enable CSR, double stranded breaks are introduced at 
the switch regions. These are located in front of the heavy chain genes. Repair of the breaks 
leads to the rearranged CH locus with the deletion of the intervening sequence. (Chaudhuri 
and Alt, 2004). 
 
 
AID functions in this process by deaminating deoxycytosines, creating U: G mismatches. 
These are repaired by base excision or mismatch repair, in an error-prone process. This error- 
prone repair process which leads to CSR requires the DNA polymerase-δ (Schenten et al., 
2009). Class switching can be detected by measuring heavy chain transcripts containing Iµ. 
During CSR Ig switch regions are exposed by transcription that is initiated from the induce (I) 
exon which precedes each Cg gene, through the switch region and into the Cg heavy chain 
genes.  Most Ig genes (with the exception of IgG3) are strictly regulated and typically only 
expressed during induction of CSR. The I µ 
 
exon upstream of the IgM switch region is constitutively active, and in non-switched cells 
produced a Iµ-Cµ transcript. After CSR to IgG3 Iµ-Cy3 hybrid transcripts  are  expressed, 
and these indicate successful Ig class switch recombination to IgG3 (Li et al., 1994). 
Commitment to an antibody class is dependent upon both the antigen, and the route of 
administration. Different cytokines drive commitment to different antibody classes. IL-4, 
which is the hallmark of a Th2 response, promotes CSR to IgG1 and IgE (Snapper and Paul, 
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1987), whereas IFNγ, which is characteristic of a Th1 response, activates STAT1 and induces 
T-bet to promote switching to IgG2a (Mohr et al., 2010; Peng et al., 2002; Snapper and Paul, 
1987). TGFβ in turn, signals to RUNX proteins to promote switching to IgA (Cazac and 
Roes, 2000; Watanabe et al., 2010). LPS in contrast induces switching to IgG2b and IgG3 
(Chaudhuri and Alt, 2004). 
Furthermore, CSR requires cell division. The frequency of switched B cells increases after 
two divisions and levels plateau at around six cell divisions (Hodgkin et al., 1996). This 
correlation with division number appears to be due to a number of factors. Firstly, the IgH 
constant region only becomes accessible after a single cell division event, this may be because 
the substrate for AID is ssDNA, AID activity requires active transcription (Chahwan et al., 
2012). Secondly, the amount of AID mRNA increases with subsequent divisions and is 
correlated with CSR (Rush et al., 2005). Moreover, double stranded breaks only occur during 
G1 phase of cell cycle (Schrader et al., 2007) and homologous repair proteins mainly 
assemble at AID targets during S-G2/M phase (Yamane et al., 2013). Therefore the events 
that are required for CSR occur at defined stages of the cell cycle. 
 
 
AID function and expression has to be tightly regulated by various mechanisms including: 
transcriptionally, post translational modification, interactions with other proteins and 
regulation of the subcellular location of AID (Vuong and Chaudhuri, 2012). 
 
Transcriptional regulation of Aicda 
 
AID has been proposed to be regulated by intermediate expression levels of IRF4 protein 
(Klein et al., 2006; Sciammas et al., 2006; 2011). AID can be induced in vitro after 
stimulation with anti-CD40 in conjunction with IL-4, but only minimally by either factor 
separately (Dedeoglu et al., 2004). Activation of AID following B-cell stimulation required 
STAT6 binding to a site in the 5’ upstream region of the AID gene (Dedeoglu et al., 2004). 
IRF4 may regulate AID through this pathway as IRF4 is known to interact and cooperate with 
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STAT6 (Gupta et al., 1999). Ligation of CD40 stimulates NFκB binding to two sites in the 5’ 
upstream region of the AID gene (Dedeoglu et al., 2004). Other studies support the 
importance of the 5’ region of the Aicda locus (Tran et al., 2009). E2A which is expressed in 
centroblasts (Goldfarb et al., 1996) has been shown to positively regulate AID, this gene 
encodes two transcription factors: E12 and E47 which are members of the E-protein family: a 
class of basic helix-loop-helix (bHLH) proteins. These proteins bind to HLH inhibitor of 
differentiation 1 (Id1) Id2, Id3 and Id4 which block the transcriptional activity of the E- 
proteins (Sayegh et al., 2003). Transduction of murine B cells with a retrovirus expressing Id3 
lead to decreased levels of Aicda whilst overexpression of E47 activated Aicda expression. 
Ectopic expression of AID in cells overexpressing Id3 resulted in a partial rescue of Ig CSR, 
indicating that there may be other roles for E-proteins in CSR besides the induction of AID 
(Sayegh et al., 2003). Furthermore E47 is a binding partner of IRF4 (Nagulapalli and 
Atchison, 1998). Binding of E-proteins to the Aicda promoter has been reported elsewhere 
(Tran et al., 2009). Restriction of AID expression to B cells may be mediated by PAX-5 (Tran 
et al., 2009), recruitment of which to the Aicda promoter has been suggested to be mediated 
by other transcription factors, as the PAX-5 binding site has not been identified (Park et al., 
2009). Within the germinal centre Homeobox C4 (HoxC4) is correlated with AID expression 
and binds to the Aicda promoter to induce CSR and SHM (Park et al., 2009). Deletion of 
forkhead box O1 (FOXO1) in B cells leads to reduced AID and CSR (Dengler et al., 2008). 
BATF, a member of the activator protein 1 (AP-1) family, regulates both AID expression, 
with BATF
KO 
B cells expressing 90% less AID protein, and undergoing less CSR. The 
requirement of BATF in the process of CSR occurs independently of AID. BATF induces IH- 
C
H 
transcripts via interactions with I-region promoters and elements of the 3’ Igh enhancer 
(Ise et al., 2011). In addition, within naïve B cells, E2F and c-Myb are bound to the Aicda 
locus and act as transcriptional repressors (Huong et al., 2013). 
29  
Post-transcriptional regulation of AID 
 
Negative regulation of AID has been reported by a number of micro-RNAs including miR- 
155 (Teng et al., 2008; Vigorito et al., 2007), miR-361 (Basso et al., 2012) and miR-181b (de 
Yébenes et al., 2008). 
 
Interactions with cofactors and post translational modification 
 
The C-terminal region of AID is important for interactions with other proteins as mutating 
this region affects CSR but not SHM (Ta et al., 2003). Indeed alterations in AID levels have 
been reported to affect CSR but not SHM indicating that the expression levels of AID 
required for these two processes may be different (Teng et al., 2008) (Muto et al., 2006). AID 
may also require post-translational modification for interactions with other proteins 
(Chaudhuri et al., 2004) and has been proposed to work in conjunction with co-factors and 
adaptor proteins. For example, the adaptor protein 14-3-3 is recruited with and targets AID to 
switch regions (Xu et al., 2010). AID protein contains a number of phosphorylation sites and 
phosphorylation of AID has been shown to have a role in interactions with cofactors in 
tetrapods but not zebrafish which undego SHM but not CSR (Basu et al., 2008). 
Phosphorylation at S38 by protein kinase A (PKA) is required for interactions with replication 
protein A, this interaction is required for AID access to DNA (Basu et al., 2008). Therefore 
this may indicate a mechanism whereby phosphorylation of AID can control these two 
different functions. 
 
Subcellular location of AID 
 
AID continually shuttles between the nucleus and the cytoplasm. It is only active within the 
nucleus but it is also rapidly degraded there (Aoufouchi et al., 2008). In addition to 
degradation, AID is also exported from the nucleus under the control of CRM1 which binds 
the nuclear export signal of AID (Geisberger et al., 2009; Ito et al., 2004). In addition there is 
a cytoplasmic retention mechanism (Patenaude et al., 2009). Some of the proposed regulators 
of AID are summarised in figure 1.6. 
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Figure 1 6 The signalling network mediating regulation of AID protein levels includes 
activators and repressors of transcription/translation 
In addition AID is regulated by its sub-cellular location, interactions with cofactors and post- 
translational modification. 
 
 
 
 
 
The role of AID and IRF4 in B-‐‐cell malignancies 
 
Both AID and IRF4 are associated with a number of malignancies. Aberrant AID expression 
can lead to mutations in tumour suppressors or other genes resulting in transformation of B 
cells and giving rise to various lymphomas. Philadelphia chromosome positive ALL, 
characterised  by  the  expression  of  BCL-ABL1,  is  associated  with  high  aberrant  AID 
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expression (Feldhahn et al., 2007). Furthermore Myc-IgH translocations in Burkitt’s 
lymphoma may be attributable to AID (Ramiro et al., 2004). 
 
 
Multiple myeloma (MM) is a plasma-cell malignancy and IRF4 was first identified as 
multiple myeloma oncogene 1 (Mum1). This was cloned from an MM cell line with a 
translocation of t(6;14)(p25;q32). This translocation put IRF4 under the control of the IgH 
promoter leading to IRF4 overexpression. This was shown to be oncogenic in vitro (Iida et al., 
1997). RNA-interference of the 3’ UTR of IRF4, which leads to a drastic inhibition of IRF4 
mRNA and protein, has been shown to lead to death of MM cell lines (Shaffer et al., 2008). 
This was found to be specific for MM cell lines but had no effect on lymphoma cell lines. 
IRF4 was found to bind to its own promoter leading to a positive feedback loop and MYC 
was found to be a direct target of IRF4 in both MM cells and normal activated B blasts. 
Expression of MYC was required for the survival of myeloma cells (Shaffer et al., 2008). 
However in MM cells IRF4 regulated a number of signalling pathways which are not active in 
normal plasma cells. This represents a fusing of normal plasma-cell differentiation pathways 
and B-cell activation pathways which may also be due to the graded expression of this 
transcription factor. IRF4 is also highly expressed in activated B-cell-like DLBCL and the 
IRF4 binding partner, SPIB has been shown to act as an oncogene in this malignancy (Lenz et 
al., 2007). In addition IRF4 is implicated in CLL with single nucleotide polymorphisms 
associated with the 3’ UTR of IRF4 (Di Bernardo et al., 2008). 
 
 
Knocking down IRF4 mRNA and protein by 50% was sufficient to kill myeloma cell lines 
(Shaffer et al., 2008). Therefore it has been proposed that targeting IRF4 therapeutically 
would kill myeloma cells whilst sparing normal B-cell responses. This is an approach that has 
been tried with BCL6 in lymphomas with some success (Polo et al., 2004).(Cerchietti et al., 
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2010). In order to utilise IRF4 protein in the treatment of malignancies, it is crucial to 
elucidate its pleiotropic effects within different cell types. 
1.9 Memory B-cell development 
Memory B cells develop after primary antigen exposure and recirculate in the blood until re- 
exposure to the same antigen prompts rapid differentiation to antibody secreting cells. In this 
manner, memory B cells can mount a fast response upon secondary antigen encounter. 
Memory B cells are derived from the germinal centre but have also been reported to develop 
independent of the GC reaction (Linterman et al., 2010) (Toyama et al., 2002) (Inamine et al., 
2005) (Chan et al., 2009) (Taylor et al., 2012) . Memory cells produced in this way are known 
as early memory (EM) cells and are detectable within 10 days of immunisation during the T- 
dependent response. They are characterised as B220
high
, BCR
high
, GL-7
low
, FAS
low 
and CD38
+
. 
These cells are not dependent upon IL21-signaling, unlike GC B cells (Linterman et al., 2010) 
and whilst they may be class-switched, they tend to be of low affinity (Inamine et al., 2005). 
Taylor et al (2012) defined the memory compartment as CD38+ GL7- cells which had 
divided in response to antigen stimulation, the peak production of these cells was found to be 
between days five and seven after immunisation. 
 
There is also a second phase of memory B-cell formation however, that of affinity-matured 
memory B cells derived from the GC reaction (Inamine et al., 2005). One week after a 
primary immunisation with NP-KLH, switched antigen-specific B cells with a memory 
phenotype can be detected in the blood. These contain mutations in their VH gene (Blink et al., 
2005). As the immune response continues, the numbers of mutations also increase, indicating 
that these cells are GC derived. 
Memory B cells have been shown to require anti-apoptotic signalling for their survival 
(Vikstrom et al., 2010) and BCR signalling may also be important for their persistence, as 
depletion of phospholipase C leads to a decreased memory B-cell compartment (Hikida et al., 
2009). Upon recall, memory B cells expand rapidly and differentiate into high affinity plasma 
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cells. Their migration is dependent upon inflammatory signals, such as LPS (Shenoy et al., 
2012). The ability to differentiate rapidly may be due to the enhanced affinity of the memory 
BCR, as well as altered surface receptor class. For example, there is evidence that signalling 
via the IgM BCR is functionally different to signalling via the IgG1 BCR. IgG1 BCRs have 
enhanced signal initiation due to micro clustering, a process which requires the cytoplasmic 
tail of IgG1(Liu et al., 2010). In contrast, the short cytoplasmic tails of IgM and IgD have not 
been shown to directly signal into the cell. The signalling pathway through IgG1 is further 
augmented as the IgG receptor is not sensitive to down-regulation of signalling through CD22 
(Wakabayashi et al., 2002). 
 
 
1.10 Conclusion 
 
The production of class switched antibody is crucial for the generation of an  effective 
humoral immune response. Class switch recombination is facilitated by the protein AID 
which in turn is tightly controlled to prevent the introduction of potentially damaging point 
mutations into the genome. IRF4 protein has been reported to modulate contradictory gene 
regulatory networks including the induction of AID protein (Klein et al., 2006; Sciammas et 
al., 2006; 2011) and plasma-cell differentiation (Klein et al., 2006). These gene regulatory 
networks are contradictory as plasma cells do not express AID (Marshall et al., 2011). These 
contradictory effects are associated with different expression levels of IRF4 protein within B 
cells in vitro (Sciammas et al., 2011) with intermediate-level IRF4 associated with AID 
induction whilst high level IRF4 is associated with plasma-cell differentiation. Intermediate- 
level IRF4 has been proposed to be expressed by GC B cells (Ochiai et al., 2013), however 
data from our group has shown that B blasts upregulate IRF4 to an intermediate level within 
minutes of activation before the formation of GC (Yang Z, UOB thesis 2010) and that 
extrafollicular B blasts temporarily acquire a capacity for Ig CSR in the first days post- 
immunisation (Marshall et al., 2011). Therefore, this thesis aims to test the role of differential 
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levels of IRF4 for the regulation of AID protein and Ig class switching within extrafollicular 
B blasts. We tested the hypothesis that — 
(i) Intermediate levels of IRF4 protein regulate AID and CSR within extrafollicular B blasts. 
 
(ii) High levels of IRF4 protein are dispensable for AID and extrafollicular CSR but are 
required for plasma-cell terminal differentiation. 
 
 
Chapter 3 explores the timing of IRF4 intermediate and high protein expression within 
activated B cells and correlates these two phases with: 
(a) Stages of B blast differentiation and 
 
(b) Expression of AID protein. 
 
To test the role of intermediate-level IRF4 for extrafollicular AID induction and CSR we used 
two approaches. Firstly we blocked high-level but not intermediate-level IRF4 protein 
expression using mice lacking the NFκB family signalling molecules NFκB1 (chapter 4) and 
C-REL (chapter 5) and tested extrafollicular AID induction and class switch recombination 
when only intermediate level IRF4 is induced normally. 
 
 
Secondly, to test extrafollicular AID induction and CSR when intermediate-level IRF4 is 
blocked we repressed IRF4 with the micro-RNA miR-125b. We then tested AID induction 
and CSR within extrafollicular B blasts (chapter 6). 
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2.MATERIALS AND METHODS 
 
 
 
2.1 Animals 
In all cases of animal studies mice were age and sex matched and used between the ages of 6- 
12 weeks. Wild type (WT) C57Bl6/j, NFκB1-/-x QMNP/NP K-/- xC57Bl6, QMNP/NP K-/- x 
C57Bl6 F1, NFκB1-/-x QM
NP/WT 
K-/- xC57Bl6, and QM
NP/WT 
K-/- x C57Bl6 F1mice were 
bred and housed in specific pathogen free conditions in the animal facility at the University of 
Birmingham Biomedical Services Unit. All procedures were approved by the University 
Ethics Committee and covered by Home Office licenses’. 
 
 
2.2 Mouse Models 
 
 
Quasi-monoclonal 
NP/NP κKO 
 
Quasi-monoclonal (QM) mice were utilised to test early B-cell activation, due to their high 
frequency of B cells specific for the hapten 4-Hydroxy-3-nitrophenylacetyl (NP). QM mice 
contain a targeted insertion of the rearranged VHDJH 17.2.25 segment derived from an NP- 
specific BALB/c hybridoma (Cascalho et al., 1996). This heavy chain, combined with a λ 
light chain, confers specificity for NP with high affinity. However, due to secondary heavy 
chain rearrangements only around 60% of peripheral B cells are specific for NP (Cascalho et 
al., 1996). These mice produce a strong extra follicular response to NP-Ficoll. They also 
develop GCs in response to NP-Ficoll that show little evidence of hypermutation. 
Consequently B cells do not undergo affinity maturation during these responses (Toellner et 
al., 2002). 
QMxC57BL/6 F1 hybrid mice were also used in experiments. These mice have one copy of 
the rearranged VHDJH genes and one copy of the κ light chain gene. In these mice around 5% 
of B cells are NP-specific. Immunisation with NP-Ficoll induces germinal centres and 
plasma-cell foci with similar kinetics to the secondary T-dependent response when T-cell help 
is available. 
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NFκB1KO 
 
As an approach to test Ig CSR and AID induction in a system lacking plasma-cell 
differentiation, NFκB1KO mice were used. These mice were first described by Sha et al 
(1995). Part of the gene encoding the p50 subunit is ablated via a targeted insertion. A PGK- 
neo-cassette is inserted into exon 6 of the NFκB1 gene. Exon 6 encodes residues 134-187 
within the Rel homology domain, this is designed so as not to affect the synthesis of IκB-γ. 
Disruption produces a truncated polypeptide that is unable to bind other NFkB members, 
dimerise, or bind DNA. These mice are more prone to death from infection but otherwise 
have no difference in lifespan up to a year (Sha et al., 1995). 
NFκB1KO mice were also bred onto the QM background. This results in mice that possess B 
 
cells specific for NP but lacking NFκB1 protein. 
 
 
C-REL
KO
 
This mouse was utilised to test class switching when IRF4
high 
expression is deficient. C-REL 
KO 
mice were as described (Liou et al., 1999). Briefly, the genomic DNA fragment containing 
exon 5, which encodes amino acids 102-130 of the Rel homologous domain, was deleted and 
replaced with an insertion of the neomycin resistance gene. These mice do not express C-REL 
protein and contain equivalent amounts of other NFκB family members such as p50, p65 and 
IκBα. B and T-cell compartments are normal, although T-cell proliferation is defective. 
 
 
eYFP reporter strain 
This strain was first described in 2001 (Srinivas et al., 2001). In brief: a targeted insertion of 
eYFP into the ROSA26 locus preceded by a loxP-flanked stop sequence leads to ubiquitous 
expression of this autofluorescent protein when crossed with transgenic strains expressing Cre 
in a ubiquitous pattern (β-actin-Cre). This allows the tracking of eYFP+ cells following 
transfer into non-EYFP
+ 
hosts. These mice were crossed with QM mice to produce QM x 
eYFP
+
. These were then crossed with NFκB1KO or CRELKO to produce QM x NFκB1KO 
eYFP
+ 
or QM x CREL
KO 
eYFP
+ 
mice. 
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2.3 Antigens and Immunisations 
 
Immunisations were performed intravenously (i.v) or intraperitoneally (i.p). Mice were 
primed with 50 µg of alum precipitated chicken γ globulin (CGG, Sigma) per mouse i.p. This 
was prepared by mixing one part CGG to one part 9 % aluminium hydroxide (alum). The pH 
was adjusted to 6.5 with NaOH, and left in the dark at room temperature for one hour to 
precipitate. This was followed by two washes in sterile pH 7.4 1x phosphate buffered saline 
 
 
(PBS) in a centrifuge. After which the precipitated CGG was re-suspended to a final volume 
of 200 µl/mouse in PBS with 10
7 
Bordetella Pertussis (Dako) per mouse for i.p injection. 
Secondary responses were induced via immunization with 50 µg of 4-Hydroxy-3- 
nitrophenylacetyl (NP) conjugated to CGG in a volume of 200 µl of PBS per mouse. NP- 
CGG was prepared by Ms Chandra Raykundalia. Briefly NP-OSu (Cambridge Research 
Biochemicals, UK) was dissolved in dimethylformamide (DMF) (Sigma, Poole, UK) at 200 
mg/ml. CGG (Sigma) was dissolved in PBS at a concentration of 5 mg/ml. 200 µl of NP in 
DMF was added to 1 ml of CGG solution followed by incubation for 2 hours at room 
temperature on a rotating mixer. Protein was dialysed against PBS pH 7.4. The resulting 
conjugation ratio is NP18-CGG. 
For the study the of TI-II responses, sterile NP-Ficoll (Biosearch Technologies, Novato, CA) 
 
was diluted in sterile PBS to a concentration of 30µg in 200µl of PBS per mouse. This was 
administered i.p. 
Sheep red blood cells (SRBC, TCS Biosciences) were injected i.v at 2x10
8
/200µl. SRBC were 
 
washed three times and resuspended in sterile PBS. 
 
Mice were sacrificed at the indicated time points and spleen and whole blood harvested. 
 
 
2.4 Tissue Sections 
 
Spleens were harvested from sacrificed mice at time points indicated and immediately frozen 
in liquid nitrogen (N2) before storage at -80°C until required.  When ready for use, tissues 
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were mounted on a chuck through a bed of pre-cooled OCT compound (Bright Instruments, 
Huntingdon, UK) and 5 µm sections obtained on a cryostat (Bright Instruments, Huntingdon, 
UK) and mounted onto multispot glass slides (Hendley, Essex). Sections were air dried under 
a fan at room temperature for one hour and then directly frozen or fixed in cold acetone (4°C) 
for 20 minutes before further air drying at room temperature for 10 minutes. Slides were 
stored in polythene bags at -20°C until ready for use. 
2.5 Immunohistochemistry 
 
Frozen sections were allowed to reach room temperature and rehydrated in Tris Buffer (pH 
7.6: Table  2.3)  for  10  minutes.  For  AID  and  IRF4  staining  sections  were  fixed  in  4% 
paraformaldehyde for 20 minutes before washing in Tris buffer supplentented with 0.1% 
saponin (Sigma). Appropriately diluted primary antibodies (Table 2.1) were added, and slides 
were placed in an incubation chamber for 1 hour at room temperature. Sections were washed 
again in two changes of Tris buffer for 10 minutes before addition of secondary antibody for 
45 minutes at room temperature. Secondary antibodies (Table 2.2) were pre-adsorbed for 30 
minutes with normal mouse serum to remove any non-specific binding. Tertiary stains were 
used when necessary and incubated as per secondary antibodies. Sections were again washed 
for 10 minutes before the addition of Streptavidin complex (Vector Laboratories Inc, 
Burlingame) pre-mixed 30 minutes before use. Stains were developed with 3,3 
diaminobenzidine tetrahydrochloride (DAB) for horseradish peroxidise conjugated antibodies. 
After washing for 5 minutes in Tris buffer (pH 7.6) slides were developed with fast blue for 
biotinylated antibodies. Both substrates are made up freshly before use. After washing in 
distilled water, slides were mounted with immunomount (Thermo, Basingstoke, UK). 
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Table 2.1 Primary antibodies used in immunohistochemical staining 
 
Target Isotype Dilution Clone Supplier 
AID Rat anti-Human/ms 1/50 mAID-2 eBioscience 
BCL6 Rb anti-ms 1/30 N-3 Santa-Cruz  Biotechnology 
CD3 Rat anti-ms 1/1000 17A2 Gift  of  Professor  Peter  Lane 
(University of Birmingham) 
FDC-M1 Rat anti-ms 1/300 FDC-M1 BD PharMingen 
Idiotype 
17.2.25 
Rat anti-ms 1/100 R2.438.8 T. Imanishi-Karni 
IgD Shp anti-ms 1/1500 Polyclonal Abcam 
IgD Rat anti-ms 1/1000 11-26C.2a BD PharMingen 
IRF4 Goat anti-ms 1/200 M-17 Santa Cruz 
Ki67 Rb anti Ms 1/400 N/A J. Gerdes, Germany 
NP NP conjugated Shp 1/2500 N/A Gift  of  Professor  Peter  Lane 
(University of Birmingham) 
 
 
 
 
 
Table 2.2 Secondary and tertiary antibodies. 
 
Antibody  specificity Dilution Supplier 
Donkey anti-sheep biotin 1/100 The Binding Site 
Donkey anti-sheep peroxidase 1/100 The Binding Site 
Rabbit anti-rat peroxidase 1/50 Dako 
Rabbit anti-rat biotin 1/600 Dako 
Sheep anti-rat biotin 1/400 The Binding Site 
Swine anti rabbit biotin 1/400 The Binding Site 
Swine anti-rabbit Igs 1/100 Dako 
Rabbit PAP 1/100 Dako 
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Table 2.3 Buffers and substrates required for immunohistochemical staining 
 
Buffer  
Tris buffer pH 7.6 1.5L Physiological NaCl 
1.5L 0.1M Hcl 
1.0L 0.2M Tris 
Tris Buffer pH 9.2 As for Tris buffer pH 7.6 but made to pH 9.2 
Peroxidase  Substrate One 15mg tablet of DAB (Sigma) is dissolved in 15mls of TBS pH 
 
7.6. Filter 10mls into a clean universal and add one drop of 30% 
hydrogen peroxide solution (sigma) to activate the enzyme. 
Alkaline Phosphate Substrate 8mg of Levamisole (-)-tetramisole hydrochloride (Sigma) is 
dissolved in 10mls of Tris buffer pH 9.2. 4mg of naphthol AS-MX 
phosphate (Sigma) is then dissolved in 370µl of dimethyl 
formamide (Sigma) in a glass bijoux. This was then added to the 
centre of the Levamisole solution. To this 10mg of fast blue BB salt 
(Sigma) was added and the solution filtered. 
 
 
 
2.6 Assessment of spleen and germinal centre size. Quantification of antigen specific B 
cells and plasma cells (NP
+
). 
Slides were stained for NP, active Caspase3 and BCL6, and counterstained for IgD. 
 
Germinal centres were identified as IgD
- 
areas surrounded by an IgD
+ 
follicular mantle. The 
GC area was quantified by counting the number of intercepts on a 100mm
2 
eyepiece graticule 
at a magnification of x10. Numbers of NP specific plasma cells were counted in the red pulp 
over a 100mm
2 
area at x25 magnification and expressed as the average number of cells 
counted per 100mm
2 
section at a magnification of x 25. The size of the total spleen section 
was measured by counting intercepts on a 100mm
2 
eyepeice graticule at x4 magnification. 
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2.7 Immunofluorescent staining 
 
Frozen tissue sections were cut at 5 µm. Sections were firstly washed in PBS for 5 minutes 
before adsorption with 10% goat serum in PBS for 10 minutes. Antibodies were diluted in 
PBS supplemented with 10% BSA and incubated with sections in a dark shaking chamber at 
room temperature. Primary antibodies were added for one hour with the exception of anti- 
AID which was added overnight at 4°C. Sections were washed for 5 minutes in PBS and 
subsequent antibody steps were added for 45 minutes. Sections were mounted with Prolong® 
Gold antifade reagent (Life technologies). Slides were cured at room temperature in the dark 
for 24 hours then stored at −20°C. Visualisation of staining was performed on a Leica 
DM6000 microscope. Images were processed with ImageJ software. 
Table 2.4: Primary antibodies not listed for IHC staining 
 
Antibody  specificity Dilution Clone Supplier 
B220 Rat anti-ms 1/300 RA36B2 BD bioscience 
CD11c Hamster anti-ms 1/500 MCA1369 ABD serotec 
FDC-M2 Rat anti-ms bt 1/200 FDC-M2  
IgG Rat anti-ms 1/200 Polyclonal Serotec 
IgM Gt anti-ms FITC 1/100 1021-02 Southernbiotech 
MOMA-1 Rat anti-ms 1/30 Moma-1 Abcam 
 
 
Table 2.5: Secondary antibodies for immunofluorescent staining 
 
Antibody  specificity Dilution Supplier 
Dky anti rat cy3 1/300 Jackson Immunoresearch 
Rb anti-bt 1/200 1/200 Dako 
Gt anti-hmstr Cy5 1/150 Jackson Immunoresearch 
Dnky anti-sheep Cy5 1/200 Jackson Immunoresearch 
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2.8 Quantification of AID protein levels by immunofluorescence 
 
Following staining of tissue sections with anti-AID, images were captured using a Leica 
DM6000 fluorescent microscope. Images were captured using the same exposure settings for 
all pictures. QM BCR expressing B cells within follicles were measured for their expression  
of AID protein by drawing gates around the area of interest within an individual cell and 
quantifying the median fluorescent pixels. This is proportional to the quantity of protein 
within the cell. 
2.9 Measurement of serum antibody titres 
 
(a) Serum preparation 
 
For analysis of antibody, blood samples were collected at times of sacrifice of each animal 
and allowed to clot for 1 hour in a 37°C incubator. Serum was separated from clotted blood 
by centrifugation at 265 x g for 5 minutes. 
(b) ELISA 
 
96 well flat-bottomed Nunc Maxisorp plates (Fisher) were coated with 100 µl of NP15-BSA 
(to detect NP specific antibodies of all affinities) or NP2-BSA (to detect high affinity NP 
specific antibodies) at a concentration of 5 µg/ml in coating buffer (Table 2.4). Conjugated 
proteins were prepared by Mrs C Rayundalia. 
Plates were washed x3 in wash buffer, then 200 µl of blocking buffer added for 1 hour in a 
37°C incubator. Plates were washed again in wash buffer x3 before the addition of serum 
(1:10 or 1:50 starting dilution) in tripling dilutions made up in dilution buffer (Table 2.6). 
Plates were incubated for a further hour at 37°C and after washing x3 in wash buffer, 100 µl 
of the diluted AP conjugated antibody was added (Table 2.7). After one hour at 37°C the 
wells were washed x3 and 100 µl of substrate solution added to each well (Table 2.6). After 
developing in a 37°C incubator the absorbance of the plates was measured at 405nm. 
Standard calibration curves were plotted from the negative and positive control sera, and the 
43  
test serum titres calculated as a relative value of these standard controls.  Development was 
between 20 minutes and 2 hours. 
 
 
Table 2.6 Substrates and Buffer solutions required for ELISA 
 
Buffer  
Coating Buffer pH 9.6 Dissolve 1.95g (0.015M) Na2Co3     and 2.93g (0.035M) NaHCO3  in 1L of 
distilled H2O. 
Wash buffer 0.1M PBS (pH 6.8) with 15.6g of NaH2PO4x2H2O in 1L of distilled water 
Blocking buffer 0.1M PBS + 1% BSA (Sigma) 
Dilution Buffer 0.1M PBS + 1% BSA + 0.05% Tween (Sigma) 
Substrate Solution Dissolve NpNN (N2770 Sigma) in 20ml distilled H2O 
 
 
Table 2.7 Antibodies utilised in ELISA 
 
Antibody  Specificity Dilution Supplier 
Goat anti-mouse IgG 1:1000 SouthernBiotech 
IgG1 1:1000 SouthernBiotech 
IgG1a 1:500 BD bioscience 
IgG2a 1:1000 SouthernBiotech 
IgG3 1:1000 SouthernBiotech 
IgM 1:2000 SouthernBiotech 
IgMa 1:500 BD bioscience 
 
 
 
2.10 Flow cytometry staining 
 
Spleens were collected into cold RPMI-1640 (Sigma) supplemented with 10% heat 
inactivated fetal calf serum (HIFCS) with 1% penicillin/streptomycin solution (sigma). 
Splenocytes were dissociated from the splenic capsule through a 70µm nylon mesh cell 
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strainer (Falcon) in a sterile 6 well culture plate (Falcon). Cells were re-filtered back through 
the 70µm cell strainer and washed twice in a centrifuge with cold RPMI. All procedures were 
carried out at 4°C or on ice to halt the cell cycle reduce cell death. Numbers of cells were 
calculated using a haemocytometer and approximately 1x10
6  
cells were used for staining in 
100µl of FACS buffer (Sterile PBS pH 7.4 supplemented with 0.5% FCS and 0.2mg EDTA). 
Antibodies used were fluorochrome conjugated or biotinylated for use with a fluorochrome 
conjugated secondary antibody. Splenocytes were incubated with purified anti-CD16/32 to 
block non-specific antibody binding by Fc receptors. After incubation with primary antibody 
(see table 2.8) for 20-30 minutes, cells were washed twice in cold FACS buffer (1% fetal calf 
serum with 2mM EDTA in sterile PBS) and centrifuged to form a pellet. After removal of the 
supernatant, cells were resuspended in FACS buffer and stored in the dark at 4°C until 
analysis, or if required, a secondary antibody was added as described for the primary. In 
addition single colour controls were included for compensation and a negative control 
including secondary antibodies if used. Flow cytometric analysis was performed using a Dako 
Cyan analyser and FlowJo software (FlowJo, Ashland, OR). The number of events collected 
was dependent upon the frequency of the cell population of interest but was usually around 
3x10
5
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Table 2.8 Antibodies used for flow cytometric analysis 
 
Antibody  specificity Dilution Clone Supplier 
AID 1/50 m-AID-2 eBioscience + Lightning-Link PerCP/Cy.5 
(Innova  Biosciences) 
B220-Pacific Blue 1/50 RA3-6B2 BD Pharmingen 
B220-PE-Cy5.5 1/300 RA3-6B2 BD pharmingen 
CD16/32 1/200 24g2 BD Pharmingen 
CD138-APC 1/100 281-2 BD Pharmingen 
CD138-bt 1/100 281-2 BD Pharmingen 
CD138-PE 1/400 281-2 BD Pharmingen 
CD138-Brilliant  violet 1/100 281-2 Biolegend 
CD38-Pacific Blue 1/400 90 BD Pharmingen 
CD38-Alexa647 1/1000 90 Biolegend 
CD69-APC 1/200 H1.2F3 eBioscience 
CD62L-PeCy7 1/400 MEL-14 eBioscience 
CD86-PerCP-Cy5.5 1/400 GL1 eBioscience 
GL7-FITC 1/100 MP1-22E9 BD Pharmingen 
Fas-PE-Cy7 1/100 Jo2 BD Pharmingen 
IgG1-APC 1/100 X56 BD Pharmingen 
IgG3-PeCy7 1/400 Polyclonal Southern Biotech 
NP-PE 1/30,000 N/A Gift of Professor P Lane 
 
 
In addition, annexin V-Cy5 protein and 7AAD for FC were obtained from BD biosciences 
and used according to the manufacturers protocol. 
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2.11 Intracellular staining for flow cytometric analysis 
 
For intracellular staining of IRF4 and AID, cells were washed and stained as in section 2.7. 
After two washes with FACS buffer cells were fixed and permeabilised in one step with 
Fixation/permeabilisation buffer (paraformaldehyde and saponin) (BD Pharmingen) followed 
by two washes with permeabilisation wash (Fetal bovine serum plus saponin) (BD 
Pharmingen) and incubation for 30 minutes with goat anti-mouse IRF4 (1/200) followed by 
anti-goat Cy5 (1/500), or rat anti-mouse AID-PerCP-Cy5.5 (1/50). Rat anti-AID was 
conjugated to PerCP-Cy5.5 using Lightning-Link PerCP/Cy5.5 (Innova Biosciences) 
according the manufacturers instructions. 
2.12 Cell transfer 
Cells were isolated from the spleen as described in section 2.10. Red cells were lysed with 
ACK lysing buffer (life technologies) for 2 minutes at room temperature then washed in 
supplemented media as before. Splenocytes were counted and resuspended to a density of 
10
7
cells/90 µl in sterile de-gassed MACS buffer (0.5% BSA, 2mM EDTA in PBS without 
Ca
2+ 
Mg
2+
) and labeled with 10µl of anti-CD43 beads per 10
7 
splenocytes (Miltenyi Biotech). 
B-cell enrichment was performed as per manufacturers instructions by incubation at 4°C for 
15 minutes followed by one wash in MACS buffer and centrifugation at 300g for 10 minutes. 
Supernatant was removed completely and splenocytes were resuspended to 500µl /10
8 
cells. 
Splenocytes were passed through a magnetic column (Miltenyi Biotech) to collect unlabeled 
CD43
− 
resting B cells. Purified B cells were stained with NP-PE and anti-B220-PE-Cy5.5 
(Table 2.6) and analysed by flow cytometry to obtain the percentage of antigen specific B 
cells. B cells were resuspended in sterile PBS to give a minimum concentration of 1x10
5 
antigen specific B cells per 200µl for carrier primed mice and 5x10
5 
antigen specific B cells 
per 200µl for TI-II responses. 200µl of cell suspension was injected i.v. into the tail vein per 
mouse. Where stated, cells were labeled following MACS with CellTrace
® 
(life technologies) 
according to the manufacturers protocol. 
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2.13 mRNA detection 
 
 
Total mRNA extraction 
 
One 8 µm section of spleen was cut on a cryostat and stored at -80°C until use. RNA was 
extracted with the RNeasy kit (Qiagen, Crawley, UK) after homogenization of tissue using a 
QIAshredder column (Qiagen) according to the manufacturer’s instructions. The resulting 
RNA was eluted into 30µl of RNAse free water and stored at -80°C until required. For 
mRNA extraction from FACS sorted cell populations, cells were washed once with ice cold 
PBS and pelleted at 6000rpm for 15 minutes. The supernatant was discarded and the dry cell 
pellet was snap frozen in liquid N2 and stored at -80 °C until processing for RNA extraction. 
Cells were homogenized with a QIAshredder column (Qiagen) according to the 
manufacturer’s instructions RNA was extracted with an RNeasy micro kit (Qiagen, Crawley, 
UK). 
Production of cDNA 
 
30µl of RNA solution was mixed with 3µl of random oligo-dN6 (1µg/µl) (Promega) and 
denatured at 70°C for 10 minutes. Samples were then cooled by placing on ice. After this 
27µl of reverse transcription mix is added as follows: 
 
 
12µl 5x First strand buffer (Invitrogen) 
6µl 0.1M DTT 
3µl dNTP (10mM) (Invitrogen) 
 
3µl Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen) 
1.5µl RNAse inhibitor (Promega) 
1.5µl RNAse free H20 
 
This is mixed and heated at 41°C for one hour followed by 90°C for 10 minutes to inactivate 
the reverse transcriptase. cDNA was then stored at -20°C until required. 
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Semiquantitative real time PCR 
 
1.5µl of cDNA template was added to each well of a 384 well plate (Applied Biosystems) 
followed by primers and probes for the appropriate sequence to be amplified (table 2.9 and 
TaqMan universal PCR mastermix (Applied Biosystems) before covering the plate with clear 
adhesive film (Applied Biosystems) and centrifuged for 5 seconds at 1200rpm to remove any 
air bubbles. In addition to amplifying the target sequence, an internal housekeeping gene 
(β-actin or β2-Microglobulin) were also amplified to normalize the result for the amount of 
starting template. These were labelled with Yakima Yellow so as not to interfere with the 
FAM-labelled probes. Real-time PCR was performed in an ABI 7900 Real-time PCR analyser 
(Applied Biosystems) with the following cycling programme: 
 2 minutes at 50°C 
 
 10 minutes at 95° C 
 
 
 
Followed by 40 cycles of: 
 
 
 
 15 seconds at 95°C 
 
 1 minute at 60°C 
Data analysis was performed with SDS 2.2 software (Applied Biosystems). Thresholds (i.e 
cycle number (Ct) at which the signal for the housekeeping and target genes were recorded) 
were set within the logarithmic phase of the cycle. The relative quantity of target gene mRNA 
was calculated by subtracting the Ct for the housekeeping gene from the Ct of the target gene 
(ΔCt) and then calculating 2-ΔCt. 
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Table 2.9 Primers and probes required for real time PCR 
 
Name of target sequence Nucleotide  sequence 
IgG1 switch 
transcripts 
Forward 
Primer 
CGAGAAGCCTGAGGAATGTGT 
Reverse Primer GGAGTTAGTTTGGGCAGCAGAT 
TaqMan probe TGGTTCTCTCAACCTGTAGTCCATGCCA 
IgG3 switch 
transcripts 
Forward 
Primer 
GACCAAATTCGCTGAGTCATCA 
Reverse Primer ACCGAGGATCCAGATGTGTCA 
TaqMan probe CTGTCTATCCCTTGGTCCCTGGCTGC 
Recombined 
gamma3 
heavy chain 
transcript 
Forward 
Primer 
TCTGGACCTCTCCGAAACCA 
Reverse Primer ACCGAGGATCCAGATGTGTCA 
TaqMan probe CTGTCTATCCCTTGGTCCCTGGCTGC 
Prdm1 Forward 
Primer 
TTTGGAGGATCTGACCCGAAT 
Reverse Primer CTCCACCATGGAGGTCACATC 
TaqMan probe CGCTGATGTCGAACCTCTCAATTTCTTCA 
Aicda Forward 
Primer 
GTCCGGCTAACCAGACAACTTC 
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 Reverse Primer GCTTTCAAAATCCCAACATACGA 
TaqMan probe TGCATCTCGCAAGTCATCGACTTCGT 
Irf4 Forward 
Primer 
GGAGGACGCTGCCCTCTT 
Reverse Primer TCTGGCTTGTCGATCCCTTCT 
TaqMan probe AGGCTTGGGCATTGTTTAAAGGCAAGTTC 
 
 
 
2.14 In Vitro B-cell stimulation 
CD43
− 
resting B cells were enriched from total splenocytes as described in section 2.12. B 
cells were added to a 96-well sterile u-bottomed plate (Corning) at a density of  1x10
5 
cells/well in 200 µl of pre-warmed media containing 10% heat inactivated fetal calf serum 
(HIFCS) with 1% penicillin/streptomyacin solution (sigma) and stimulated with 2 µg per well 
of NP-Ficoll. At selected timepoints after incubation with antigen, cells were harvested by 
centrifugation. This was followed by either fixation with Fixation/permeabilisation buffer 
(BD Pharmingen) as described in section 2.11 for intracellular IRF4 staining, or by washing 
with ice cold PBS and snap freezing in liquid N2 for quantification of IRF4 mRNA levels by 
real-time RT-PCR. 
 
 
2.15 Preparation of miR-125b over-expressing QM B cells 
 
Lethally irradiated C57 mice were reconstituted with QM bone marrow over-expressing the 
micro-RNA miR-125b, these mice were directly immunised or used as donors for cell transfer 
experiments. Bone marrow transfections and chimera mice were prepared by Kyoko 
Nakamura (University of Birmingham). In brief: PlatE cells were infected (Morita et al., 
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2000) with an MSCV-based retrovirus plasmid vector using Lipofectamine 2000 (Invitrogen) 
in accordance with manufacturer’s instructions. This was either MIG control vector or 
contained the 500-bp gene segment for the miR-125b hairpin. The 500bp miR-125b 
containing gene segment was amplified with the primers: 
5’-agatatgtgtgttgcatatacagggctg-3’ 
5’-gaattcatctaacaatggaagcctcaaggg-3’ by AccuPrime Taq DNA polymerase, High Fidelity 
(Invitrogen). The DNA fragment was cloned into BglII and EcoRI site of the MIGR1 vector. 
Chimeras were prepared as follows; QM mice were injected with 5-fluorouracil (5-FU) 
(Sigma) at a concentration of 150 mg/kg body weight. 5-FU has a cytotoxic effect on dividing 
bone marrow progenitors; therefore after treatment with 5-FU, bone marrow is enriched for 5- 
FU resistant stem cells (Wieder et al., 1991). Femurs were harvested four days after 5-FU 
treatment and bone marrow was flushed out of the bone using a syringe containing 
supplemented media (RF10 supplemented with 10% FCS, 1% penicillin/streptomycin 
solution and 2 mM L-glutamine). Following red cell lysis, bone marrow cells were washed 
and resuspended in supplemented media before filtration through a 70 µm cell strainer. Sca1 
was used as a marker to isolate hematopoietic stem/progenitor cells (Spain and Mulligan, 
1992). Bone marrow cells were incubated with anti-Sca1-PE antibody for 30 minutes on ice at 
a concentration of 1 µl anti-Sca-1-PE per 10
7 
cells in 200 µl of MACS buffer. Cells were 
washed with 10 ml of MACS buffer followed by resuspension in 40 µl MACS buffer and 10 
µl of anti-PE magnetic beads per 10
7 
cells for 20 minutes at 4°C. Cells were washed before 
passing through a magnetic MS column as per manufacturer’s instructions. Purified Sca-1+ 
cells were plated into 24 well plates with SCF (50 ng/ml), IL6 (50 ng/ml), IL3 (10 ng/ml). 
Cells were incubated at 37°C at 5% CO2 density. Plasmid-containing supernatant from PlatE 
cells was then used to infect QM bone marrow before transfer into lethally irradiated C57 or 
RAG
KO 
host mice. 
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2.16 Statistical analysis 
 
Statistical  significance  was  calculated  using  a  one-tailed  Mann-Whitney  U  test  where 
 
* p=<0.05, ** p=<0.01, *** p=<0.0001. A one-tailed test was deemed appropriate in order to 
test whether CSR and AID induction were reduced when intermediate or high-level IRF4 are 
blocked. 
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3: INDUCTION OF IRF4 AND AID EXPRESSION 
FOLLOWING B-CELL ACTIVATION 
 
 
3.1 Introduction 
 
Ig class switching is a process that occurs with high frequency within the germinal centre (Liu 
et al., 1996). However, this process can also occur early in the B-cell response before the 
formation of germinal centres (Marshall et al., 2011; Toellner et al., 1996). The initiation of 
CSR by extrafollicular B blasts is preceded by the upregulation of Irf4 mRNA (Sciammas et 
al., 2006) and Aicda mRNA (Honjo et al., 2002). 
 
 
Activation-induced cytidine deaminase (AID) protein, encoded by the Aicda gene, was first 
identified by the subtraction of cDNAs derived from switch-induced and uninduced murine B 
lymphoma CH12F3-2 cells, the majority of which switch to IgA following stimulation. AID 
expression was subsequently found to be restricted mainly to the germinal centre (Muramatsu 
et al., 1999). This protein is required for both class switch recombination (CSR) and somatic 
hypermutation (SHM) (Muramatsu et al., 2000). AID facilitates CSR by deaminating 
deoxycytosines in S regions to create uracils, this creates U:G mismatches. Repair of these 
mismatches leads to the creation of double stranded breaks into the DNA template (Stavnezer 
et al., 2008). 
 
 
IRF4 is a transcription factor that is essential for plasma-cell differentiation (Klein et al., 
2006). Irf4-Cγ1-Cre mice have a conditional knockout of IRF4 in cells that have switched to 
IgG1. Following immunisation, these mice have no defect in germinal centre formation, yet 
completely lack plasma cells (Klein et al., 2006). Although IRF4
KO 
B cells express the 
transcription factor BLIMP-1, which is crucial for plasma-cell differentiation (Turner et al., 
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1994) (Shapiro-Shelef et al., 2003), this is not sufficient for further differentiation into plasma 
cells (Klein et al., 2006). 
 
 
It has previously been shown that IRF4 is differentially expressed in vitro (Sciammas et al., 
2006; 2011). High levels of IRF4 facilitate plasma-cell differentiation, whilst low levels are 
required for Ig class switching (Sciammas et al., 2006). It has recently been shown in our 
group (Zhang Y UOB thesis 2010, Marshall J UOB thesis 2009) that these two phases of 
IRF4 induction  during  the  B-cell  response  correlate  with  certain  stages  of  B-cell 
differentiation. 
 
 
Within the first hours of activation, during B blast migration to the border with the T zone, all 
B blasts upregulate intermediate levels of IRF4 protein. Plasmablasts in contrast, express high 
concentrations of IRF4 protein. 
Our aim was firstly to characterise the expression patterns of both IRF4 and AID during 
extrafollicular B blast and plasmablast differentiation (reviewed in (Maclennan et al., 2003)). 
Secondly, due to the published role of IRF4 for Aicda induction and Ig class switching, to test 
whether there is a correlation between the expressions of these two proteins during the early 
B-cell response. 
 
 
We aimed to address 
 
1. The timing of IRF4 protein and mRNA expression. 
 
2. Whether this correlates with the induction of AID mRNA and protein and the onset of Ig class 
switching. 
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3.2 Results 
 
 
 
 
3.2.1 IRF4 protein and mRNA are rapidly induced in vivo upon antigen-stimulation 
To determine the timing of IRF4 protein and mRNA induction, quasi-monoclonal x C57BL/6 
F1 mice (QMxB6 mice) were immunised with the TI-II antigen NP-Ficoll. QM mice 
(Cascalho et al., 1996) have one copy of a VDJ recombined heavy chain gene that codes for a 
heavy chain specific for NP (Grosschedl et al., 1984), a Jh deletion on the other allele (Chen 
et al., 1993a) and kappa light chain deficiency (Chen et al., 1993b). Due to the high frequency 
of antigen-specific B cells in these mice (60-80%) and the massive response induced post- 
immunisation, tracking of individual activated cells is difficult. Therefore, QM mice were 
crossed with B6 mice to produce offspring with one copy of the rearranged NP-specific Ig 
heavy chain and one copy of the kappa allele (QM
NP/WT κ-/WT) which results in a frequency of 
antigen-specific B cells of around 5-10% (Vinuesa et al., 2001). Due to more numerous 
antigen-specific B cells than normally physiologically present prior to immunisation (Less 
than 0.5% of lymphocytes are NP-specific B cells in C57 mice: Chapter 6 Fig. 6.5), sufficient 
numbers of activated cells can be tracked in the first hours and days after immunisation, 
before cell division has expanded the numbers. 
 
 
 
Following immunisation of QMxC57BL/6 mice with NP-Ficoll, IRF4 mRNA was tested in 
whole spleen sections 1, 2, 4 and 8 hours after immunisation by real-time RT-PCR (Figure 
3.1A). IRF4 mRNA is increased by 8x within 1 h, and remains high 2 h post-immunisation. 
IRF4 mRNA levels are slightly decreased at 4 h post-immunisation, however mRNA levels 
remain higher  than  in  non-immunised  spleens  by  nearly  3x.  IRF4  is  also  expressed  by 
activated macrophages (Satoh et al., 2010) and T cells (Li et al., 2012) (Bollig et al., 2012). 
To determine the expression of IRF4 within the activated B-cell population, NP-binding B 
cells were sorted before immunisation and 1, 2, 4, 24 and 48 h after activation (Figure 3.1B). 
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In addition, three days after activation, plasma cells (NP-binding, CD138
+
) and germinal 
centre cells (NP-binding, CD138
- 
B220
+
) were tested for IRF4 expression. Similar to whole 
spleen sections, 1 h post-immunisation, IRF4 mRNA is rapidly and strongly induced in sorted 
antigen-specific B cells. IRF4 mRNA levels remain high 2 h post-immunisation before 
decreasing again at 4 h post-immunisation. IRF4 mRNA levels remain largely unchanged 
until B cells differentiate further into germinal centre cells (Figure 3.1B red) and plasma cells 
(Figure 3.1B blue). Germinal centre cells express low amounts of IRF4 mRNA, whereas 
plasma cells express IRF4 mRNA levels similar to that seen at 1 h post-immunisation. 
 
 
In the QM spleen, NP-Ficoll immunisation activates follicular and MZ B cells which migrate 
to the border of the T zone after activation (Vinuesa et al., 2001). Before immunisation, NP- 
binding cells are visible in the marginal zone and the follicle and these cells express low 
levels of IRF4 protein (Figure 3.1C, top panel). Some background plasma cells are located at 
the bridging channel (interphase between T zone and red pulp) and show high IRF4 protein 
levels (Figure 3.1C, top panel, arrow). Four hours post-immunisation, antigen-specific B cells 
have migrated to the border with the T-zone and are expressing IRF4 (Figure 3.1C, bottom 
panel, arrow). Antigen specific B cells remain in the outer T zone until they form germinal 
centres within the follicles or plasma-cell foci in the red pulp. IRF4 protein expression within 
the marginal zone and follicles, outer T zone and both plasma and germinal centre B-cell 
populations were quantified by measuring immunostaining from tissue sections. Within 1 h of 
immunisation, B cells in the marginal zone and follicles upregulate IRF4 protein (Figure 
3.1D). IRF4 protein levels continue to increase until 8h post-immunisation within activated B 
blasts which have migrated to the outer T zone (Maclennan et al., 2003), thereafter IRF4 
protein remains at an intermediate level until differentiation to germinal centre or plasma cells 
occurs four days after immunisation. Germinal centre cells do not express IRF4 protein, 
whilst IRF4 protein levels are high in plasma cells (Figure 3.1D).   Therefore, whilst IRF4 
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mRNA peaks between 1 h and 2 h post-immunisation in both spleen sections and sorted B 
cells, IRF4 protein levels continue to increase to an intermediate level, until expression of 
both IRF4 protein and mRNA stops in germinal centre B cells. Alternatively, upon plasma 
cell differentiation, IRF4 mRNA is upregulated to levels seen in B blasts 1 h post- 
immunisation, whereas IRF4 protein is expressed at a much higher level than seen in B blasts 
during the first hours and days of activation. 
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B cells internalise their BCR immediately after activation (Malhotra et al., 2009), this makes 
identification of antigen-specific B cells by staining of their antigen-specific B-cell receptors 
difficult. To address this problem, QMxB6 mice were immunised with Fluorescein labelled 
NP-Ficoll (NP-Fluorescein-AECM-Ficoll). This enabled the identification by flow cytometry 
(FC) of FITC
+ 
cells that had bound antigen in vivo. In addition, splenocytes were incubated 
with PE conjugated with the hapten NP (NP-PE) and stained with antibodies against B220 
and IRF4 0, 1, 2 and 4 hours after immunisation. FITC
+ 
and B220
+ 
B cells (Figure 3.2A left 
plots) were tested for binding to NP-PE. The intensity of NP-PE staining was found to 
decrease in the hours following immunisation probably due to receptor internalisation (Figure 
3.2A right plots). NP-PE binding B220
+ 
cells (pre-immunisation) or FITC
+ 
B220
+ 
B cells 
(post-immunisation) were tested for expression of intracellular IRF4 protein by flow 
cytometry (FC). The median fluorescence intensity of IRF4 staining within this population 
was significantly increased (p<0.05) by approximately 2x within 1h of immunisation (Figure 
3.1B and C). The median fluorescence intensity continues to increase by another 30% 
between one and two hours post-immunisation and by 70% between two and four hours post- 
immunisation (p<0.05). The median fluorescence intensity of IRF4 staining increases by a 
median of 3.4x between B cells pre-immunisation and four hours post-immunisation (Figure 
3.2B and C). To address whether IRF4 protein levels increase post-immunisation, or whether 
the increased median fluorescence intensity of IRF4 reflects an increase in the proportion of 
IRF4
+ 
cells, B220
+
, NP-binding B cells were gated which expressed >95% the IRF4 protein 
expressed by NP-binding B220
+ 
cells pre-immunisation (Figure 3.2D). The percentage of NP- 
binding IRF4
+ 
cells increased within 1 h of immunisation by >2x. The percentage of NP- 
binding IRF4
+ 
cells further increased at 2 h and 4 h post immunisation. Therefore increased 
median fluorescent intensity of IRF4 protein following immunisation was found to be due to 
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an increase in the percentage of IRF4 expressing B cells. FITC
+
B220
+ 
B cells (antigen- 
activated) or B220
+  
B cells from non-immunised mice were FACS sorted using the gating 
strategy in Figure 3.2A and tested for expression of IRF4 mRNA by real time RT-PCR 
(Figure 3.2E). IRF4 mRNA is strongly increased within one hour of immunisation (p<0.05) 
with median mRNA levels increasing by 6.6x. In contrast to protein levels, which continue to 
increase after one hour, mRNA levels significantly decrease from the peak levels at one hour. 
Between one and two hours post-immunisation, IRF4 mRNA levels decrease by 16% and 
decrease by a further 20% between two and four hours post-immunisation (p<0.05). However 
within four hours of immunisation, IRF4 mRNA remains around 4x higher than that 
expressed in non-activated cells. This indicates that IRF4 protein levels are transcriptionally 
regulated. Slightly lower transcription levels follow the initial strong burst of IRF4 
transcription that occurs within the first hour. This facilitates intermediate expression levels of 
IRF4 protein in B blasts. 
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3.2.2 BCR stimulation is sufficient to rapidly induce IRF4 mRNA and protein 
To test whether the microenvironment is important for B-cell activation and IRF4 induction, 
or whether IRF4 can be induced solely via BCR stimulation in vitro, B cells were incubated 
for 0.5, 1, 2, 4 and 48 h with NP-Fluorescein-AECM-Ficoll. To exclude contamination by 
other cell types capable of capturing FITC-conjugated polysaccharides (Sallusto et al., 1995) 
such as dendritic cells, CD43
−  
resting B cells were purified by MACS for stimulation. 
Expression of the B-cell marker B220 was analysed on total CD43
− 
purified splenocytes to 
confirm B-cell purity. More than 90% of CD43
− 
purified splenocytes expressed B220 (Figure 
3.3A). Post-stimulation, cells were fixed and incubated with NP-PE and stained with 
antibodies specific for B220 and IRF4. FITC
+
, NP-binding B220
+ 
cells were analysed by FC 
(Figure 3.3B). Antigen specific B cells express little IRF4 before stimulation (Figure 3.3C 
and D). Within 30 minutes of stimulation however, IRF4 protein is significantly increased by 
a median of 90%. Similar to that seen in vivo (Fig. 3.2C) there is a significant increase in 
IRF4 protein expression by one hour post-activation (p<0.05) (Figure 3.3C and D). There is a 
further significant increase in IRF4 protein by 1.6x between four and 48 hours after activation 
of B cells in vitro (p<0.05). IRF4 protein is upregulated to a similar degree in vitro 30 minutes 
after antigen stimulation as that observed in vivo one hour post-immunisation. This more 
rapid IRF4 upregulation in vitro may be due to an acceleration of B-cell activation, as similar 
IRF4 protein levels are observed after 4 h whether B cells were stimulated in vitro or in vivo 
(140% in vitro vs 180% in vivo). After i.p immunisation, antigen must travel to the spleen in 
order to activate B cells (Kool et al., 2008) and this delay in vivo may explain the relatively 
faster IRF4 upregulation in vitro. 
 
 
 
IRF4 mRNA peaks within one hour in vivo (Figure 3.2E). To test the kinetics of IRF4 mRNA 
expression  in vitro, real-time  RT-PCR  was  performed  on  B  cells  stimulated  with  NP- 
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Fluorescein-AECM-Ficoll. IRF4 mRNA was significantly increased (p<0.05) by a median of 
5.9x within 30 minutes of activation in vitro (Figure 3.3E). IRF4 mRNA further increases 
significantly by 3x one hour post-activation and 1.60x two hours post-activation (p<0.05). 
This represents a median increase above baseline of 50x within two hours of activation. This 
is followed by a small (40%) but significant decrease in IRF4 mRNA from the peak levels 
observed at two hours post-activation. Therefore in vitro IRF4 protein levels increase within 
30 minutes of antigen-activation and continue to increase until 1 h post-activation after which 
levels remain steady before further increasing 48 hours after antigen activation. Whereas in 
vivo, protein levels increase within 1 h of immunisation but continue to increase at 2 and 4 h 
after immunisation. mRNA levels in vitro increase within 30 minutes and are highest 2 h after 
incubation with antigen before decreasing at 4 hours after activation. This is similar to IRF4 
mRNA expression in vivo where levels peak 1-2 h after immunisation but are decreased by 4 
h post-immunisation. 
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3.2.3 In later stage B-cell differentiation IRF4 protein increases within the plasmablast 
population whereas germinal centre B cells are IRF4 negative 
To test IRF4 expression in emerging germinal centre B-cell and plasmablast populations, QM 
mice were immunised with NP-Ficoll as described before. Spleens were processed by FC 2, 3, 
and 4 d after immunisation. B cells were stained with antibodies against B220, IRF4, FAS 
and CD138, followed by incubation with NP-PE. Activated B cells were gated as NP-binding 
B220
high/int 
(Fig. 3.4.A). Within two days of immunisation, a small proportion of antigen- 
specific B cells express CD138 protein (Figure 3.4A top panel) and these express higher 
levels of IRF4 protein. This population appears at a similar percentage three days post- 
immunisation (Figure 3.4A middle panel), but is increased four days after immunisation 
(Figure 3.4A bottom panel). In addition, a B220
high
, NP-binding FAS
+ 
germinal centre 
population has developed (Figure 3.4A, bottom panel). Whilst non-activated B cells express 
low amounts of IRF4 protein, IRF4 protein is up-regulated two days after immunisation 
within the NP-binding population (Figure 3.4B, purple). By three days post-immunisation 
there is a slight loss of IRF4 expression in the majority of B cells (Figure 3.4B, green), while 
a small population of cells have increased IRF4 protein levels further. These IRF4 low and 
high populations correspond to emerging germinal centre B cells and plasmablasts 
respectively. The differential IRF4 expression is more apparent four days after immunisation, 
following  further  differentiation.  Four  days  after  immunisation,  germinal  centre  B  cells 
express similar levels of IRF4 protein to non-activated B cells (Figure 3.4B, blue) whereas 
plasma cells express the highest levels of IRF4 (Figure 3.4B, red). 
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To test whether IRF4 mRNA shows a similar expression pattern, cell sorting experiments 
were performed. Resting CD43
− 
eYFP
+ 
QM B cells were transferred into wild-type hosts and 
immunised with NP-Ficoll i.p. Two hours and two days after immunisation, eYFP
+ 
and NP- 
binding B cells were sorted. Four days post-immunisation, germinal centre B cells (NP-PE
low
, 
B220
high
, FAS
+
) or plasmablasts (NP-PE
high
, B220
low
, CD138
+
) were sorted. Antigen-specific 
B cells were found to significantly upregulate IRF4 mRNA by 6x (p<0.05) within two hours 
of immunisation (Figure 3.4C). IRF4 mRNA then significantly decreases two days post- 
immunisation to 1.8x higher than background (p<0.05). Four days after immunisation, 
germinal centre B cells express similar levels of IRF4 mRNA as non-activated B cells, 
whereas plasma cells express significantly higher amounts of mRNA (Figure 3.4C) (p<0.01). 
3.2.4 Timing of AID mRNA expression 
To follow the timing of Aicda mRNA expression during the earliest stages of the B-cell 
response, QM mice were immunised with NP-Ficoll and RNA extracted from spleen sections 
at selected timepoints. Aicda mRNA levels decrease within 4 h of immunisation (Figure 
3.5A). However QMxB6 mice contain background GC before immunisation, these GC 
rapidly shut down upon the initiation of a specific immune response. Therefore it is likely that 
in frozen tissue sections the Aicda signal is so low in activated B blasts that it is masked by 
background GC, and a specific increase in Aicda can only be detected at 72 hours post- 
immunisation when GC founder cells appear, at this time Aicda mRNA levels are increased 
by around 1.40x compared to two days post-immunisation (Figure 3.5A). To test which B- 
cell populations were expressing Aicda and to remove contamination from non-specific 
background GC, we performed cell sorting. Resting CD43
− 
eYFP
+ 
QM B cells were 
transferred into wild-type hosts as described above and immunised with NP-Ficoll one day 
later. Antigen-specific B cells (two days post-immunisation), germinal centre B cells and 
plasma  cells  (four  days  post-immunisation)  were  sorted  by  FACS  from  the  spleen  as 
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previously described. Aicda mRNA was found to be strongly increased two days post- 
immunisation in activated antigen-specific B cells (Fig. 3.5B). Levels remained high in 
germinal centre B cells four days post-immunisation, whereas plasma cells lost Aicda mRNA 
(Figure 3.5B). Figure 3.5C shows the gating strategy and representative samples of the purity 
of sorted populations. 
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Figure 3.5: Kinetics of AID mRNA expression during  the TI-II response. A: QMxB6 
mice were immunised with NP-Ficoll. RNA was isolated from spleen sections and 
analysed for Aicda mRNA expression by real-time RT-PCR pre-immunisation and 4, 
48, 72 and 96 hours after immunisation. B: eYFP
+
 QM B cells were transferred into 
C57 hosts and immunised with NP-Ficoll. At selected timepoints post-immunisation, 
QM B cells were sorted by FACS, based on the gating in (C). Sorted cells were tested 
for AID mRNA by real-time RT-PCR, relative to B
2
-microglobulin. C: Top panel, 
example of purity of antigen-specific B blasts two days post-immunisation (left) and 
purity post-FACS (right). B cells were sorted as Hoechst
−
, B220
+/int 
eYFP
+
. Middle 
panel: representative plot of pre-sort sample four days after immunisation. Cells were 
gated as Hoechst
−
, plasma cells were defined as B220
low
, CD138
+
,
 
whereas germinal 
centre B cells were defined as B220
high
 NP-binding
low
, FAS
+
. Bottom panel: example of 
purity of germinal centre B cells four days after immunisation.  
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Immunohistochemistry was used to confirm AID protein expression within the spleen. QM 
mice were immunised with NP-Ficoll and spleens collected two or four days later. Two days 
after immunisation, sections were stained with antibodies against IgD and NP or IgD and 
AID. NP-specific B cells are located within the follicles and at the border of the follicles with 
the T zone (Figure 3.6A blue) and AID
+ 
B cells are visible in similar locations (Figure 3.6B 
blue). Four days post-immunisation, large antigen-specific germinal centres have developed, 
these bind low levels of NP compared to plasma cells located in the red pulp (Figure 3.6C, 
blue), and contain some CD3
+  
T cells (Figure 3.6D blue). Germinal centres express high 
levels of AID protein whereas plasma cells are AID
− 
(Figure 3.6E). 
 
 
 
This shows that AID mRNA and protein are induced within two days of immunisation, while 
B cells reside in the follicles and T zone. It is highly expressed in germinal centre B cells, 
while plasma cells do not express AID mRNA any longer, and therefore do not undergo 
further CSR. 
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3.2.5 IRF4 and AID are co-expressed in B blasts two days post-immunisation 
 
 
 
As IRF4 and AID are both expressed within two days of immunisation, we tested whether 
IRF4 expression correlates with AID expression within single cells. AID and IRF4 were 
stained and analysed by FC and immunohistology. 
 
 
Resting QM eYFP
+ 
B cells were transferred into wild-type hosts and immunised with NP- 
Ficoll i.p. Two days later splenocytes were stained with antibodies against B220, AID and 
IRF4 and incubated with PE labelled NP. Activated B cells were defined as NP-binding and 
B220
+ 
and these cells were collected for FC and found to co-express AID and IRF4 protein at 
higher levels than non-antigen specific B cells (Figure 3.7A red vs blue). Similar observations 
were done on splenic B blasts differentiating in situ. Spleen sections were stained with 
labelled antibodies against IRF4 and AID (Figure 3.7B). As described above, two days post 
immunisation; activated B cells are located within B220
+ 
inner follicles near the T-zone, or in 
the outer follicles. Approximately half of activated B blasts express nuclear AID protein 
compared to cytoplasmic AID protein, with slightly more nuclear AID expression when B 
cells are located at the border with the T zone compared to the outer follicle. The cellular 
location of AID protein is one of the mechanisms in which AID function is regulated. AID 
continually shuttles between the nucleus and cytoplasm and whilst it is only active when 
located in the nucleus, it is also more sensitive to degradation (Aoufouchi et al., 2008). The 
export of AID from the nucleus is mediated by CRM1 which binds to a nuclear export signal 
on AID (Geisberger et al., 2009; Ito et al., 2004). AID is also maintained in the cytoplasm by 
a cytoplasmic retention mechanism(Patenaude et al., 2009). Interestingly all AID
+ 
B cells co- 
expressed nuclear  IRF4. After  quantification of  AID and  IRF4 staining  intensity  within 
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individual cells there was found to be a positive correlation between the quantity of AID and 
IRF4 protein (Figure 3.7C). 
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3.3 Summary 
 
IRF4 and AID are expressed within antagonistic gene regulatory networks during terminal B- 
cell differentiation to germinal centre B cells or plasma cells. Plasma-cell differentiation is 
regulated by the transcription factors BLIMP1 encoded by the gene Prdm1 (Turner et al., 
1994) and IRF4(Klein et al., 2006). BLIMP1 (Klein and Dalla-Favera, 2008) and IRF4 (Saito 
et al., 2007) supresses BCL6 which is the master regulator of the germinal centre phenotype 
(Klein and Dalla-Favera, 2008). BCL6 in turn represses Prdm1 (Calame, 2008). Whereas 
IRF4 is required for plasma-cell generation and is not expressed by most germinal centre cells 
with the exception of some centrocytes, AID is highly expressed in the germinal centre with 
higher levels expressed in the GC dark zone (Leuenberger et al., 2010). Here it is required for 
somatic hypermutation and Ig class switching (Muramatsu et al., 2000). Conversely, it is not 
expressed in plasma cells. We  have shown however, that  both IRF4 and AID are also 
expressed at an earlier stage of B-cell activation. IRF4 is expressed within minutes of 
activation, whereas AID is upregulated within two days of immunisation. This occurs whilst 
B blasts are located in the follicles. 
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4: INTERMEDIATE LEVEL IRF4 IS SUFFICIENT FOR 
NORMAL EXTRAFOLLICULAR IMMUNOGLOBULIN CSR 
 
 
4.1 Introduction 
 
In order to test the role of the two expression levels of IRF4 protein for extrafollicular Ig 
CSR, we used mice lacking the transcription factor NFκB1. NFκB1 has been reported to be 
required for the upregulation of IRF4 (Berberich et al., 1994; Saito et al., 2007). Therefore we 
aimed to test: 
1. Whether expression of intermediate or high level IRF4 is altered in mice lacking NFκB1 
 
2. Whether blocking intermediate or high levels of IRF4 led to reduced extrafollicular Ig 
CSR. 
4.1.1 NFκB family members 
 
The NFκB family are pleiotropic transcription factors first described in 1986 (Sen and 
Baltimore, 1986). These factors have been implicated in inflammation (Karban et al., 2004) 
and are required for B-cell activation and differentiation (Saito et al., 2007). 
The NFκB family consists of 5 members: RelA (p65), RelB, C-REL, NFκB1 (p50/p105) and 
NFκB2 (p55/p100) (Caamano and Hunter, 2002). NFkB1 (p50) is synthesised as a large 
precursor of 105 kDa (p105). This precursor is processed to the p50 subunit, whereas NFκB2 
(p52) is processed from a 100 kDa precursor (p100), the active subunits p50 and p52 are 
encoded within the N terminal region of both precursor proteins. Processing of both p100 and 
p105 to p52 and p50 requires cleavage of the C terminus ankyrin repeats which are then 
degraded (Fan and Maniatis, 1991). These ankyrin repeats function as IκB-like inhibitors of 
NFκB. However, a cotranslational mechanism of p50 production has also been described 
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which does not require proteolytic cleavage from p105 (Lin et al., 1998). Proteins of this 
family have the ability to induce or repress gene transcription by binding to DNA regions 
known as κB elements in gene promoters or enhancers. The family is characterised by an N- 
terminal Rel homology domain (RHD) of 300 amino acids which is important for DNA 
binding, nuclear localisation and subunit dimerisation (Figure 4.1). 
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Figure 4 1 The Structure of the NFκB, IκB and IKK families of proteins 
 
 
A: The NFκB family includes RelA (p65), RelB, C-REL, p105 (NFκB1) and p100 (NFκB2). 
p50 and p52 are created from the proteolytic cleavage of p105 and p100 respectively. The 
family are characterised by the presence of a REL-homology domain (RHD). The RHD 
contains the nuclear localisation domain essential for protein function. C-terminal 
transactivation domains (TAD) are only present in the REL subfamily of NFκB. TA1 and 
TA2 are subdomains of the RelA transactivation domain. B: The inhibitors of NFκB family 
(IκB). This family is comprised of IκBα, IκBβ, IκBε and BCL-3. Ankyrin-repeat motifs 
(ANK) are located at their c-termini; these are also present in p100 and p105. C: The IκB 
Kinase (IKK) complex is comprised of three subunits: NEMO (IKKγ), IKKα and IKKβ. 
IKKα and IKKβ are catalytic subunits whereas NEMO is a regulatory subunit. CC, coiled 
coil; DD, region with homology to a death domain; HLH, helix-loop-helix; LZ, RElB- 
transactivation-domain containing a putative leucine-zipper-like motif; NBD, NEMO-binding 
domain; PEST, domain rich in proline (P), glutamate (E), serine (S) and threonine (T); ZF, 
zinc finger domain  (Reproduced from Perkins, 2007). 
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In resting cells, NFκB homo- or heterodimers are maintained in the cytoplasm by the 
inhibitors of NFkB (IkBs) of which there are three mammalian forms: IkBα, IkBβ, and IkBε 
(Figure 4.1). These can prevent movement to the nucleus by masking the nuclear localisation 
sequence contained in the RHD. However the nuclear localisation sequence of p50 remains 
accessible when bound to IkBα. Therefore IkBα also contains a nuclear export sequence 
(Hayden, 2004). Uncleaved p105 and p100 can also act in an inhibitory manner, retaining 
their subunit partners in the cytoplasm, as these proteins have ankyrin-repeat motifs like those 
in IκB proteins ((Baldassarre et al., 1995). 
When cells are stimulated, the IkB kinase complex (IKK) is activated. IKK is comprised of at 
least three components: IKKα, IKKβ and NFκB essential modifier (NEMO). This complex 
phosphorylates and targets IkB protein for degradation, releasing NFκB protein and exposing 
its nuclear localisation sequence. This leads to NFkB translocation to the nucleus where it can 
bind κB motifs in gene promoters. NFκB dimers also induce the transcription of IκB genes, 
providing a feedback loop for their own regulation (Caamano and Hunter, 2002). Activation 
is mainly via four pathways. These are the canonical, atypical and non-canonical pathways 
which are all IKK dependent and the atypical, IKK independent pathway (Figure 4.2). The 
canonical pathway is induced by pro-inflammatory cytokines such as TNFα and interleukin 1 
(Hayden, 2004). In this pathway the IKK complex is activated by the ubiquitinylation of a 
regulatory subunit, NEMO. This does not lead to protein degradation, but rather interactions 
with proteins that contain ubiquitin-binding domains. Various kinases are recruited to the IKK 
complex such as TGFβ activated kinase 1 (TAK1) which phosphorylates IKKβ in its 
activation loop (Perkins, 2007). Yet the role of IKKβ in the canonical pathway remains 
unclear. The phosphorylation of IκBα at Ser32 and Ser36 by the IKK complex, leads to the 
degradation of IκBα. This occurs within the 26S proteasome in an ubiquitin dependent 
manner due to polyubiquitination on Lys21 and Lys22 by the E3 SCF
β-TrCP 
and E2UbcH5. 
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In the atypical, IKK dependent pathway, NEMO activates the canonical pathway in response 
to genotoxic stimuli. NEMO moves into the nucleus and is sumoylated and phosphorylated by 
ataxia telangiectasia mutated ATM (Figure 4.2). It then moves back to the cytoplasm and 
activates IKKβ. IKK independent atypical pathways of NFκB activation can also be induced 
in response to hypoxia or UV damage. In these pathways IκBα is phosphorylated via casein 
kinase-II (CK2) or tyrosine kinase. 
 
 
The non-canonical pathway is activated by stimuli such as BAFF, LPS, and CD40 (Bonizzi 
and Karin, 2004) which leads to the activation of NFκB inducing kinase (NIK). This activates 
IKKα and causes the formation of p52 from p100. p52 then associates with RelB for the 
induction of genes, including chemokines and cytokines. 
 
 
Members of the NFκB family can form various homodimers or heterodimers after activation. 
Homodimers of p50 or p52 act as transcriptional repressors unless they are bound to BCL-3 
as they contain a DNA binding domain but not a transactivation domain. Homodimers of p50 
or p52 also evade regulation by the IκB proteins, as when bound to IκB proteins, the nuclear 
localisation sequence is not masked (Hayden, 2004). p50 and p52 can however be regulated 
by the IκB proteins if they form heterodimers with a Rel subunit. RelB in contrast, does not 
form homodimers but forms heterodimers with p100, p52 and p50. Heterodimers of the latter 
have a role in reducing inflammation (Hayden, 2004). C-REL may form homodimers and 
heterodimers with p50 or p65. 
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Figure 4 2 The atypical, canonical and non-canonical pathways lead to the activation of NFκB 
Upon initiation of the canonical pathway, IKKβ is activated to phosphorylate IκBα at serines 
32 and 36. This leads to degradation of the latter and the release of the RelA/p50 complex 
which moves to the nucleus. In the atypical pathway, genotoxic stress leads to the relocation 
of NFκB essential modifier (NEMO) to the nucleus. Here it is sumoylated and ubiquitinylated 
in a process requiring ATM (ataxia telangiectasia mutated) checkpoint kinase. NEMO and 
ATM move back to the cytoplasm and IKKβ is activated as before. There are also IKK 
independent atypical pathways which require casein kinase-II (CK2) and tyrosine kinase 
pathways. In the non-canonical pathway NFκB inducing kinase (NIK) activates IKKα which 
leads to the phosphorylation of the p100 subunit and cleavage to p52, enabling p52-RelB 
heterodimers to form (Perkins, 2007). 
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An added level of regulation is present in this family of transcription factors besides the 
various hetero- and homodimer combinations available. This is facilitated via the cell type 
and tissue specific expression patterns of the proteins. NFκB1/p50 and RelA are expressed in 
all tissues, whereas NFκB2/p52, Rel-B and C-REL are expressed only in lymphoid cells and 
tissues. During B-cell development the p50/C-REL heterodimer becomes the dominant NFkB 
complex in mature B cells (Liou et al., 1994). 
4.1.2 Regulation of IRF4 by NFκB family members 
 
IRF4 has been reported to be regulated by members of the NFκB family (Berberich et al., 
1994; Grumont and Gerondakis, 2000; Saito et al., 2007). 
Saito et al (2007) studied the regulation of BCL6 by CD40-NFκB-IRF4. When cells were 
stimulated with CD40, two potential NFκB regions of the Irf4 promoter could be 
immunoprecipitated by antibodies to p50 and p65. This indicates that CD40 signals via the 
canonical NFkB pathway to activate IRF4 as has been previously reported (Berberich et al., 
1994). Interestingly, although no C-REL binding site was identified, IRF4 upregulation was 
blocked in the absence of functioning C-REL (Saito et al., 2007). This is supported by several 
other studies which found absent IRF4 protein in C-REL
KO  
lymphocytes (Grumont and 
Gerondakis, 2000) and a role for p50/C-REL in signalling from CD40 (Berberich et al., 
1994). In addition, the BCL6 promoter was found to contain IRF4 binding sites. 
Cotransfection experiments demonstrated that NFkB activation was associated with IRF4 
upregulation and BCL6 reduction. This may indicate the pathway by which T-cell derived 
signals (CD40L) induce germinal centre B cells to differentiate into plasma cells and exit the 
germinal centre. NFκB can also be activated directly via the BCR, a process which requires 
BCL-10 expression. BCL-10 in turn regulates the IKK complex. BCL-10
KO 
B cells have 
normal Ca
2+ 
influx following BCR stimulation but fail to upregulate NFκB (Ruland et al., 
2001). Activation of NFκB following BCR stimulation with anti-IgM requires PKCβ (Su et 
84  
al., 2002), phosphorylation of IKKα (Saijo et al., 2002) and degradation of IKBα (Bajpai et 
al., 2000; Petro et al., 2000). 
4.1.3 Aims 
 
The aim of this project is to test whether NFκB1/p50 has a role for Ig class switching via 
induction of IRF4 protein expression, and whether changes in IRF4 expression impact on 
AID expression and CSR. The detailed aims are as follows: 
1. Does NFκB1 regulate the early intermediate phase of IRF4 protein expression? 
 
2. Does NFκB1 regulate the late high phase of IRF4 protein expression? 
 
3. Does blocking either of these phases of IRF4 block AID induction and Ig class switching? 
 
To address these questions we used a variety of techniques. AID and IRF4 protein induction 
were measured by flow cytometry (FC) and immunofluorescence (IF). IRF4 and Ig switch 
transcripts were detected by real-time RT-PCR following fluorescence activated cell sorting 
(FACS). B-cell differentiation was measured via FC and immunohistochemistry. In addition, 
ELISA and ELIspot were used to measure antibody production and frequency of antibody 
producing cells respectively. 
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4.2 Results 
 
 
 
 
4.2.1 NFκB1 deficient B cells have reduced plasma-cell differentiation and germinal 
centre formation 
In order to test the role of NFκB1 for B-cell differentiation, we immunised QM x B6 
NFκB1WT or QMNP/WT κ-/WT NFκB1KO (henceforth referred to as QMxB6 NFκB1WT  or 
QMxB6 NFκB1KO) with the TI-II antigen NP-Ficoll i.p. This induces the synchronous onset 
of differentiation of large numbers of B cells (5% of all B cells), resulting in large plasma-cell 
foci and the development of large germinal centres that are sustained without T-cell help until 
day 6 post immunisation (Vinuesa et al., 2000). This was followed by histological staining of 
spleen  sections.  Four  days  after  immunisation,  QMxB6  NFκB1WT   B  cells  have  formed 
plasma-cell foci in the red pulp (Figure 4.3A, arrows) and germinal centres within the IgD
+
 
 
follicles. Plasma-cell foci and germinal centres are NP-binding (Figure 4.3A, top left panel). 
WT germinal centre B cells do not express IRF4, whereas plasma cells in the red pulp express 
high levels of IRF4. There are also IRF4 intermediate NP-binding blasts in the outer T zone, 
and IRF4 intermediate T cells in the T zone (Figure 4.3A, bottom left panel). Mice deficient 
in NFκB1 fail to form germinal centres or plasma cells (Figure 4.3A right panel). Instead a 
large number of NP-binding B cells are located in the IgD
+ 
follicles and express intermediate 
levels of IRF4 protein (Figure 4.3A bottom panel). 
 
To better quantify altered IRF4 protein levels in the absence of NFκB1, flow cytometry (FC) 
analysis of splenocytes was performed four days after immunisation. In QMxB6 NFκB1WT 
spleen, NP-specific B cells differentiate into IRF4
high 
CD138
+ 
plasma cells that express lower 
levels of B220 (Figure 4.3B, top panel). In addition, B cells that express intermediate levels of 
IRF4 are also found (Fig. 4.3B). Further, many B cells lose IRF4 expression and become 
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IRF4
neg 
similar to non-activated B cells (Figure 4.3 C). In contrast, in QMxB6 NFκB1KO 
spleens NP-binding B cells constitute a homogenous, undifferentiated population. This 
population expresses higher levels of B220 compared to the antigen-activated B cells from 
QMxB6 NFκB1KO mice; whilst levels of IRF4 protein after activation remain at a level which 
is slightly higher than intermediate levels observed in WT cells with no differentiation of 
IRF4
high 
plasma  cells  or  IRF4
neg 
GC  B  cells  (figure  4.3B,  lower  panel  and C).  CD138 
expression is absent. 
 
The reduced number of plasma cells due to deficiency of NFκB1 leads to profound reduction 
of antibody titres in blood. Sera were collected 4, 48, 72 and 96 hours after immunisation. 
Due to their high frequency of B cells specific for NP, QM mice already possess low titres of 
circulating anti-NP specific antibodies before immunisation. Four hours after immunisation, 
titres of anti-NP IgM decrease by >95% in QMxB6 NFκB1WT mice and >85% in QMxB6 
NFκB1KO mice (Figure 4.4A). This is probably due to immune complex formation following 
the injection of free antigen. Anti-NP IgM antibody is detectable again in sera from QMxB6 
NFκB1WT and QMxB6 NFκB1KO mice two days after immunisation, however B cells lacking 
NFκB1 produce significantly lower titres compared to QMxB6 NFκB1 wild-type mice 
(Figure 4.4A). Whereas titres of anti-NP IgM increase by >140x in sera from QMxB6 NFκB1 
wild-type mice, titres of anti-NP IgM from QMxB6 NFκB1KO mice increase by only around 
14x. Three and four days after immunisation, titres of NP-specific IgM continue to increase in 
sera from QMxB6 NFκB1WT mice and to a lesser degree in sera from QMxB6 NFκB1KO 
mice, with QMxB6 NFκB1KO sera containing around 1x times less antibody at both time 
points. 
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Figure 4.3: NFκB1 deficient B cells do not form germinal centres or plasma cells. A: 
Four days after immunisation with NP-Ficoll i.p, spleen tissue from QMxB6 NFκB1
WT
 
(left) or QMxB6 NFκB1
KO
 (right) were stained for NP (Blue) and IgD (Brown) (top 
panel) or IRF4 (Blue) and IgD (Brown) (bottom panel). Plasma cells have developed in 
QMxB6 NFκB1
WT 
spleens (arrow). GC: germinal centre, TZ: T cell zone, F: follicle 
B: Representative FC plots of QMxB6 NFκB1
WT 
(top) or QMxB6 NFκB1
KO 
(bottom) 
splenocytes four days after NP-Ficoll immunisation. NP-binding, B220
+
 B cells were 
tested for expression of IRF4 and CD138. Antigen-specific QMxB6 NFκB1
WT 
B cells 
contained a CD138
+
 IRF4
+
 population (green) and an IRF4 intermediate population 
(blue). QMxB6 NFκB1
KO 
B cells lack a CD138
+ 
population and express 
intermediate/high levels of IRF4 (red). C: Representative histogram of IRF4 protein 
expression within the cell populations shown in (B). Purple: goat isotype control, Grey: 
NP
neg
, B220
+
 B cells, Blue: NP-binding QMxB6 NFκB1
WT 
B cells; Green: NP-binding, 
CD138
+
 QMxB6 NFκB1
WT  
B cells; Red: NP-binding CD138
−
, QMxB6 NFκB1
KO  
B 
cells.  
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Absence of NfkB1 leads to severe deficiency of IgG. The reduction in total NP-specific IgG 
(tested by binding to NP15-BSA coated ELISA plates) in QMxB6 NFκB1
KO 
deficient sera was 
even more than the defect observed in IgM three and four days after immunisation (Figure 
4.4B). Higher affinity NP-specific IgG (tested by binding to NP2-BSA) was not detectable in 
QMxB6 NFκB1KO deficient sera. However, during the TI-II response germinal centres are not 
productive due to lack of help from Tfh cells. Therefore affinity matured B cells are not 
produced. This is reflected by the fact that titres of high affinity IgG do not significantly 
increase beyond those present in non-immunised mice (Figure 4.4C). The main class of 
antibody induced in the TI-II response is IgG3 (Vinuesa et al., 2000). This was also 
significantly reduced in NFκB1 deficient mice by >98% compared to wild-type controls three 
days after immunisation. Four days after immunisation, sera from QMxB6 NFκB1KO  mice 
 
contain on average >89% less IgG3 (Figure 4.4D). Despite reduced titres of IgG and IgG3, 
there is no significant decrease in the ratio of IgG3/IgM in the absence of NfkB1 (Figure 
4.4E). This indicates that there is no defect in IgG3 class switching when NFκB1 is absent. 
 
To further test whether there was a defect in Ig class switching in the absence of NFkB1, we 
measured the expression of Ig switch transcripts (heavy chain germline). While IgG3 is the 
most abundant isotype induced during the QM B-cell response to NP-Ficoll, IgG3 switch 
transcripts are not good indicators of induction of IgG class switching, as there is high 
background activity of the Ig3 exon in non-activated B cells(Rothman et al., 2004). IgG1 is 
the second most common isotype produced in responses to NP-Ficoll (Vinuesa et al., 2000), 
therefore, we tested induction of IgG1 switch transcripts. IgG1 switch transcripts are 
significantly increased within four hours of immunisation (p=0.029) in both QMxB6 
NFκB1WT and QMxB6 NFκB1KO spleens (Figure 4.4F). Two days after immunisation, when 
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IgG1 switch transcript production peaks, QMxB6 NFκB1KO spleens contain significantly less 
IgG1 switch transcripts compared to QMxB6 NFκB1WT  spleens, however this difference is 
small and not significant during the following days. Heavy chain transcripts for Cγ3 
containing Iµ were also quantified. The Iµ exon upstream of the IgM switch region is 
constitutively active, and non-switched cells produce an Iµ-Cµ transcript. After CSR to IgG3 
Iµ-Cγ3 hybrid transcripts are expressed, and these indicate successful Ig class switch 
recombination to IgG3 (Li et al., 1994). Recombined Iµ-Cγ3 transcripts have been previously 
found to be induced within 48 hours of immunisation in the TI-II response in FACS-sorted 
activated B blasts compared to FACS-sorted non-activated B cells (Marshall et al., 2011). 
When testing RNA extracted from spleen sections we found that Iµ-Cγ3 transcripts were not 
significantly increased above levels found in non-immunised mice until three days after 
immunisation (Figure 4.4G). This may be because the Iγ3 exon is not as strictly regulated as 
the other Iγ exons, there are also some background IgG3 secreting plasma cells pre- 
immunisation.  Interestingly, whilst Iµ-Cγ3 transcripts do not further increase between three 
and four days after immunisation in QMxB6 NFκB1WT mice, transcripts significantly increase 
in QMxB6 NFκB1KO spleens. This may be due to some ongoing CSR in non-differentiated B 
blasts in follicles of QMxB6 NFκkB1KO mice, while CSR ceases after plasma-cell 
differentiation in QMxB6 NFκkB1WT mice. 
 
 
 
 
The absence of splenic germinal centres and plasma cells in mice lacking NFκB1 may be 
attributed to a stromal deficiency causing an inability to support B-cell differentiation, or due 
to B-cell intrinsic effects. Follicular dendritic cells (FDCs) are important for germinal centre 
formation and B-cell selection, due to the ability of FDC to bind and present antigen to B 
cells. It has been proposed that FDC defects are responsible for the defective GC development 
in NfkB1 deficient mice (Sukumar et al., 2008; Tew et al., 2001). Indeed the canonical 
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pathway of NFκB1 activation is known to be required for FDC differentiation − deletion of 
IKKβ in FDC prevents the upregulation of the adhesion molecules ICAM-1 and VCAM-1 
which characterise light zone FDC in secondary follicles (Victoratos et al., 2006). In addition, 
immune complex trapping by FDC is less efficient in the absence of NFκB1 (Ferguson and 
Corley, 2005). Therefore to test the status of FDC in mice lacking NFκB1 we performed IF 
and IHC staining on spleen sections. Anti-FDC-M2 detects the complement component C4 
(Taylor et al., 2002) and can be utilised to specifically detect FDC via the immune complex 
that are deposited on FDC. Two days after immunisation, spleens were analysed by IF for 
FDC-M2 expression and CD11c, the latter is expressed on dendritic cells. We found a 
reduction in FDC-M2, and therefore immune complex deposition on FDC, in mice lacking 
NFκB1 compared to QMxB6 NFκB1WT spleens (Figure 4.5A). 
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Anti-FDC-M1 recognises mfge8 on macrophages and FDC and their processes in the light 
zone of the germinal centre (Kranich et al., 2008). This network is already apparent at day 3 
after NP-Ficoll immunisation in NFκB1 sufficient mice which have started to form IgD- 
germinal centres within the follicles. In contrast, there are no FDC dendrites visible in 
QMxB6 NFκB1 deficient spleens although there is FDC-M1 staining, some of which may be 
due to the presence of macrophages (Figure 4.5B). As this defect is already published, no 
further analysis of FDC function was carried out. 
 
 
 
4.2.2 NFκB1 deficient B cells upregulate IRF4 in the first hours after activation 
As shown in chapter 3, in the response to the TI-II antigen NP-Ficoll IRF4 mRNA production 
peaks in activated B blasts within 1h of immunisation. This is followed by a gradual decrease 
in IRF4 mRNA expression over the following hours. Simultaneously, IRF4 protein gradually 
increases in quantity between one and 24 hours following immunisation. In order to test the 
effect of NFκB1 deficiency on IRF4 mRNA upregulation, we immunised QMxB6 NFκB1WT 
and QMxB6 NFκB1KO mice with NP-Fluorescein-AECM-Ficoll. FITC+  B220+ B cells were 
sorted 1h post-immunisation (Figure 4.6A). Both QMxB6 NFκB1WT and QMxB6 NFκB1KO B 
cells upregulate IRF4 mRNA at similar levels within 1h post-immunisation. This indicates 
that initial IRF4 upregulation does not require NFκB1 in either the stromal or lymphocyte 
compartments. To confirm that intermediate IRF4 protein upregulation is normal, we 
measured expression of IRF4 by FC six hours later. Splenocytes were stained with 
fluorescent antibodies against B220 and IRF4 and incubated with fluorescently labelled NP. 
We found similar upregulation of IRF4 protein in QMxB6 NFκB1 sufficient or deficient 
splenic antigen-specific B cells (Figure 4.6B and C) and this was significantly higher than that 
found in non-activated B cells. 
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To assess whether early migration to the T zone-follicular border was normal, and to confirm 
IRF4 upregulation in the population of responding B cells, we performed 
immunohistochemical staining. Six hours after immunisation, NP-specific cells (Figure 4.7A, 
top panel) are located at the follicular T zone border and express intermediate levels of IRF4 
protein (Figure 4.7A, bottom panel). This occurs similarly in QMxB6 NFκB1 sufficient or 
deficient spleens. As other cell types including macrophages (Satoh et al., 2010) and T cells 
(Bollig et al., 2012) can also express IRF4, we confirmed with fluorescent staining that these 
migrating cells are B lymphocytes. IRF4
+  
cells at the follicle-T-zone border were found to 
 
express the B-cell marker B220 (Figure 4.7B). This confirmed that early IRF4 upregulation 
and migration of B cells to the B-T border was normal in the absence of NFkB1. 
 
 
Induction of other markers of early B-cell activation also occurred normally in the absence of 
NFκB1: CD69 is upregulated on B cells within 4 hours of stimulation (Arvå and Andersson, 
1999). This receptor appears to have a negative regulatory role, at least in T cells, with a lack 
of CD69 causing an exacerbated phenotype in models of autoimmune disease (la Fuente et al., 
2012). As measured by FC, QMxB6 NFκB1 deficient B cells had no defect in the 
upregulation of this molecule after 6h and actually expressed significantly more CD69 
receptor in the responding population of B cells (Figure 4.8A). 
 
 
In contrast to CD69, CD62L is lost from B cells within 2h of TLR stimulation (Morrison et 
al., 2010) and is required for lymphocyte entry into lymph nodes across high endothelial 
venules. Loss of this receptor following activation occurs via receptor shedding and is 
important for the targeting B cells to the spleen after BCR/TLR signalling (Morrison et al., 
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2010; Tang et al., 1998). QMxB6 NFκB1 deficient B cells had no defect in CD62L shedding 
after activation (Figure 4.8B). 
 
 
The co-stimulatory molecule CD86 is expressed on B cells and binds to  CD28.  This 
molecule has been shown to be upregulated within the first hours of B-cell activation after 
simulation via the BCR(Lenschow et al., 1994). QMxB6 NFκB1 deficient B cells expressed 
significantly higher protein levels of CD86 post-activation (Figure 4.8C). 
 
 
Taken together, these results indicate that there is no defect in the initial induction of IRF4 
and transmigration into the T zone in QMxB6 NFκB1 deficient B cells, and if anything there 
is stronger B-cell activation, as assessed by expression of CD69, CD62L or CD86. However, 
late B-cell differentiation into germinal centre and plasma cells is defective when mice are 
deficient in NFκB1. This may be due in part to stromal defects such as absence of functional 
FDC, or due to a role for NFκB1 expression in B cells for differentiation of GC phenotype, 
and for the induction of high level expression of IRF4 in plasmablasts. 
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4.2.3 Defects in plasma-cell differentiation are B-cell intrinsic 
NFκB1 is involved in signalling in many different cell types. To test whether B-cell intrinsic 
or B-cell environmental effects are responsible for the defects seen in QM x B6 NFκB1KO 
mice, antigen specific QM
NP/NP κ-/- NFκB1WT or QMNP/NP κ-/- NFκB1KO (hereafter referred to 
as QM
WT 
and QM
KO
) B cells were transferred into C57BL/6 or NFκB1KO host mice. This was 
followed by antigen challenge 24 hours later with NP-Ficoll (Figure 4.9A). Before cell 
transfer resting B cells were enriched from total splenocytes using negative selection with 
anti-CD43 magnetic beads. The percentages of NP-binding B cells were measured by FC to 
ensure similar numbers of antigen-specific cells were transferred (Figure 4.9B). 
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Four days following immunisation, QM
WT 
B cells transferred into WT hosts have formed 
germinal centres and plasma-cell foci (Figure 4.10A left panel). Germinal centres and plasma- 
cell foci are both NP-binding (blue). In contrast, NFκB1KO B cells transferred into a WT 
environment have formed smaller germinal centres and lack plasma-cell foci (Figure 4.10a, 
centre panel). QM
WT 
B cells transferred into an NFκB1KO environment form large plasma-cell 
foci yet produce small germinal centres (Figure 4.10A right panel). Quantification from 
tissue sections confirms that lack of NFκB1 in QM B cells results in significantly fewer 
plasma cells, whereas NFκB1-deficiency in the B cells’ environment produces similar 
numbers of plasma cells to QM
WT 
B cells in a WT environment (Figure 4.10B left). In 
contrast, germinal centre formation is partly dependent upon NFκB1 expression in both B 
cells as well as stromal cells (Figure 4.10B, right). 
 
 
Flow cytometry was performed to quantify the number of exogenous cells and their 
specificity for NP. Transferred cells can be tracked by flow cytometry by their expression of 
eYFP. Four days after immunisation antigen-specific QM cells have expanded. In addition, 
QM
WT 
cells contain two populations: B220
int./low 
CD138
+ 
plasma cells and B220
high 
germinal 
centre B cells (Figure 4.10C, D). 
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Figure 4.10: NFκB1 deficient B cells have impaired germinal centre and plasma cell 
differentiation four days after NP-Ficoll immunisation. B cells were transferred as 
described in Figure 4.9. A: Four days after NP-Ficoll, spleen sections were stained 
from WT mice which received QM
WT
 B cells (left), WT mice that had received QM
KO
 
B cells (centre) and NFκB1
KO
 mice which had received QM
WT
 B cells (right). Spleen 
sections were stained for antigen-specific cells (NP: blue), and counterstained with IgD 
(brown). B: Quantification of plasma cell numbers and germinal centre area from 
histology sections, stained as in (A). C: Representative FC plots of spleens from mice 
receiving QM
WT
 (top) and QM
KO 
B cells (centre) and NFκB1
KO
 mice receiving QM
WT
 
B cells (bottom). FC was performed on splenocytes labelled with antibodies against 
B220 and CD138 and incubated with NP-PE. Transferred cells were gated as eYFP
+
 
(left plots). The majority of eYFP
+
 cells were B220 low and NP-binding in both QM
WT
 
and QM
KO 
populations (centre plots).  Plasma cells were quantified as eYFP
+
 CD138
+
 
(right plot) D: Plasma cells were quantified from FACS as shown in (C) for WT mice 
receiving QM
WT
 (blue) or QM
KO
 (red) B cells and NFκB1
KO
  mice receiving QM
WT
 B 
cells (green). Scale bar indicates 200μm. GC: germinal centre, TZ: T cell zone, F: 
follicle, RP: red pulp. 
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Testing of antigen-specific IgM revealed that titres are similar in all groups until three days 
after immunisation, yet four days post-immunisation there is no further increase in IgM titres 
in mice receiving QM
KO 
B cells, while mice receiving QM
WT 
B cells produce 25x more IgM 
(Figure  4.11A).  There  in  no  difference  in  antibody  production  between  QM
WT   
B  cells 
differentiating in a NFκB1KO environment compared to QMWT B cells transferred to a WT 
host. QM B cells produce allotype IgM
a 
and specific detection of IgM
a 
excludes host-derived 
antibodies. As expected, anti-NP IgM
a 
titres were significantly reduced in the sera from mice 
receiving NFκB1KO B cells (Figure 4.11B). The production of similar levels of IgM between 
QM
WT 
and QM
KO 
B cells early in the response indicates that the early differentiation of B 
blasts occurs normally in the absence of NFκB1. 
 
 
 
The main antibody class stimulated during a TI-II response is IgG3 (De Vinuesa et al, 2000). 
IgG3 production has been reported to be deficient in NFκB1KO animals (Kenter, 2004; Sha et 
al., 1995; Snapper et al., 1996). IgG3 production was found to be deficient when NfkB1 was 
absent from B cells (Figure 4.11C). NFκB1KO mice which received QMwt splenocytes did not 
have any defect in IgG3 production, showing that class switching to IgG3 is not dependent on 
NFκB1-expression in stromal cells. Switching to other Ig classes in the response to NP-Ficoll 
occurs less frequently. Low titres of IgG1 (Figure 4.11D) and IgG2a (Figure 4.11E), and 
although not as easily detectable showed similar results. 
Although deficiency of NfkB1 in B cells leads to significantly reduced production of IgG, this 
seems not due to a reduction of CSR, but solely due to less efficient plasma-cell 
differentiation: the ratio of IgG3 to IgM, which indicates of the efficiency of class switching 
independently of plasma-cell numbers, was not decreased in the sera of mice which received 
NFκB1KO B cells (Figure 4.11F). 
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ELISA produces good quantitative data on the amount of antibody secreted by plasma cells. 
However, it provides no information on numbers of antibody secreting plasma cells or 
efficiency of antibody production by individual plasma cells. ELIspot quantifies both the 
number of antibody producing cells and the quantities antibody produced by individual cells. 
NFκB1KO B cells formed 90% fewer IgMa secreting and  65% fewer IgG secreting cells than 
both  QM
WT   
cells  in  a  WT  environment  or  NFκB1KO  environment  (Figure  4.11G-H).  If 
 
anything, the ratio of Ig class switched to non-switched cells was increased when B cells lack 
NFκB1, again indicating that there is no defect in CSR in the absence of NFκB1 in B cells 
(Figure 4.11H, right panel). 
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Figure 4.11: NFκB1 deficient B cells have impaired plasma cell differentiation and 
antibody responses. B cell transfers were carried out as shown in Figure 4.9 and mice 
were immunised with NP-Ficoll. ELISAs were performed for the detection of anti-NP 
antibodies using sera from stated timepoints:  IgM binding to NP
2
-BSA (A), IgM
a
 
binding to NP
15
-BSA (B), IgG3 binding to NP
15
-BSA (C), IgG1 binding to NP
15
-BSA 
(D), IgG2a binding to NP
15
-BSA (E). F: Ratio of class switching to IgG3 calculated 
from the relative antibody titres obtained from ELISA four days after immunisation. G: 
Representative ELIspot photograph of IgM
a
 (top) and IgG (bottom) plasma cells four 
days after immunisation from spleens from WT mice which received QM
WT
 (left) or 
QM
KO
 B cells (centre) or NFκB1
KO
 mice which received QM
WT
 B cells (right). H: 
Quantification of plasma cell numbers from ELIspot for IgM
a
 (left), IgG (centre) and 
the ratio of Ig class switching to IgG (right). Each data point represents one mouse. 
Data are representative of two experiments. 
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4.2.4 Early IRF4 induction is independent of NFκB1, whereas late IRF4 induction is 
dependent on B-cell intrinsic NFκB1 . 
As shown in chapter 3, two days after cell transfer and immunisation, IRF4 protein is present 
at intermediate levels and at this stage may be essential for induction of Aicda expression. To 
test whether NFκB1 has a role during this phase QMWT and QMKO B cells were tested for 
IRF4 expression at the mRNA and protein level. Similar to what was seen in complete 
NFκB1 deficient animals (Fig. 4.7), QMWT and QMKO B cells upregulate IRF4 protein to 
similar levels two days after cell transfer and immunisation (Figure 4.12A). However, four 
days after immunisation QM
KO 
B cells have formed a homogenous IRF4 intermediate 
population (Figure 4.12B) similar to that found in NFκB1KO mice (Figure 4.3C). B220+ NP- 
binding, CD138
−
, eYFP
+ 
B cells were sorted by FACS and tested for their expression of IRF4 
mRNA. This was expressed at a similar level in all groups tested (Figure 4.12C). 
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As plasma cells do not undergo Ig class switching (Marshall et al., 2011), it is likely that late 
high-level IRF4 induction − associated with plasma-cell differentiation – is dispensable for 
extrafollicular Ig class switching. As intermediate level IRF4 was expressed at normal levels 
in QM
KO 
B cells and class switching by ELIspot and ELISA appear normal (Fig. 4.11), we 
tested whether AID was induced at normal levels in NFκB1 deficient B cells two days after 
activation. AID protein levels were quantified from spleen sections by IF. Spleens were 
stained with labelled antibodies against AID, IRF4, IgD and the QM BCR (Figure 4.13A). 
AID protein was quantified from IF sections by gating on individual cells with ImageJ 
software and measuring the median fluorescence. Two days after immunisation, transferred B 
cells are located within the IgD
+ 
follicle and express IRF4 and AID protein (Figure 4.13A). 
Normal upregulation of AID (Figure 4.13B) and IRF4 (Figure 4.13C) occur in the absence of 
NFκB1.  This  was  confirmed  by  FC  staining:  NFκB1KO   eYFP+B220+   expressed  similar 
amounts of AID protein as NFκB1WT B cells (Figure 4.13C and D). 
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Figure 4.13: AID protein induction is normal in B cells lacking NFκB1. A: Spleen 
sections from mice receiving either QM
WT
 or QM
KO
 B cells were stained with 
antibodies against the QM BCR (transferred cells), AID, IRF4 and IgD. Scale bar 
indicates 50μm. B: AID induction was measured in individual cells from images using 
ImageJ software and expressed as the median number of fluorescence pixels. Each data 
point represents one cell and data are taken from a minimum of two different mice for 
each group. C: Representative histogram of AID protein expression within eYFP
+
 
B220
+
 QM
WT 
or QM
KO
 cells transferred into a WT environment 1.5 days after 
immunisation. D: The median fluorescent intensity of AID protein by FC within eYFP
+
 
B220
+
 B cells gated as before (C). Each data point represents one mouse. 
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As intermediate level IRF4 and AID protein were induced normally when B cells lack 
NFκB1, we wished to confirm that early, GC independent Ig class switching also occurred 
within the spleen, despite low numbers of plasma cells. As discussed previously, Ig switch 
transcripts begin to be expressed two days after B-cell activation. B cells were transferred into 
wild-type hosts and immunised with NP-Ficoll before being sorted 1.5 days after 
immunisation.  Figure  4.14A  shows  that  IgG3ST  are  already  upregulated  1.5  days  after 
immunisation and this occurs in both QM
WT 
and QM
KO 
B cells equally. To confirm that this 
 
translates to switching in the few plasma cells that develop, we stained tissues sections with 
antibodies against the QM BCR, IgG and IgM (Figure 4.14B). NFκB1KO B cells switch to IgG 
with the same frequency as NFκB1WT B cells. 
 
As NFκB1 has a role in apoptosis and proliferation (Sha et al., 1995; Snapper et al., 1996) we 
tested NFκB1KO B cells for changes in cell division and death. Apoptosis was measured by FC 
utilising the marker annexin V. This is a phospholipid binding protein with a high affinity for 
phosphatidylserine, the latter becomes exposed at the cell surface in the early stages of 
apoptosis. In conjunction with a dead cell marker 7AAD, this can be used to differentiate live 
cells from both dead cells and those in the early stages of apoptosis (van Engeland et al., 
1996). QM
WT 
or QM
KO 
B cells were transferred into wild-type hosts and immunised with 
NP-Ficoll. Two days after activation, splenocytes were incubated with annexin V, 7AAD and 
PE-labelled NP. B cells were gated as eYFP
+ 
and NP-binding and tested for the percentage of 
annexin V
+ 
7AAD
- 
cells. Two days after activation NFκB1KO B cells are undergoing 
apoptosis at higher frequency (Figure 4.15A). However by three days after immunisation 
frequencies of apoptotic cells are similar (Figure 4.15B). 
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In order to test induction of cell division, enriched B cells from the spleens of QM
WT 
or 
QM
KO 
mice were labelled with the division tracker dry CellTrace
TM
. Before transfer into WT 
hosts and immunisation with NP-Ficoll, QM
WT 
or QM
KO 
B cells express similar levels of 
CellTrace
TM 
dye (Figure 4.16A). B220
+
eYFP
+ 
cells were tested for cell division. Two days 
post-immunisation NFκB1 deficient B cells had undergone the same number of divisions 
whether they expressed NFκB1 or not (Figure 4.16B). However after three days post- 
immunisation when B cells are beginning to differentiate into plasma cells and germinal 
centre cells, cell division slows down in NFκB1KO B cells (Figure 4.16C). Four days after 
immunisation the cell tracker dye has diluted too much to analyse cell division, however 
significantly more QM
KO 
B cells are still labelled stronger with the dye (Figure 4.16D).   To 
test whether NFκB1KO B cells have reduced proliferation four days after immunisation, Ki-67 
staining was performed on tissue sections. Ki-67 is a marker that is expressed in dividing cells 
only. Four days after immunisation there is no defect in the proliferation of NFκB1KO B cells 
located in the splenic red pulp (Figure 4.16E). This indicates that extrafollicular plasmablasts 
are capable of cell division. Ki67 labels cells in active phases of cell cycle such as: G1, S, G2 
and mitosis but is not expressed by resting G0 cells (Scholzen and Gerdes, 2000). Therefore it 
is still possible that NFκB1KO B cells may be arrested in one of these phases of cell division 
despite expressing this division marker. 
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Figure 4.16: NFκB1
KO
 B cells have an intrinsic defect in proliferation from three days 
post-immunisation. A: QM
WT 
(left) or QM
KO
 B cells (centre) were enriched from total 
splenocytes and labelled with the cell division tracker CellTrace
TM
 before transfer into 
WT hosts. The percentage of NP-binding B220
+
 B cells were calculated by staining a 
small number of donor cells. 1x10
6
 NP-binding B220
+
 cells were transferred into each 
host mouse followed by immunisation with NP-Ficoll. B-D: Transferred B cells were 
analysed by FC two (B), three (C) and four days (D) after immunisation. Proliferation 
was assessed within the eYFP
+
 donor derived population and measured by dilution of 
CellTrace
TM
 dye. D: Right hand plots: the percentage of eYFP
+
 QM
WT
 (blue) or QM
KO
 
(red) B cells which had undergone more than six divisions (Centre) or less than six 
divisions (right hand plot) were quantified using the gates shown in (C). E: Spleens 
from mice receiving NFκB1
KO
 B cells were stained for transferred B cells (idiotype: 
brown) and expression of Ki67 (blue). The percentage of transferred cells undergoing 
proliferation within the red pulp was quantified from tissue sections. Each data point 
represents one mouse.  
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4.3 Summary 
 
 
 
B cells lacking the signalling protein NFκB1 exhibit impaired survival and proliferation. In 
addition, the proportion of B cells which differentiate into germinal centre B cells and plasma 
cells are reduced. Defects in germinal centre formation were found to be due partly to stromal 
defects and partly due to B-cell intrinsic defects. Stromal defects were due to the failure of 
FDC to differentiate and trap immune complex. Plasma-cell defects in contrast, were due to a 
failure to fully upregulate IRF4 protein levels, although IRF4 mRNA levels were not altered 
when B cells lacked NFκB1. 
 
 
In contrast, early migration and activation of NFκB1KO B cells was normal and this leads to 
normal IRF4 intermediate level induction. We have shown that even in the absence of normal 
plasma-cell differentiation, expression of intermediate level IRF4 is sufficient for normal AID 
protein induction and this leads to a normal frequency of CSR. 
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5: C-REL
KO  
MICE LACK HIGH BUT NOT INTERMEDIATE 
LEVEL IRF4 AND SHOW NORMAL CSR 
5.1 Introduction 
 
The results described in the previous chapter used mice lacking NFκB1 to indicate that 
intermediate level IRF4 protein was sufficient for extrafollicular CSR. To confirm these 
results, we utilised a different mouse model whereby the signalling molecule C-REL is 
absent. 
C-REL is also a member of the NFκB family, the structure and signalling of which are 
described in detail in chapter 4. In unstimulated, or mitogenically stimulated B cells, the main 
NFκB complexes are formed of p50 and C-REL heterodimers (Grumont and Gerondakis, 
1994; Liou et al., 1994). C-REL
KO 
splenocytes fail to upregulate IRF4 two hours after 
stimulation with LPS or anti-IgM in vitro and induction of IRF4 by REL proteins was found 
to require two NFκB elements within the IRF4 promoter at −1733 and −686 (Grumont and 
Gerondakis, 2000). Additionally C-REL may act in synchrony with IRF4 to induce IRF4 
target genes: in T cells, C-REL protein has been shown to form a complex with IRF4 in order 
to induce the expression of IL-4 and IL-2 (Shindo et al., 2011). This interaction occurs 
between the N-terminus of C-REL and the C-terminal IRF association domain of IRF4. 
Therefore, as for NFκB1, we predicted that high level IRF4 induction and plasma-cell 
differentiation would be deficient in mice lacking C-REL protein. 
 
Within B cells, C-REL is also expressed in the nucleus of BCL6
+ 
IRF4
− 
centrocytes in the 
light zone of the human tonsil, but also in some IRF4
+ 
PRDM1
+ 
cells (Cattoretti et al., 2006). 
Therefore C-REL may have a role within the GC, inducing genes that determine cell fate 
decisions. In addition, C-REL protein is required for signalling via BAFF-R (Rickert et al., 
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2011), which is important for PC differentiation and survival (Mohr et al., 2009; Moisini and 
Davidson, 2009). 
 
Mice lacking C-REL protein maintain normal weight and have normal percentages of 
lymphoid cells under pathogen free conditions. In contrast, C-REL deficient mice exhibit 
reduced survival in a non-pathogen-free environment and show defective clearance of 
L.monocytogenes (Carrasco et al., 1998), yet LMCV clearance, which requires cytotoxic T 
lymphocytes, (CTL) is normal. Decreased immunity to L.monocytogenes may be due to 
reduced nitric oxide (NO) production by C-REL
KO 
macrophages (Carrasco et al., 1998). B 
cell responses and germinal centre formation are impaired and interestingly, naïve C-REL
KO 
mice have increased titres of IgG2a, IgM and IgA, whilst titres of IgG1, IgG2b and IgG3 are 
reduced (Carrasco et al., 1998). 
 
 
 
 
 
 
Similar to the experiments described in the last chapter for NFkB1, in this series of 
experiments I tested whether C-REL deficient mice (Hsia et al., 2002) express normal levels 
of intermediate and/or high level IRF4 protein following immunisation. This was then 
correlated to extrafollicular AID protein induction and CSR. 
 
 
 
5.2 Results 
 
 
5.2.1 C-REL protein deficiency leads to impaired TD responses 
To test whether C-REL is required for B-cell differentiation, we immunised C-REL
WT 
or C- 
REL
KO 
mice with 2x10
8 
sheep red blood cells i.v and tracked subsequent B-cell 
differentiation. Immunisation with SRBC induces a large polyclonal TD response (Stamm et 
al., 2013), the kinetics of which are similar to that induced within lymph nodes by alum 
precipitated NP-CGG following footpad immunisation (Toellner et al., 1998). By three days 
123  
after immunisation, B cells have started to expand and migrate into the follicles. This is 
followed by further proliferation and differentiation into germinal centre B cells and plasma 
cells five days post immunisation. 
 
Activated B blasts upregulate expression of GL7 whilst still expressing CD38 (Taylor et al., 
2012), in contrast to germinal centre B cells which express GL7 but lose CD38 expression. 
Two days after immunisation, GL7
+
CD38
+
B220
+ 
activated B cells become detectable by FC 
in the spleens of CREL
WT 
as well as CREL
KO 
mice (Figure 5.1A). The  percentage  of 
activated B cells two days after immunisation was significantly lower when mice lacked C- 
REL expression (Figure 5.1D). Despite their lower numbers, activated antigen-specific B cells 
show similar upregulation of IRF4 protein between 4 h and 2 d post-immunisation in both C- 
REL
WT 
and C-REL
KO 
B cells (Figure 5.1E and F). 
 
 
 
B cells during extrafollicular differentiation upregulate AID mRNA and protein within two 
days of activation (Chapter 3). We found significant upregulation of AID protein two days 
after immunisation and this occurred similarly in both C-REL
WT 
and C-REL
KO 
B cells (Figure 
5.1E and F). 
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Figure 5.1. Mice lacking C-REL have fewer activated cells, but these have similar 
IRF4 and AID induction compared to WT. C57 or C-REL
KO 
mice were immunised with 
SRBC i.v. A: Representative flow cytometry analysis of the number of activated B 
cells (GL7
+
CD38
+
B220
+
) in the spleens of C-REL
WT
 (top panel) or C-REL
KO
 mice 
(bottom panel), two days after immunisation. B and C: Representative histogram of 
IRF4 protein expression (B) or AID protein expression (C) within the activated 
population shown in (A) for C-REL
WT
 (blue) and C-REL
KO
 cells (red). D: The 
percentage of activated splenic (GL7
+
CD38
+
B220
+
) B cells gated according to (A) are 
fewer two days after immunisation in C-REL
KO
 mice (red) compared to C-REL
WT
 mice 
(blue). E and F: Median fluorescence intensity of IRF4 (E) and AID protein (F) within 
activated B cells gated according to (A), two days after immunisation 
Each data point represents one mouse. 
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To test whether downstream B-cell differentiation into plasma-cell and germinal centre cells 
was affected, we examined C-REL
WT 
and C-REL
KO 
spleens five days after immunisation by 
FC. Plasma-cell numbers were significantly reduced in C-REL
KO 
spleens compared to C- 
REL
WT 
spleens (Figure 5.2 A and B). In addition, germinal centre B cells (CD38-GL7+) were 
strongly reduced in number in mice lacking C-REL protein (Figure 5.2C and D). Tissue 
sections from C-Rel deficient mice five days after immunisation show no detectable germinal 
centres and no IRF4
high 
plasma-cell foci in the T zone – red pulp junction (Figure 5.2E). 
 
 
To be able to follow IRF4 protein expression in large cohorts of antigen-specific B cells 
during the early extrafollicular differentiation in vivo, QM
NP/NP κ-/- C-RELWT were crossed 
with C-REL
KO 
mice to create QM
NP/WT κ-/WT C-RELKO (henceforth referred to as QMWT or 
QM
KO
). QM
WT 
or QM
KO 
mice were immunised with the TI-II antigen NP-Fluorescein- 
AECM-FICOLL. Six hours after immunisation, fluorescein
+ 
B cells were tested by FC for 
their expression of IRF4 protein. Similar proportions of QM
KO 
as QM
WT 
B cells had taken up 
the antigen 6 h after immunisation (Figure 5.3A). There was no significant difference in 
IRF4-protein induction between QM
WT 
and C-Rel deficient QM B cells within six hours of 
immunisation (Figure 5.3B and C). 
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To further test whether early B-cell activation was normal 6 h post immunisation, expression 
of B-cell activation markers were analysed by FC. After gating on cells which had bound the 
antigen in vivo (FITC
+
) significant loss of CD62L is seen. This occurred at similar levels in 
QM
WT  
as well as QM
KO 
B cells (Figure 5.4A). CD86 protein is significantly upregulated 
(Figure 5.4B) and this occurred to the same degree in QM
WT 
or QM
KO 
B cells. However there 
were significantly fewer cells that were CD69
+
, leading to significantly lower CD69 mean 
fluorescence intensity in the QM
KO 
population on activated B cells (Figure 5.4C). 
 
 
Although the experiments in BCR non-transgenic mice (Fig. 5.1) showed a significant 
reduction of antigen-specific B cells 2 days post immunisation, the experiments with QM B 
cells show that C-Rel-deficient B cells bind antigen as efficiently as QM
WT 
B cells. Further, 
following antigen binding, IRF4 protein induction is normal. B cells show grossly similar 
expression of activation markers (CD62L, which is required for their retention at the site of 
activation and the expression of the co-stimulatory molecule CD86), although expression of 
CD69 is slightly reduced. CD69 is reported to have a negative regulatory role on T cells (la 
Fuente et al., 2012) and has been shown to be regulated by NFκB family members. The 
discrepancy between initially similar numbers of C-REL
WT 
and C-REL deficient B cells being 
activated and significantly lower numbers 2 days post immunisation probably means that 
proliferation in C-REL deficient B cells in the extrafollicular response in inhibited. 
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5.2.2 Defects in plasma-cell and germinal centre formation are B-cell intrinsic 
C-REL is implicated in signalling pathways in many cell types, and the slight reduction in 
numbers of activated B cells discussed in the last paragraph may be due to an impact of C- 
REL deficiency on accessory cells. Therefore, adoptive transfer experiments were done to 
study the responses of C-REL
KO 
B cells in a wild-type environment. 5x10
5 
antigen-specific 
QM
NP/NP κ-/- C-RELWT or QMNP/NP κ-/- C-RELKO (hereafter referred to as QMWT and QMKO) B 
cells were transferred into C57BL/6 mice. This was followed 24 hours later by challenge with 
NP-Ficoll. Resting B cells were enriched from total splenocytes using negative selection with 
anti-CD43 magnetic beads. The percentages of NP-binding B cells were measured by FC to 
ensure similar numbers of antigen-specific cells were transferred. 
 
 
 
Two hours post-immunisation, eYFP
+ 
NP-binding donor cells were tested for their expression 
of IRF4 protein. We found that QM
KO 
B cells did not have any defect in their early 
upregulation of IRF4 protein. QM
KO 
B cells expressed similar amounts of IRF4 protein 
compared to QM
WT 
B cells two hours (Figure 5.5A) and four hours post immunisation 
(Figure 5.5B). 
 
 
 
To exclude that differences in the numbers of transferred, C-REL deficient antigen-specific B 
cells were causing the lower amounts of cells developing from transferred QM
KO 
cells, the 
percentage of eYFP
+ 
transfer cells were measured over the first 5 days in a single experiment. 
Two hours post-immunisation, B cells have not yet started to divide, and similar numbers of 
QM
WT 
and QM
KO 
B cells were detected within spleens (Figure 5.6A). Likewise two days 
post-immunisation the percentage of transferred cells were also similar, whether B cells were 
QM
WT 
or QM
KO
. Still, five days after immunisation there are significantly fewer eYFP
+ 
cells 
(>80% reduction) when C-REL is absent in B cells (p<0.05). 
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To test whether defects in plasma-cell differentiation observed in C-REL
KO 
mice were B-cell 
intrinsic, numbers of plasma cells were quantified by FC. The percentage of QM
KO 
transfer 
cells which differentiated into plasma cells (Figure 5.6B and C) were reduced by around 70% 
(p<0.001) and plasma-cell numbers are reduced by >95% (Figure 5.6D, p<0.001). Spleen 
sections of hosts of QM
KO 
B cells were analysed by immunohistology five days after 
immunisation. Spleen sections were stained with antibodies against the QM idiotype BCR 
(blue) and IgD (brown) to visualise donor-derived germinal centres and plasma cells. Whilst 
QM
WT 
B cells form large germinal centres and plasma-cell foci, QM
KO 
B cells produce small 
germinal centres and plasma cells are mostly absent (Figure 5.6E). 
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To test whether levels of IRF4 protein were sustained two days post immunisation, IRF4 
protein levels were tested by FC. QM
KO 
B cells were found to express similar levels of IRF4 
protein two days after immunisation (Figure 5.7A). We found that similar to early 
intermediate level IRF4 expression, upregulation of AID protein is not impaired in QM
KO 
B 
cells either (Figure 5.7A). Two days after immunisation, antigen specific B cells are still 
located at the border between the T-zone and the follicles. There is no significant difference in 
B-cell location between QM
KO 
and QM
WT 
B cells (Figure 5.7B). 
 
 
 
To test whether effects of early or late stage IRF4 expression cause defective plasma-cell 
differentiation in C-REL deficient B cells, QM
WT 
or QM
KO 
B cells were FACS sorted at 
selected time points after immunisation. There is no difference in IRF4 mRNA expression 
within the first 2 days post immunisation, with a normal rapid peak in Irf4 expression 2 h 
after immunisation (Figure 5.8A) and normal loss of IRF4 mRNA levels two days post- 
immunisation. Five days post immunisation IRF4 is down-regulated equally within the 
germinal centre population. When the few plasma cells that develop from QM
KO 
B cells 5 d 
post immunisation were sorted, there was not significant difference in Irf4 mRNA levels 
compared to QM
WT 
plasma cells. Prdm1 mRNA, encoding the transcription factor BLIMP1, 
is essential for the plasma-cell differentiation programme (Nutt et al., 2011). Lack of plasma 
cells may be due to failure to upregulate Prdm1. To test if changes in Prdm1 expression cause 
the reduction in the number of plasma cells developing, Prdm1 mRNA was measured in 
sorted QM
WT 
and QM
KO 
B cells and plasma cells. Prdm1 mRNA becomes detectable within 
two days of immunisation, due to the first differentiation of small numbers of plasma cells 
(Marshall et al., 2011). Two days after immunisation both QM
WT 
and QM
KO 
B cells have 
similar upregulation of Prdm1 mRNA (p<0.05) (Figure 5.8B). Five days after immunisation, 
Prdm1 mRNA is further strongly induced in both QM
WT  
and QM
KO  
plasma cells (p<0.05). 
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Therefore reduced plasma-cell numbers do not seem to be due to a defect in Prdm1 induction, 
at least not in the small numbers of plasma cells that do develop from QM
KO 
B cells. 
 
 
IRF4 protein expression was also tested by FC within QM
KO 
derived plasma cells and 
germinal centre B cells. Germinal centre B cells showed similar absence of IRF4 protein 
whether they expressed C-REL protein or were C-REL deficient (Figure 5.8C), while plasma 
cells (gated as shown in figure 5.6B) express similar high levels of IRF4 protein whether 
derived from B cells that are QM
KO 
or QM
WT 
(Figure 5.8C and D) (p<0.05). 
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5.2.3 Normal AID protein and mRNA induction when B cells are C-REL deficient 
 
 
The initial upregulation of IRF4 protein to intermediate levels is normal when B cells lack C- 
REL protein (Figure 5.1D, Figure 5.3C). However, plasma-cell differentiation is impaired 
(Figure 5.7A-D). Two days after immunisation, AID protein becomes detectable within 
differentiating antigen-specific B blasts within the follicles (Figure 3.7). To test effects of C- 
REL deficiency on AID protein induction the adoptive transfer system was used. Spleen 
sections were stained with antibodies against the QM BCR idiotype in conjunction with AID 
and IgD in order to locate AID expressing cells in the outer T zone and follicles (Figure 
5.9A). Similar proportion and similar levels of AID protein expression were detected within 
nuclei of individual QM
WT 
and QM
KO 
B cells (Fig. 5.9B). 
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5.2.4 Normal induction of Ig Class Switching in C-REL deficient B cells 
NFκB1 deficiency in B cells does not affect IRF4 intermediate level protein or AID induction, 
and early GC independent Ig class switching is not diminished. Following transfer of QM
WT 
or QM
KO 
B cells into WT hosts, Ig class switching was quantified by measuring the titres of 
unswitched and class switched antibodies in sera. NP-specific IgM titres increase within five 
days of immunisation. Although there is a trend to lower IgM levels from QM
KO 
B cells, the 
difference was not significant (Figure 5.10A). When testing NP-specific IgM
a 
only, which is 
derived solely from the transferred QM B cells, lower production derived from QMKO cells 
becomes clearly detectable by two days after immunisation (Figure 5.10B). 
NP-specific IgG and IgG1
a 
produced by QM
KO 
cells show a similar reduction, however, due 
to the low number of mice analyzed differences between WT and C-REL deficiency are never 
significant (Figure 5.10C, D,). There is no significant difference the ratio of IgG1
a 
to IgM
a 
indicating that there is no change in the frequency of Ig class switching events of QM
KO 
B 
cells before they differentiate into plasma cells (Figure 5.10E). As IgG1
a 
titres were 
undetectable in the sera of several mice, Ig class switching frequency was confirmed by FC 
and IF staining. For FC, eYFP
+
, NP-binding, CD138
+ 
plasma cells were gated (Figure 5.11A) 
and analysed for expression of IgG3 and IgG1. The main isotype produced in TI-II responses 
is IgG3 (Vinuesa et al., 2000). Significantly fewer IgG switched plasma cells were seen in 
spleens from mice receiving QM
KO 
B cells. IgG3
+ 
and IgG1 switched plasma-cell frequencies 
are reduced by >97% when B cells lack C-REL protein (p<0.05, Figure 5.11B, C). 
Unswitched plasma cells are also reduced by >95% in QM
KO 
B cells compared to QM
WT 
B 
cells (p<0.05, Figure 5.11D). While there was no obvious reduction of switched cells when 
QM
WT 
B cells were transferred into a C-REL
KO 
environment, QM
WT 
B cells did produce 
significantly fewer IgG1
−
/IgG3
− 
negative plasma cells in a C-REL
KO 
environment (p<0.05, 
Figure 5.11D). This may represent increased Ig class switching to other isotypes such as 
IgG2a when C-REL is absent in stromal cells. 
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To confirm results from FC and to quantify class switching specifically in extrafollicular 
plasma cells, IF staining was performed on spleen sections from mice that received QM
WT 
or 
QM
KO 
B cells followed by immunisation with NP-Ficoll. Transferred B cells were identified 
by their expression of the QM BCR idiotype. Counterstaining with antibodies against IgM 
and IgG was used to identify non-switched or switched plasma cells (Figure 5.12A). Five 
days after immunisation, QM
WT 
B cells have formed large plasma-cell foci in the red pulp. In 
contrast, few QM
KO 
extrafollicular plasma cells are visible (Figure 5.12A). Transfer of QM
KO 
B cells result in a slightly lower frequency of IgM expressing extrafollicular plasma cells than 
transfer of QM
WT 
B cells (p<0.05, Figure 5.12B). Further, if anything, higher percentages of 
IgG switched plasma cells form (Figure 5.12C), resulting in a slightly increased ratio of IgG 
to IgM expressing cells. (Figure 5.12D), confirming that C-REL-deficient B cells have no 
defect in CSR. 
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To further confirm this we tested the induction of IgG3 germline heavy chain transcripts in 
sorted QM
WT 
and QM
KO 
B cells after in WT environments after immunization. eYFP
+ 
NP- 
binding B cells were FACS sorted before and 2 or 48 hours after immunisation with NP- 
Ficoll. Five days after immunisation, plasma and germinal centre B cells were sorted. As 
expected, IgG3ST  are significantly  increased within  two hours  of immunisation  (Figure 
5.14A). Increase in IgG3ST expression is similar in both QM
WT 
and QM
KO 
B cells.  IgG3ST 
are further upregulated two days after immunisation in both QM
KO 
and QM
WT 
B cells. Five 
days after immunisation both QM
KO 
germinal centre and QM
KO 
plasma cells express 
significantly higher quantities of IgG3ST than QM
WT 
cells (p<0.05). To test the frequency of 
cells which have completed switching to IgG3 five days after immunisation, expression of 
rearranged Iµ-Cγ3 hybrid transcripts were tested (Figure 5.14B). Both QMWT and QMKO B 
cells produce increased levels of rearranged Iµ-Cγ3 transcripts, in all populations tested, and 
transfer of QM
KO 
B cells resulted in at least the same or more CSR. 
 
 
 
5.3 Summary 
 
 
 
Similar to the phenotype observed in B cells lacking NFκB1, B cells which lack functional C- 
REL protein upregulate intermediate level IRF4 mRNA and protein normally. Far fewer 
plasma are produced, but in the few plasma cells that do develop IRF4 is induced normally. 
The presence of normal intermediate level IRF4 protein results in induction of normal 
induction of AID. This leads to normal, or possibly slightly enhanced, Ig class switching to 
IgG3 and IgG1. 
147  
148  
 
 
 
6: IRF4 INTERMEDIATE EXPRESSION IS REQUIRED FOR 
AID INDUCTION AND CLASS SWITCHING 
 
6.1 Introduction 
 
The previous  two chapters indicate, using mice lacking NFκB family members, that 
intermediate IRF4 protein levels are sufficient for normal AID upregulation and 
extrafollicular CSR. In order to test whether extrafollicular CSR is decreased when 
intermediate level IRF4 protein is blocked, we repressed IRF4 protein with a micro-‐‐ 
RNA. We chose the micro-‐‐RNA miR-‐‐125b for our study as it is predicted to bind the 3' 
UTR of IRF4. Furthermore gururajan et al (2010) showed direct binding of miR-‐‐125b to 
a target sequence (GGGACUC) in the 3' UTR of IRF4 that is conserved between humans 
and mice. Moreover, overexpression of miR-‐‐125b led to inhibition of terminal plasma 
cell differentiation in vitro (Gururajan et al., 2010). 
6.1.1 Protein regulation by miRNAs 
 
Small, single-stranded, non-coding RNAs can modulate the expression of genes (Ambros, 
2004; Zhang et al., 2009). These highly conserved micro-RNAs (miRNA) are typically 18-25 
nucleotides long and can negatively regulate target protein levels post-transcriptionally 
through two mechanisms. The first mechanism is by facilitating the degradation of target 
mRNA, the second mechanism is via inhibition of translation (Mishima et al., 2012). Both of 
these processes are mostly mediated by binding of miRNA to the 3’ untranslated regions 
(UTR) of the target gene. miRNAs are encoded within genomic DNA and their transcription 
occurs via RNA polymerase II. The main pathway of mature miRNA development is shown 
in figure 6.1. The unprocessed, primary miRNA transcript (pri-miRNA), must be converted to 
the pre-miRNA by the enzyme drosha and DiGeorge syndrome critical region gene 8 
(DGCR8). The pre-miRNA is then exported from the nucleus to the cytoplasm by exportin 5. 
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Within the cytoplasm, Dicer processes the pre-miRNA into a duplex. Only one strand (the 
guide strand) forms part of the RNA-induced silencing complex (RISC). The RISC then binds 
to the target 3’ UTR to inhibit translation and direct the mRNA for degradation (O'Connell et 
al., 2010b). 
 
 
miRNAs are regulated not only at the transcriptional level, but also via their subcellular 
localisation and at the processing stage. For instance, interferons can inhibit Dicer expression 
(O'Connell et al., 2010b). miRNAs can be up-regulated or down-regulated by TLR signalling 
and other stress response elements (O'Neill et al., 2011). IL-10 has been shown to 
downregulate miR-155 (McCoy et al., 2010), this miRNA has an important role in B-cell 
differentiation (Turner and Vigorito, 2008). miR-155 has been shown to be necessary for the 
production of IgG1 switched cells and for the formation of GC. Furthermore miR-155 was 
found to directly repress Pu.1 (Vigorito et al., 2007). In addition miR-155 represses AID 
expression (Teng et al., 2008; Vigorito et al., 2007), therefore miR-155 may be important for 
the terminal differentiation and the shutting down of AID expression within plasma cells. 
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Figure 6 1 Processing and regulation of miRNAs 
 
 
Pri-miRNA is transcribed in the nucleus following signalling via TLR ligands, antigen or 
cytokines. Pri-miRNAs are then processed within the nucleus to Pre-miRNA. This is 
regulated by a number of factors such as Drosha, which are themselves subject to regulation 
during inflammation. Pre-miRNA is exported to the cytoplasm by exportin 5. Within the 
cytoplasm pre-miRNA is processed by Dicer. This creates a miRNA duplex which must be 
unwound. The guide strand is incorporated into the RNA-induced silencing complex (RISC). 
Importin 8 transports the complex to the target 3’ UTR. Image taken from {(O'Connell et al., 
2010b). 
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6.1.2 miRNA functions in B cells 
 
Regulation of several events in B-cell differentiation is thought to be under the control of 
miRNAs. This includes B-cell development in the bone marrow where miRNAs are required 
at the transition of pro-B cell to pre-B cell stages. In addition, in mature B cells micro-RNAs 
are involved in cell fate decisions and maintenance of the germinal centre phenotype, this will 
be discussed in more detail later. As well as these roles, miRNAs have been shown to have an 
important role in inflammation and response to TLR signalling. 
 
 
In haematopoiesis, miR-181 is expressed in normal B-lymphoid cells in mouse bone marrow. 
Over-expression of miR-181 causes an increased number of B cells, but no increase in other 
cell types such as T cells or myeloid cells (Chen et al., 2004). In support of this role of miR- 
181 for B-cell differentiation, when Dicer is ablated in early B-cell progenitors there is a 
complete block in B-cell differentiation at the pro- to pre-B cell stage. This may be due to 
increased levels of the pre-apoptotic protein Bim (Koralov et al., 2008). In contrast when 
miR-150 is constitutively expressed there is a differentiation block at the pro-B to pre-B 
transition. Deficiency of miR-150 leads to an accumulation of B-1 B cells in the spleen and 
peritoneal cavity and a decrease in B-2 cells (O'Connell et al., 2010b). In mature B cells, miR- 
150 is expressed at a 10 fold lower level in GC B cells than in naïve and memory B cells (Tan 
et al., 2009) and it is responsible for reducing levels of c-myb, survivin and Foxp1 in B cells 
(Tan et al., 2009). 
 
 
Several studies  have aimed  to define  the miRNAs  expressed  in different  mature B-cell 
populations (Basso et al., 2009; Tan et al., 2009) and many miRNAs have specific expression 
profiles. Germinal centre B cells express high levels of miR-17-5p, miR-181b (Tan et al., 
2009; Zhang et al., 2009), miR-106a (Tan et al., 2009), miR-20b, miR-28 and miR-93 (Zhang 
et al., 2009). Moreover, miR-17-5p, miR-106a and miR-181b are expressed at higher levels in 
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dark zone centroblasts, than in light zone centrocytes. In addition, miR-125b is highly 
expressed in centroblasts located in the dark zone of the germinal centre (Gururajan et al., 
2010) (Malumbres et al., 2009) (Tan et al., 2009). Memory cells in contrast, express high 
levels of miR-223 and this micro-RNA down-regulates the expression of the transcription 
factor LMO2. LMO2 is expressed in germinal centre B cells (Malumbres et al., 2009) (Zhang 
et al., 2009). During antigen-specific responses, miR-9 and members of the miR-30 family 
(miR-30b, miR-30d) block plasma-cell differentiation via repression of BLIMP1 (Zhang et 
al., 2009). miRNAs have also been reported to regulate AID protein, these include miR-155 
(Teng et al., 2008; Vigorito et al., 2007), miR-361 (Basso et al., 2012) and miR-181b (de 
Yébenes et al., 2008). miR-155 also regulates PU.1 (Vigorito et al., 2007). 
 
 
Dysregulation of micro-RNAs have been implicated in a number of B-cell cancers such as 
Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic 
leukemia (CLL) (Zhang et al., 2009). For example, high expression of miR-222, miR-146b- 
5p, miR-146a, miR-21, miR-155, miR-500, miR-363, miR-574-3p and miR-574-5p have been 
detected in activated B-cell (ABC)-like DLBCL cell lines. In addition, high expression of 
miR-222 is correlated with inferior patient survival (Malumbres et al., 2009). miR-17-92 is 
over-expressed in acute lymphoblastic leukaemia (ALL) DLBCL and chronic myeloid 
leukaemia (CML) (O'Connell et al., 2010b) whilst miR-155 is overexpressed in CLL, DLBCL 
and acute myeloid leukaemia (AML)(O'Connell et al., 2010b). 
 
 
 
6.1.3 miR-125b in B-cell differentiation and IRF4 repression 
 
MiR-125b is a 22 nucleotide long, highly conserved micro-RNA found amongst mammals, 
vertebrates and nematodes. The seed region is unchanged throughout these species. There are 
three homologues of miR125: hsa-miR-125a, hsa-miR-125b-1 and hsa-miR-125b-2. miR- 
125a is located on chromosome 17 in mice, whereas miR-125b-1 is located on chromosome 9 
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and miR-125b-2 is located on chromosome 16. miR-125b-1 and miR-125b-2 have differing 
pre-miRNA sequences but identical sequences post-DICER processing. 
miR-125 is over-expressed in B-ALL with a translocation of t(11;14)(q24;q32) and has been 
shown to enhance proliferation by repressing B-cell regulator of immunoglobulin heavy-chain 
transcription (Bright)/ARID3a. This protein activates immunoglobulin heavy chain 
transcription. Repression of this gene blocks differentiation and provides a survival 
advantage. Caspase activation is blocked and therefore apoptosis is reduced when miR-125 is 
over-expressed (Puissegur et al., 2012). Another target of miR-125 in B-ALL that is involved 
in apoptosis, is Trp53inp1, a pro-apoptotic gene induced by cell stress (Enomoto et al., 2011). 
 
Studies addressing the role of miR-125 in haematopoietic stem cells have been contradictory. 
Over-expression of miR-125 can skew cells towards the lymphoid lineage. This is 
characterised by an increase in the number of early B-progenitor cells in the spleen and a 
reduction in the mRNA expression of two pro-apoptotic genes: Bmf and KLF13 (Ooi et al., 
2010). Other reports have found increased numbers of CD11b
+ 
Gr-1
+ 
myeloid cells after 
overexpression of miR-125 in bone marrow progenitors. (Enomoto et al., 2012). Additionally, 
studies have shown that in hepatocellular carcinoma (HCC) miR-125b actually suppresses 
proliferation and promotes apoptosis by inhibiting gene expression of Bcl-2 which is anti- 
apoptotic (Zhao et al., 2012). In addition the negative NFκB regulator TNFAIP3 is a direct 
target of miR-125a and miR-125b in diffuse large B-cell lymphoma (DLBCL) and expression 
of these micro-RNAs increased levels of NFκB (Kim et al., 2012). All these studies use over- 
expression of miR-125 to define its role in the immune system, however this may render 
some of these results misleading, as the micro-RNA is not necessarily expressed at 
physiological levels, and the temporal expression as well as cell types which normally express 
it are different. 
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In mature human B cells, miR-125 is highly expressed in centroblasts within the germinal 
centre (Gururajan et al., 2010). This micro-RNA has been shown to bind to and down- 
regulate the expression of both IRF4 and BLIMP-1, which are both required for plasma-cell 
differentiation. Therefore miR-125 may be required for the maintenance of the germinal 
centre phenotype and preventing premature differentiation into plasma cells (Gururajan et al., 
2010; Malumbres et al., 2009). The experiments described here aim not to study the effects of 
expression of miR-125 in a physiological situation, but rather to use the micro-RNA as a tool 
to repress IRF4 and study the effects of IRF4 absence. 
Our aims during this project were: 
 
1. To repress both early intermediate and late level IRF4 induction 
 
2. To  test  whether  AID  protein  and  mRNA  can  be  upregulated  in  a  system  where  IRF4  is 
deficient 
3. To test downstream Ig class switching after repression of IRF4 protein levels 
 
To address these questions we utilised a system whereby miR-125 is over-expressed by a 
retroviral vector. We then performed cell transfer experiments and tested IRF4 and AID 
expression, Ig class switching and B-cell differentiation. These were tested by flow 
cytometry, immunohistochemistry, immunofluorescence, real-time RT-PCR and ELISA. 
6.2 Results 
 
 
6.2.1 Forced expression of miR-125b leads to splenic expansion 
 
Due to the published role of miR-125b in the repression of IRF4 gene expression, bone 
marrow was infected in vitro with an MSCV-based retrovirus vector which was either empty 
(control) or contained a 500-bp gene segment for the miR-125b hairpin. Both vectors also co- 
express GFP to enable the sorting of successfully infected cells. Lethally irradiated C57 host 
mice were reconstituted with GFP
+ 
infected bone marrow and between five and eight weeks 
later, mice were culled and spleen and bone marrow analysed. As this micro-RNA is highly 
expressed in haematopoietic stem cells (O'Connell et al., 2010a; Ooi et al., 2010),   we 
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questioned whether B-cell development in the bone marrow was altered when miR-125b is 
over-expressed. To test this, bone marrow was analysed by FC. Late pro-B cells express the 
markers B220, CD43, HSA and LY51 (Dautigny et al., 1996). B cells expressing these 
markers were found to be reduced in mice with forced expression of miR-125b compared to 
control mice (Figure 6.2A). In addition, percentages of immature B cells (IgM
+
B220
+
) were 
also reduced. 
 
We next sought to test whether the reduced proportion of pre-B and immature B cells leads to 
fewer B cells in the spleen and whether the numbers of other myeloid and lymphoid cells in 
the spleen are normal, as there have been conflicting reports on the effect of miR-125b over- 
expression in haematopoietic cells within the bone marrow. Whilst miR-125b has been 
reported to cause a myeloid cell expansion (O'Connell et al., 2010a) with no effect on the 
lymphoid compartment, another study showed expansion in the lymphoid compartment, 
specifically of CD8
+ 
T cells (Ooi et al., 2010). Spleens were expanded when miR-125b was 
over-expressed (Figure 6.2B). Spleens from mice over-expressing miR-125b contain 
significantly more splenocytes than control spleens (p=0.0039), by a median value of 1.65x 
(Figure 6.2C). To address whether this could be due to increased numbers of lymphocytes, FC 
was performed. B-cell numbers were found to be unaltered in the spleens of miR-125b over- 
expressing mice compared to control spleens (Figure 6.2D). Likewise T-cell numbers were 
also similar between the two groups (Figure 6.2E). In contrast, CD11c
+ 
cell numbers are 
significantly increased (p=0.0465) by a median of 3x when miR-125b is over-expressed. 
CD11c is an integrin which binds to the complement fragment iC3b, fibrinogen, ICAM-1, 
ICAM-2, VCAM-1 (Sadhu et al., 2007), ICAM-4 (Ihanus et al., 2007), LPS (Ingalls and 
Golenbock, 1995) and collagen (Garnotel et al., 2000). This integrin is mainly expressed by 
dendritic cells, although it is capable of being expressed by inflammatory spleen monocytes 
(Drutman et al., 2012) and neutrophils under certain circumstances ((Loike et al., 1991)).  In 
156  
addition, we found that over-expression of miR-125b led to significantly increased numbers 
of natural killer (NK) cells (p=0.0043) by a median of 75%. Therefore splenic expansion is 
partly due to increased cell numbers in both the lymphoid and myeloid compartments. 
However this does not account for the total increase in splenocytes, therefore other cell types 
may also be increased in number besides CD11c
+ 
and NK cells 
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6.2.2 Over-expression of miR-125b leads to enlarged red pulp volume following 
immunisation 
We next aimed to test whether increased numbers of dendritic and NK cells led to an altered 
splenic architecture. C57 mice were lethally irradiated and reconstituted with GFP
+ 
infected 
bone marrow. Mice were immunised three times with NP coupled to chicken γ–globulin (NP- 
CGG) and spleens were processed four days after the final immunisation. IHC staining was 
performed with antibodies against antigen specific B cells and IgD
+ 
follicles (Figure 6.3A). 
Whilst mice which received control vector infected B cells have well defined IgD
+ 
follicles, 
mice  infected  with  miR-125b  have  disorganised  follicles  and  larger  red  pulp  areas. 
Quantification from histology reveals miR-125b over-expression leads to significant 
expansion of the red pulp (p=0.05) by a median of 57% compared to control spleens (Figure 
6.3B). B-cell follicles are significantly reduced as a proportion of the spleen area (p=0.05) by 
a median value of 73% when miR-125b is over-expressed (Figure 6.3C). The proportion of 
the spleen comprised of GC are not significantly reduced however (Figure 6.3D). However 
because miR-125b over-expression leads to larger spleens composed mainly of red pulp, this 
leads to a reduction in the relative GC area as a percentage of the spleen. Accordingly the 
absolute GC area is very similar (Figure 6.3E). Additionally, plasma cells per mm
2 
of red pulp 
 
area are significantly reduced (p=0.05) by a median of 89% when miR-125b is over- 
expressed (Figure 6.3F). However this is most likely due to the larger red pulp area in miR- 
125b over-expressing mice. 
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6.2.3 Over-expression of miR-125b leads to a block in plasma-cell differentiation and 
larger germinal centres 
To test the role of miR-125b on B cells undergoing an immune response, C57 wild-type mice 
were primed with CGG in alum. Five weeks later, mice received control or miR-125b infected 
QM B cells, followed by immunisation with NP-CGG twenty-four hours later. Mice were 
culled at selected timepoints after immunisation (Figure 6.4A). Control or miR-125b over- 
expressing donor cells were isolated from splenocytes using CD43 beads to enrich for resting 
B cells. These were FACS sorted for GFP expression before transfer and equal numbers of 
NP-binding B cells were transferred into host mice (Figure 6.4B). Priming hosts with CGG 
five weeks before cell transfer allows the generation of T-cell memory. Memory T cells are 
rapidly activated following immunisation to provide survival and differentiation signals to 
naïve NP-specific B cells. In this system, the B-cell response occurs with similar dynamics to 
the T-independent responses described earlier, with GC and extrafollicular plasma cells 
generated four days after immunisation. Extrafollicular plasma cell numbers peak at between 
four and five days after immunisation whereas GC continue to increase in size and reach a 
peak at 14 days after immunisation. 
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To test whether B-cell activation and differentiation occur normally in this model, FC staining 
was performed on splenic B cells five and eight days after immunisation. To test the 
development of germinal centres, splenocytes were stained with antibodies against B220, 
FAS and GL7 and cells were incubated with NP-PE. GC B cells were gated as NP-binding, 
B220
high 
cells expressing both FAS and GL7 (Figure 6.5A). Five days after immunisation, 
numbers of GC cells are similar whether mice received control cells or miR-125b over- 
expressing cells (Figure 6.5B). However, numbers of GC B cells are 1.5x higher (P<0.05) 
eight days after immunisation in mice receiving miR-125b over-expressing cells. While this 
increase seems very low, further experiments (described below) confirm an effect on the size 
of the germinal centre population due to overexpression of miR-125b. 
 
 
GFP
+ 
antigen-specific plasma cells were identified by their down-regulation of B220 and 
expression of CD138 (Figure 6.5C). In contrast to germinal centres, plasma cells are 
significantly reduced (P<0.05) by 80% five days after immunisation when B cells over- 
express miR-125b (Figure 6.5D). Extrafollicular plasma-cell numbers reach a peak during the 
TD response at between four and five days after immunisation before decreasing again due to 
onset of apoptosis in non-sustainable plasma cells. This is followed by a plateau phase with 
constant number of plasma cells sustainable by the splenic environment (Sze et al., 2000). 
Between five and eight days after immunisation, plasma-cell numbers in recipients of control 
infected QM B cells have decreased by a median of 52%. However plasma-cell numbers 
increase further between five and eight days after immunisation in mice which received miR- 
125b over-expressing B cells, reaching similar levels to control infected plasma cells by day 
 
8. The further expansion of plasma cells after day 5 is probably due to plasma-cell numbers 
not having filled niches available in the spleen in recipients of miR-125b infected B cells by 
day 5 (Sze et al., 2000). 
163  
164  
Figure 6.5: miR-125b over-expressing B cells form larger germinal centres and 
produce fewer plasma cells than control B cells. CD43
-
 GFP
+
 infected B cells were 
isolated by MACS column and transferred into wild-type hosts. 24 hours later, mice 
were immunised with NP-CGG i.p.  A: Representative FC plots from either non-
immunised C57 mouse (top), or eight days after immunisation with NP-CGG in mice 
which had received control QM B cells (centre) or miR-125b over-expressing QM B 
cells (bottom). Germinal centre B cells were identified by binding of NP-PE and by 
staining with labelled antibodies against B220, FAS and GL7. B: Absolute numbers of 
control (blue) or miR-125b over-expressing germinal centre cells five and eight days 
after immunisation gated as shown in (A). C: Representative FC plots of control B 
cells (top) or miR-125b over-expressing plasma cells (bottom) within the spleen, five 
days after immunisation. Plasma cells were identified as NP-binding, GFP
+
 (left plot) 
and B220
low
, CD138
+
 D: Number of CD138
+
 plasma cells within the spleen five and 
eight days after immunisation gated as in (C).  
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To confirm the results obtained by FC and to identify the location of transferred B cells 
within the splenic microarchitecture, spleens were analysed by IHC, four, five and eight days 
after immunisation. Antibodies against IgD and the QM BCR (idiotype) were used to detect 
B-cell follicles and transferred B cells. Five days after immunisation, small germinal centres 
are detectable in mice that received control B cells and in those receiving miR-125b over- 
expressing B cells (Figure 6.6A top panel). Mice receiving control B cells have also formed 
plasma-cell foci five days after immunisation (Figure 6.6A, arrow), whereas plasma cells are 
infrequent in mice receiving miR-125b over-expressing B cells. Eight days after 
immunisation, numbers of extrafollicular plasma cells have decreased, whereas germinal 
centres remain visible (Figure 6.6A bottom panel). Following quantification of tissue sections 
stained as in Figure 6.6A, germinal centre sizes four and five days after immunisation were 
found to be similar between mice which received miR-125b over-expressing B cells and mice 
which had received control B cells (Figure 6.6B and C). However, eight days after 
immunisation GCs from mice receiving miR-125b infected B cells are significantly larger 
(p=0.0383), by a median of 100% (Figure 6.6C). 
In contrast to germinal centre sizes, miR-125b infected plasma-cell numbers are significantly 
decreased throughout the response (p=0.0383) compared to control B cells. While control 
plasma-cell numbers decrease after day 5, due to onset of apoptosois of non-sustainable B 
cells (Sze et al., 2000), there is a slight increase in plasma-cell numbers from miR-125b 
overexpressing B cells between day 5 and day 8. This is probably due to plasma-cell niche 
space (Sze et al., 2000) still available for expansion of the few plasma cells that differentiate 
despite over-expressing miR-125 (Figure 6.6E). 
166  
 
 
 
167  
Figure 6.6: miR-125b over-expressing B cells form larger germinal centres and 
produce fewer plasma cells than control B cells. CD43
-
 GFP
+
 infected B cells were 
isolated by MACS and transferred into wild-type hosts. 24 hours later, mice were 
immunised with NP-CGG i.p. A: Spleen sections from mice which had received 
control B cells (left) or miR-125b over-expressing cells (right) were cut and stained for 
the QM BCR (idiotype) and IgD at five days after immunisation (top) and eight days 
after immunisation (bottom). Scale bar indicates 100μm. B: Four days after 
immunisation ID
+
 germinal centres sizes were quantified from histology. C: Idiotype
+
 
germinal centre sizes 5 and 8 days after immunisation were measured from tissue 
sections. D: Idiotype
+
 plasma cells were quantified within the red pulp. from IHC 
staining four days after immunisation. E: Idiotype
+
 plasma cells were counted on tissue 
sections 5 and 8 days after immunisation and expressed as the number of cells per mm
2
 
of red pulp area. Each data point represents one mouse.  Data are representative of at 
least two experiments. Data from four days after immunisation and data from 5 and 8 
days after immunisation are from two separate experiments.  
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6.2.4 B cells over-expressing miR-125b locate to the marginal zone of the spleen 
Within four days of immunisation, B cells have differentiated into germinal centre cells or 
plasma cells. However some idiotype
+ 
cells are located in the outer follicles (Figure 6.7A). At 
four and five days after immunisation, numbers of these cells are similar (Figure 6.7B and C), 
however, eight days after immunisation there are significantly more of these cells in the 
spleens of mice which received miR-125b over-expressing B cells (Figure 6.7C, 
increase=89% P=0.05). Memory B cells locate to the marginal zone and follicles during T- 
dependent responses (Anderson et al., 2007) and are visible as early as four days after 
immunisation when T-cell help is readily available (Liu et al., 1988). As activated B cells also 
initially migrate to the outer follicles (Gatto and Brink, 2013), IF staining was used to test 
whether the idiotype
+ 
cells visible eight days after immunisation are located within the 
marginal zone or the outer follicles. The marginal zone is defined as a ring of IgD
− 
IgM
+ 
B 
cells separated from the follicles by a ring of MOMA-1 expressing macrophages which are 
localised at the marginal sinus (Kraal and Janse, 1986). NP-binding, QM BCR expressing 
transferred cells were found to be located preferentially outside of the ring of MOMA-1 
macrophages (Figure 6.7D) within the IgD
− 
IgM
+ 
marginal zone (Figure 6.7E). Upon closer 
investigation, transferred cells within the marginal zone were found to be largely IgM
+ 
but not 
IgD
+ 
whether they were infected with control vector or miR-125b (Figure 6.8). Antigen- 
specific memory B cells have been shown to be IgD
− 
IgM
+ 
and express marginal zone 
markers (LIU et al., 1988), whereas recirculating cells which transit through the marginal 
zone are IgD
+
. 
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To test whether over-expression of miR-125b increases the number of memory cells we tested 
the expression of memory cell markers in the blood. Memory cells can be detected within the 
blood as early as one week after primary immunisation (Blink et al., 2005). There are few 
markers available for memory B-cell identification, however a larger proportion of memory B 
cells than naïve antigen-specific cells express the cell surface proteins FAS (CD95), CD80 
and CD62L. In addition, memory B cells express a higher quantity of these proteins on their 
surface (Anderson et al., 2007).  GFP
+ 
cells in the blood (derived from control cells or miR- 
 
125b over-expressing cells) were more numerous in mice which received miR-125b over- 
expressing B cells (Figure 6.9A) These cells were tested by FC for expression of memory 
markers five days after cell transfer and immunisation with NP-CGG (Figure 6.9A). The 
majority of antigen-specific B cells in the blood were found to express high levels of CD80 
(Figure 6.9B), CD62L (Figure 6.9C) and FAS (Figure 6.9D) compared to endogenous non- 
activated B cells. miR-125b over-expressing B cells within the blood expressed similar levels 
of CD80 and CD62L protein on their surfaces compared to control infected B cells (Figure 
6.9B and C). However miR-125b over-expressing B cells did express significantly more FAS 
protein (p=0.05, increase=64%) (Figure 6.9D). This indicates that miR-125b may affect the 
generation of memory cells. In contrast, eight days after immunisation the proportion of 
‘memory-type’ cells in the blood were found to be similar (data not shown). 
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6.2.5 miR-125b directly regulates IRF4 mRNA and protein levels 
 
In human GC B cells, miR-125b is highly expressed in centroblasts and can inhibit IRF4 and 
BLIMP-1 expression in human cell lines (Gururajan et al., 2010; Malumbres et al., 2009). 
Malumbres et al (2009) show repression of IRF4 at the protein level, whilst mRNA levels of 
IRF4 were minimally affected and mRNA transcripts for BLIMP1 were actually increased. 
To confirm that miR-125b reduces protein levels of IRF4, a luciferase reporter assay was 
performed using HEK293 cells. Both miR-125b-1 and miR-125b-2 were shown to reduce 
levels of IRF4 (Figure 6.10A) by approximately 23%. Interestingly miR-125a shows a strong 
reduction of IRF4. Similarly to miR-125b, this micro-RNA is also expressed in human 
centroblasts, although at much lower quantities, but has never before been shown to bind 
BLIMP-1 or IRF4 (Gururajan et al., 2010). 
 
 
Repression of IRF4 by miR-125b has never been shown in murine B cells. To investigate 
whether miR-125b over-expression is capable to repress IRF4 expression in vivo, we FACS 
sorted antigen-specific B cells two days after immunisation from the spleens of mice that 
received control or miR-125b over-expressing B cells. These were tested for their expression 
of Irf4 transcripts (Figure 6.10B). Two days after immunisation, Irf4 transcripts are 
significantly upregulated in control infected B cells compared to non-activated B cells 
(p=0.0076). At the same time miR-125b over-expressing B cells contain significantly less Irf4 
mRNA transcripts compared to control B cells (p=0.0325). 
 
 
Transcript levels are not always directly proportional to protein concentration; therefore to 
test whether decreased mRNA transcripts lead to reduced translation to IRF4 protein, FC 
staining was performed. Transferred cells were identified as GFP
+ 
NP
-
binding and B220
+ 
(Figure 6.10C).  Two days after immunisation protein levels of IRF4 are 61% lower in miR- 
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125b infected B cells compared to control infected B cells (p=0.05) (Figure 6.10D). Four days 
after immunisation, IRF4 protein levels are still decreased by 84% (p=0.0143) in miR-125b 
over-expressing B cells. Taken together this shows that miR-125b decreases mRNA 
transcripts of Irf4 and this leads to reduced translation of IRF4 protein. 
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6.2.6 Repression of IRF4 by miR-125b leads to decreased Aicda mRNA and AID protein 
levels 
Our hypothesis was that the early intermediate phase of IRF4 protein expression is required 
for the upregulation of AID protein and Ig class switching. As shown in chapter 3, AID 
mRNA and protein become detectable as early as 48 hours after B-cell activation. As we 
found that miR-125b repressed the expression of IRF4 protein at all stages of its bimodal 
expression, we questioned whether this led to decreased Aicda transcripts and AID protein 
levels. MiR-125b over-expressing and control B cells were FACS sorted two, five and eight 
days after immunisation with NP-CGG. Plasma cells were excluded. We found that two days 
after immunisation Aicda mRNA levels were significantly reduced by a median of 86% 
(p=0.05) when B cells over-express miR-125b, compared to mock-infected control cells. 
Aicda transcripts  remain  lower  throughout the  response  five  and  eight days  after 
immunisation. To test whether this leads to reduced expression of AID protein, tissue sections 
were fluorescently labelled with antibodies against IgD, AID and the QM BCR to identify 
transferred cells (Figure 6.11B). Whilst AID protein is detectable within mock-infected B 
cells, very little AID protein is detectable when miR-125b is over-expressed in B cells (Figure 
6.11C). This is a significant decrease in AID protein (Figure 6.11D) (p=<0.0001) by a median 
value of 10%. 
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6.2.7 Inhibition of early stage IRF4 and AID  leads to reduced extrafollicular class 
switching 
Over-expression of miR-125b leads to diminished plasma-cell responses. To test whether 
CSR is reduced, serum titres of switched antibodies and NP-specific IgM
a 
were tested. A 
difference of the ratio of these would indicate a block in Ig class switching. Two days after 
immunisation NP-specific IgM is largely undetectable, whereas four days after immunisation, 
titres have increased in the sera of all mice (Figure 6.12A). Interestingly, sera from mice 
which received miR-125b over-expressing B cells actually contain significantly higher levels 
of anti-NP IgM antibodies despite containing fewer plasma cells (p=0.0454, increase= 67%). 
Titres of anti-NP IgM are similar however eight days after immunisation with NP-CGG 
whether mice received control or miR-125b over-expressing B cells (Figure 6.12A).  Titres of 
total NP-specific IgG become detectable four days after immunisation and are further 
increased eight days after immunisation (Figure 6.12B). Four days after immunisation, sera 
obtained from mice receiving miR-125b over-expressing B cells contains similar titres of anti- 
NP IgG compared to sera from mice receiving control infected B cells. However eight days 
after immunisation, sera from mice that received miR-125b over-expressing B cells contains 
significantly less anti-NP IgG compared to mice receiving control B cells (p=0.0383 
decrease=61%). To test for development of higher affinity, NP-specific IgG, binding to NP2- 
BSA coated ELISA plates was tested. NP-specific high affinity IgG molecules become 
detectable eight days after immunisation (Figure 6.12C). These are produced at similar titres 
in mice receiving control B cells and mice receiving miR-125b over-expressing B cells. When 
the ratio of high affinity IgG to total IgG is compared there is no significant difference in 
affinity when miR-125b is over-expressed in B cells on day 8 (Figure 6.12D). Therefore 
transfection of B cells which leads to IRF4 inhibition and AID reduction does not vastly 
affect affinity maturation. 
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CSR is tested by measuring the ratio of IgG to IgM. Whilst this ratio is not significantly 
altered four days post-immunisation, the ratio is significantly decreased in the sera of mice 
receiving miR-125 infected B cells eight days post-immunisation (Figure 6.12E). Increased 
titres of anti-NP IgM were not due to higher numbers of miR-125b infected B cells being 
transferred into wild-type hosts as four and eight days after immunisation, numbers of NP- 
binding GFP
+ 
cells in the spleens detected by FC are similar between the two groups (Figure 
 
6.12F). Likewise eight days after immunisation numbers of NP-specific infected cells are not 
significantly different between the two groups. 
 
To exclude NP-specific antibodies produced by endogenous plasma cells, ELISAs were 
repeated with QM allotype specific antibodies. IgM
a
, expressed by QM B cells, becomes 
detectable four days after immunisation. Until eight days after immunisation, IgM
a 
titres are 
similar between the two groups (Figure 6.12G). IgG1
a 
titres in contrast are significantly 
reduced at both four (p=0.0407 decrease=52%) and eight days (p=0.05 decrease=70%) post- 
immunisation in sera from mice that received miR-125b infected B cells (Figure 6.12H). The 
reduced ratio of IgG1
a 
to IgM
a 
fig. 6.12I shows that there is reduced switching until eight 
days after immunisation. Interestingly IgG1 switch transcripts are induced normally when B 
cells are infected with miR-125b (Figure 6.12J). 
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Figure 6.12 Class switching is impaired when B cells over-express miR-125b. Control 
(blue) or miR-125b infected B cells (red) were transferred into CGG primed hosts and 
immunised with NP-CGG. A:  IgM binding to NP
2
-BSA. B: IgG binding to NP
15
-BSA. 
C: IgG binding to NP
2
-BSA, D: Relative affinity: ratio of IgG binding to NP
2
/IgG 
binding to NP
15
. E: Ratio of IgG binding to NP
15
-BSA compared to IgM binding to 
NP
2
-BSA. F: Numbers of GFP
+
 NP-Binding B cells were quantified by FC. G: IgM
a
 
binding to NP
15
-BSA, H: IgG1
a
 binding to NP
15
-BSA, I: Switching ratio of IgM
a
 to 
IgG1
a
. J: IgG1 heavy chain germline transcripts in sorted control vector or miR-125b 
infected B cells two days after immunisation. Each data point represents one mouse. 
Data are representative of x2 experiments. 
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6.2.8 Inhibition of IRF4 and AID protein induction leads to reduced Ig class switching in 
situ 
To test whether reduced AID protein leads to a reduction in Ig class switching in situ, spleen 
sections were analysed by IF. Control infected or miR-125b over-expressing plasmablasts 
within the extrafollicular foci were tested for expression of IgM or IgG five days after 
immunisation. During the carrier primed NP-CGG response, IgG1 (Toellner et al., 1996) is 
the major isotype which B cells switch to. Sections were stained with antibodies against IgM, 
IgG and the QM BCR to identify transferred cells that had switched to IgG production (Figure 
6.13A). The proportion of IgM expressing cells was significantly increased in miR-15b over- 
expressing B cells compared to control infected B cells (increase=1.5%, p=0.05) (Figure 
6.13B). In addition, the proportion of IgG expressing cells is significantly reduced when mice 
over-express miR-125b (p=0.0129, decrease=40%) (Figure 6.13C). This leads to a decreased 
ratio of Ig class switching when miR-125b is over-expressed (p=0.05 decrease=75%) (Figure 
6.13D). 
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Figure 6.13 Class switching is impaired when B cells over-express miR-125b. Control 
or miR-125b infected B cells were transferred into CGG primed hosts and immunised 
with NP-CGG. A: Five days later spleens from mice receiving control cells (top) or 
miR125b over-expressing cells (bottom) were stained with labelled antibodies against 
IgM (green), IgG (red), and the QM BCR (blue). B and C: Ig class switching within 
control (blue) or miR-125b infected B cells (red) was quantified from fluorescently 
stained sections and expressed as the percentage of cells expressing IgM (B) and the 
percentage of cells expressing IgG (C). Circles indicate QM BCR expressing 
transferred cells. Scale bar indicates 50μm. 
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6.2.9 IRF4 does not regulate AID expression within the germinal centre 
 
AID protein expression is also required for affinity maturation and Ig class switching within 
the germinal centre reaction. We found that affinity maturation was unaffected when B cells 
over-express miR-125b (Figure 6.12D) yet AID mRNA was reduced in the germinal centre 
population at all timepoints tested (Figure 6.11A). Therefore we tested induction of AID at 
the protein level. Spleen sections were tested for expression of AID protein within germinal 
centre B cells. Four days after immunisation germinal centres derived from miR-125b 
infected B cells express similar levels of AID protein (Figure 6.14A). Therefore IRF4 
intermediate level expression is dispensable for the regulation of AID within the germinal 
centre. The few IRF4int cells in the light zone (Figure 6.14B) are not likely to be the cells that 
go on to express AID. 
6.3 Summary 
 
We found that overexpression of miR-125b lead to a reduction in early plasma-cell generation 
four and five days after immunisation. In contrast, numbers of germinal centre B cells were 
increased eight days after immunisation in mice overexpressing miR-125b. Additionally 
numbers of memory-type cells within the marginal zone of the spleen accumulated with time 
after immunisation and memory cells within the blood were increased. Furthermore, 
overexpression of miR-125b in B cells was found to repress all stages of IRF4 expression at 
the mRNA and protein level. This leads to reduced Aicda transcripts and reduced AID protein 
levels in B cells. Moreover, reduced AID protein levels resulted in reduced CSR frequency 
within the extrafollicular plasmablast population. 
In contrast, affinity maturation was not affected by IRF4 repression and AID protein levels 
appeared normal within the GC compartment. This indicates that AID protein is not regulated 
by IRF4 within the GC compartment, indeed the majority of GC B cells do not express IRF4 
protein. 
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7: DISCUSSION 
 
 
7.1 Divergent GC and extrafollicular responses 
 
Following binding of antigen via their surface Ig, B cells migrate from the marginal zone or 
follicles to the border between follicles and T zone where they are able to interact with 
antigen-primed T cells (Liu et al., 1991; Toellner et al., 1996). This induces proliferation of B 
blasts and later migration to different regions of the spleen occurs (Maclennan et al., 2003). B 
blasts differentiate into germinal centre cells within the follicles whereas extrafollicular B 
blasts differentiate within the extrafollicular regions of the spleen. Whilst extrafollicular foci 
produce fast, generally non-mutated antibody, the slower, GC pathway is important for the 
long-term production of affinity-matured antibody. It is largely unknown which signals decide 
these divergent cell fates. This thesis is largely concerned with differentiation via the 
extrafollicular pathway and Ig CSR within this population. 
7.2 Extrafollicular Ig CSR 
 
CSR is a process which occurs at a high frequency within the GC (Liu et al., 1996). However 
class switched antibody is generated during TI-II responses that do not induce GC (García De 
Vinuesa et al., 1999) and in responses which produce non-productive GC (Vinuesa et al., 
2000), also during the carrier-primed response to TD antigen γ1 switch transcripts are 
detectable within 12 h of secondary immunisation, while B cells still reside in the outer T 
zone and before GC are formed (Toellner et al., 1996) and during a primary T-dependent 
response, switch transcripts are detectable within three days of immunisation while GCs 
appear after day 5 (Toellner et al., 1998). The slightly later induction of Ig switch transcripts 
during the primary T-dependent response is due to the requirement for T-cell priming, which 
delays the B-cell response. Marshall et al (Marshall et al., 2011) have shown directly that Ig 
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CSR occurs before formation of the GC in activated B blasts . These B blasts express Aicda in 
the absence of Bcl6 and are the precursors of switched plasmablasts produced during the 
extrafollicular T-independent response (Marshall et al., 2011). In this manner Aicda induction 
within activated B blasts may be responsible for the small amount of extrafollicular Ig gene 
hypermutation that occurs in some autoimmune responses (William et al., 2002) as well as 
during the QM TI-II response (Toellner et al., 2002). 
T-independent class switching can be induced not only by polysaccharide antigens, but also 
by viral proteins such as the latent membrane protein 1 (LMP1) of Epstein-Barr virus. LMP1 
induces class switching to Cγ, Cα, and Cε via upregulation of BAFF and APRIL on B cells (He 
et al., 2003). These TNF family members and their receptors have been shown previously to 
be crucial for T-independent responses (Bülow et al., 2001; Stein et al., 2002). DCs and 
monocytes express BAFF and APRIL and this induces Ig CSR to Cγ, and/or Cα in the presence 
of IL-10 or TGF-β (Litinskiy et al., 2002). T-independent class switching to IgA is also 
common within the intestine (Fagarasan and Honjo, 2003) and class switching to IgA can be 
induced in vitro in the absence of T cells if lamina propria stromal cells are present 
(Fagarasan et al., 2001) This process requires secretion of TGF-β (Cazac and Roes, 2000; 
Coffman et al., 1989; Sonoda et al., 1989; van Ginkel et al., 1999) which may originate from 
lamina propria stromal cells. 
 
 
 
7.3 IRF4 for B-cell differentiation 
 
 
7.3.1 Regulation of AID, GC response and Ig CSR 
 
IRF4 is a transcription factor which binds DNA with high affinity when interacting with 
members of the Ets family (PU.1 or SpiB) in B cells (Brass et al., 1999; Eisenbeis et al., 1995; 
Nagulapalli and Atchison, 1998). IRF4 has been proposed to have multiple functions in B 
cells. A role for IRF4 in Ig CSR was first proposed when it was noted that stimulation of B 
cells with CD40 and IL-4, which induces CSR rather than plasma-cell differentiation, lead to 
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upregulation of IRF4 protein (Gupta et al., 1999). Mice lacking IRF4 failed to upregulate AID 
and had defective production of class switched antibody (Sciammas et al., 2006; 2011). 
Mixed bone marrow chimeras of IRF4
WT 
and IRF4
KO 
cells demonstrated that IRF4
KO 
B cells 
failed to form BCL6
+ 
GC cells (Ochiai et al., 2013). In addition, mice which lacked IRF4 in 
the B-cell compartment (CD19-cre) had impaired GC responses but normal B-cell maturation 
(Ochiai et al., 2013).When IRF4
KO 
hen egg lysozyme (HEL)-specific mice were immunised 
with HEL-SRBC, they failed to form GC and mRNA transcripts of BCL6, Obf1, which 
encodes Bob-1, and Aicda were reduced, whilst PAX5 mRNA was unaffected (Ochiai et al., 
2013). Interestingly Bob-1 is important in B-cell signalling as its direct target is Btk, required 
for signalling via the BCR (Brunner, 2006). IRF4 bound DNA with high affinity when 
interacting with members of the Ets family (PU.1 or SpiB) or E2A, however the PU.1/SpiB 
interaction surface was dispensable for class switching and AID did not appear to be a direct 
target of IRF4 (Sciammas et al., 2006). This is in contrast to chicken cells where PU.1 and 
IRF4 in conjunction have been shown to directly regulate AID (Luo and Tian, 2010). In 
addition, whilst partial rescue of CSR occurred with retroviral AID expression, retroviral 
expression of IRF4 was more efficient at normalising CSR (Sciammas et al., 2006) indicating 
that this effect is not direct. This defect in CSR was not due to locus accessibility as germline 
switch transcripts for Cγ1 were induced normally but Iµ-Cγ1 post switch transcripts were 
reduced in IRF4
KO 
B cells (Klein et al., 2006; Sciammas et al., 2006). 
 
 
7.3.2 Regulation of terminal plasma-cell differentiation 
 
IRF4 has also been shown to be crucial for plasma-cell differentiation and was associated 
with downregulation of BCL6 and activation of BLIMP-1 (Klein et al., 2006; Saito et al., 
2007; Sciammas et al., 2006). Immunising IRF4
KO 
hen egg lysozyme (HEL) specific mice 
with HEL-SRBC lead to a failure to form PC and mRNA transcripts of Prdm1 were reduced 
(Ochiai et al., 2013). Immunisation with HEL of varying affinities for the HyHEL10 BCR 
demonstrates that higher affinity drives B cells to IRF4
high 
plasma cells (Ochiai et al., 2013). 
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Strong signalling via the BCR has been shown previously to induce higher numbers of 
extrafollicular plasmablasts (Paus et al., 2006). This was found to be due to greater 
proliferation of this B-cell population (Chan et al., 2009) 
 
 
These functions of IRF4 appear contradictory, since AID and IRF4 are components of 
mutually antagonistic gene regulatory networks. AID protein is expressed within the GC 
(Muramatsu et al., 1999), the site of B-cell somatic hypermutation and Ig class switching (Liu 
et al., 1996). With the exception of a few cells in the light zone (Falini et al., 2000), germinal 
centre B cells do not express IRF4 protein or mRNA. Conversely, AID is downregulated in 
plasma cells that express high levels of IRF4 (Marshall et al., 2011). 
 
 
This apparent discrepancy can be explained by the dual expression pattern of IRF4. We have 
shown that following immunisation of QMxC57BL/6 mice with NP-Ficoll, IRF4 mRNA 
levels peak within all blasts within one hour. Furthermore B blasts within the follicles and 
marginal zone express intermediate levels of IRF4 protein within one hour of activation. 
Within 4 hours, B blasts migrate to the border between the follicle and the T zone. This level 
of IRF4 protein is lower than the expression detected within plasmablasts and precedes the 
first expression of AID mRNA and protein. Furthermore, BCR stimulation alone is sufficient 
for this rapid upregulation of IRF4, as purified B cells stimulated in vitro upregulate IRF4 
mRNA and protein within 30 minutes of stimulation. Interestingly AID mRNA and protein 
are detectable within 48 hours of activation, before germinal centres or plasma cells have 
formed, whilst B cells are located in the inner/outer follicle. Furthermore we detected co- 
expression of IRF4 and AID protein in activated B blasts two days after activation. As these B 
blasts do not express Bcl-6 mRNA (Marshall et al., 2011) this suggests that Ig class switching 
is regulated in a different manner in B blasts compared to GC B cells. Cells expressing lower 
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levels of IRF4 protein than found in plasma cells have been reported previously in vitro 
following BCR stimulation (Sciammas et al., 2011) and this was associated with CSR. 
However Sciammas et al (2013) proposed that the intermediate phase of IRF4 induction is 
important for GC B-cell differentiation and CSR within the GC. We show that intermediate 
level IRF4 is upregulated in all B blasts regardless of whether they go on to differentiate into 
germinal centre or extrafollicular plasma cells and this occurs immediately after activation, 
long before GC are formed. 
 
Two models have been proposed for the regulation of BLIMP1 and AID by IRF4. These are 
the basic bistability model, and the kinetic control model. In the former the initial IRF4 
production rate does not affect the time spent in a CSR state. In the latter model, all cells pass 
through a transient CSR state, the duration of which is set by the initial IRF4 production rate. 
This in turn is set by the strength of the BCR signal. Stronger stimulation through the BCR 
leads to greater IRF4 protein expression and less time spent in the transient CSR state 
(Sciammas et al., 2011). Experiments manipulating the strength of signaling through the BCR 
indicate that stronger BCR signaling does induce a higher concentration of IRF4 (Sciammas 
et al., 2011). We were unable with our model to test whether the production rate of IRF4 
affected the time spent in CSR, this will be an interesting question to address in future. This 
could be tested by using mice with different BCR affinities for antigen, such as B1-8
hi 
and 
B1-8
low 
B cells (Shih et al., 2002), these have BCR with a 40-fold difference in affinity for 
NP. Activated antigen-specific cells could be sorted within the first hours of activation and 
IRF4 mRNA and protein levels tested for differences in production rate. This could be 
followed by testing of the timing of AID induction which is required for extrafollicular CSR. 
With the first model, any variation in B-cell IRF4 production betwen the two mouse strains 
should not affect the timing of AID induction or the frequency of CSR. In the latter model 
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B1-8
hi 
B cells would induce AID earlier than B1-8
low 
cells and/or demonstrate higher CSR 
frequency. 
 
 
To further test the role of intermediate-level IRF4 protein for AID induction and Ig class 
switching, we used a number of approaches. We used mice lacking signalling molecules or 
over-expressing the micro-RNA miR-125b. Within these models we measured induction of 
both early intermediate-level IRF4 and late high-level IRF4. This was correlated with 
induction of AID protein and Ig CSR. 
 
 
 
7.4 Induction of high-level IRF4 protein and plasma-cell differentiation and GC 
formation via NFκB1 
NFκB1/p50 had been shown to facilitate B-cell signalling, both via the BCR, and by ligation 
of CD40 (Francis et al., 1998). In addition, NFκB1 was involved in the induction of IRF4 
protein expression (Berberich et al., 1994; Grumont and Gerondakis, 2000; Saito et al., 2007). 
We  found  that  blocking  signalling  through  NFκB1  inhibits  plasma-cell  generation  and 
germinal centre formation in NFκB1 deficient mice. Four days after immunisation of 
NFκB1KO mice, antigen-specific B cells are located in the follicles and express intermediate- 
high levels of IRF4 protein, whereas wild-type B cells differentiate into germinal centre IRF4- 
low cells or form IRF4-high plasma-cell foci. 
 
 
The absence of low-level IRF4 expression four days after immunisation of NFκB1KO mice is 
due to a defect in germinal centre formation. Germinal centre B cells do not express IRF4, 
with the exception of some individual IRF4
high 
cells located in the light zone. The majority of 
these light zone IRF4
high 
cells express BLIMP-1. These are probably positively-selected 
plasmablast precursors which are exiting the germinal centre (De Silva et al., 2012). IRF4
high 
cells could also be identified on the border between the GC dark-zone and the T zone, and 
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these cells express plasmablast markers and probably represent migration of plasma cells out 
of the GC (Zhang, Y unpublished). 
 
 
Cell transfer experiments reveal that inhibition of germinal centre formation is partly due to a 
defect in the stroma, and partly due to a B-cell defect. FDC are essential for the formation of 
germinal centres due to their production of chemokines such as CXCL13 (Cyster et al., 2000) 
and their capture and display of opsonised antigen via complement and antibody receptors 
(Sukumar et al., 2008). Defects in these cells are most likely responsible for the lack of 
germinal centres in NFκB1 mice (Ferguson and Corley, 2005; Victoratos et al., 2006), indeed 
we found that FDC networks fail to differentiate following immunisation and that immune 
complex trapping by FDC is reduced in the absence of NFκB1. In addition, NFκB1KO B cells 
produce smaller germinal centres when transferred into wild-type hosts. Taken together with 
the failure of NFκB1KO B cells to downregulate IRF4, this may indicate that NFκB1 is 
required for the transcriptional network leading to IRF4 downregulation in the germinal 
centre. Homodimers of the NFκB1 subunit p50 act as transcriptional repressors (Zhong et al., 
2002) due to their lack of a transactivation domain. Homodimers of p50 have been shown to 
form a complex with the histone deacetylase HDAC-1 and these complexes bound DNA to 
supress expression of NFκB target genes (Zhong et al., 2002). NF-κB1 deficient mice have 
been reported to form small germinal centres ten days after SRBC immunisation (Weih et al., 
2001). Although we did not observe germinal centre formation following immunisation of 
QM NFkB1 deficient mice with NP-Ficoll, small non-specific germinal centres are present 
pre-immunisation, indicating that NFκB1KO B cells are capable of germinal centre formation. 
These may develop more slowly, or may only differentiate in response to  TD  antigen. 
CD40L signalling is crucial for generation of GC during the TD response (Castigli et al., 
1994; Chirmule et al., 2000; Kawabe et al., 1994; Xu et al., 1994) whereas in the absence of 
T-cell  derived  signals  during  the  TI-II  response,  signalling  via  FDC  may  be  of  more 
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significance. CD40 has two other ligands which are C4BP, a protein which binds to the 
activated complement component C4b (Brodeur et al., 2003) and the heat shock protein 
(Hsp70) from Mycobacterium tuberculosis (Lazarevic et al., 2003). Germinal centre 
formation during the TI-II response has been shown to require CD40 but not T-cell derived 
CD40L and blocking interactions between complement C4 and FDC lead to decreased GC 
volumes (Gaspal et al., 2006). Therefore due to decreased immune complex trapping on FDC, 
a lack of C4BP is the most likely reason that TI-II antigen induced GC do not develop in NF- 
κB1 deficient mice. Reduced C4BP in NFκB1KO spleens could be confirmed by IHC and real 
 
time RT-PCR. In addition, an agonistic anti-CD40 antibody could be administered following 
immunisation of NFκB1KO mice, in order to test whether the defect in GC formation could be 
rescued by signaling through CD40. 
 
 
The lack of IRF4
high 
cells, in contrast, is due to the absence of plasma cells. NFκB1 deficient 
B cells arrest at an intermediate/intermediate-high level of IRF4 expression, which seems 
insufficient for further differentiation towards plasma cells, except in a very few B cells. Lack 
of plasma-cell differentiation leads to reduced titres of both non-switched and switched 
antibodies. This is similar to previous studies following immunisation of NFκB1 deficient 
animals with NP15-CG (Sha et al., 1995).This defect is B-cell intrinsic. However, the ratio of 
switched to non-switched antibody and therefore the efficiency of CSR is not reduced in the 
absence of NFκB1. 
7.5 NFκB1KO B cells display impaired proliferation and survival 
NFκB1KO B cells transferred into wild-type hosts undergo higher levels of apoptosis two days 
after activation. This is supported by previous studies which show that NFκB1KO B cells had 
impaired survival (Sha et al., 1995; Snapper et al., 1996). This may occur via a number of 
pathways; signalling via NFκB1 was required for the degradation of the pro-apoptotic protein 
Bim (Banerjee et al., 2008). In addition, signalling through BAFF-R activated NFκB1 and 
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increased protein levels of the anti-apoptotic protein Bcl-XL (Hatada et al., 2003). In contrast, 
apoptosis is not increased in NFκB1KO  B cells, three days after activation. Signalling via 
NFκB1 may not be required for B-cell survival at this phase of B-cell differentiation but does 
appear to be required for IRF4 induction and plasma-cell differentiation. Conversely, 
proliferation  of  NFκB1KO   B  cells  is  decreased  only  at  three  days  after  immunisation. 
Although  there  are  fewer  cells  derived  from  the  transferred  NFκB1KO   population,  the 
 
percentage these transferred cells which become plasma cells is less. 
 
 
 
B cells require a number of factors to differentiate into antibody secreting cells. B cells from 
NFκB1 deficient mice do not migrate from the follicles. Positioning of B cells within the 
white pulp is required for plasma-cell differentiation, as demonstrated by studies with EBI2 
deficient B cells. Lack of migration to the extrafollicular region lead to a failure to form 
plasmablasts (Gatto et al., 2009) in EBI2
KO 
mice. Extrafollicular plasmablasts produced in a 
GC-independent manner are usually located around the bridging channels connecting T zones 
with the red pulp. Migration to this location may be essential for access to DC derived factors 
such IL-6 and APRIL, which promoted plasma-cell differentiation and survival (Mohr et al., 
2009). 
 
 
The absence of high-level IRF4 expression in NFκB1KO B cells led us to investigate whether 
induction of early, intermediate level IRF4 was normal when NFκB1 was absent. 
 
7.6 Intermediate level IRF4 expression is sufficient of Ig class switching in mice lacking 
NFkB1. 
We found no significant difference in this phase of IRF4 induction both at the mRNA and the 
protein level. This is supported by previous studies (Grumont and Gerondakis, 2000). In 
addition, NFκB1 deficient B cells migrate normally to the border with the T zone and express 
activation markers to a similar or greater degree than NFκB1 wild-type cells. This indicates 
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that NFκB1 is not required for the early phase of IRF4 induction and that these two phases are 
regulated differently. 
 
 
As high-level IRF4 is blocked when NFκB1 was absent, but intermediate level IRF4 was 
unaffected, we tested whether this was sufficient for AID induction and Ig class switching. 
Following differentiation in a wild-type environment, two days post-activation we found that 
NFκB1KO B cells locate within the follicles and upregulate nuclear AID protein to the same 
level as found in NFκB1WT B cells. This was confirmed with FC staining of AID protein. 
Within the few NFκB1KO cells that become plasma cells, we found that Ig class switching is 
normal. There is no reduction in the IgG3/IgM ratio by ELISA, ELispot or within 
extrafollicular plasma cells differentiating in situ on tissue sections. In addition IgG3 germline 
switch transcripts are normally induced within two days of immunisation in NFκB1KO B cells, 
as tested following cell transfer and immunisation. In summary, whilst deficiency of NFκB1 
leads to a selective defect in plasma-cell differentiation and high-level IRF4, the early 
intermediate phase of IRF4 expression is unaffected and this leads to normal expression of 
nuclear AID protein and Ig class switching. 
7.7 C-RELKO mice recapitulate the phenotype of NFκB1KO mice 
We found that C-REL
KO 
mice have impaired responses to SRBC, with reduced numbers of 
responding B cells two days after immunisation. Furthermore, five days after immunisation 
there is a complete absence of germinal centres and a dramatic reduction in plasma-cell 
numbers. We then went on to test induction of intermediate level IRF4 in response to NP- 
Ficoll and found that six hours after immunisation, IRF4 protein levels are normally 
expressed in C-REL
KO 
mice. This is in contrast to a previous study which showed that 
CREL
KO 
lymphocytes failed to upreguate IRF4 2 h post-stimulation with LPS or anti-IgM in 
vitro (Grumont and Gerondakis, 2000). It is possible that ligation of surface BCR by anti-IgM 
stimulated a different signalling pathway to that induced by NP-Ficoll and that C-REL is not 
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required following NP-Ficoll stimulation. Stimulation of B cells with anti-IgM lead to 
inhibition of terminal differentiation and Ig secretion, regardless of the specificity of the anti- 
IgM antibody (Grandien et al., 1993), whereas NP-Ficoll immunisation induces 
differentiation of plasmablasts. We have also found that stimulation of B cells in vivo with 
anti-IgD-dextran leads to initial B-cell activation and migration but an inhibition of terminal 
differentiation of plasma cells (data not shown). 
 
 
Alternatively our results may be due to the mouse knockout model used. Grumont et al 
(2000) used an earlier C-REL
KO 
model whereby the region encoding amino acids 145-588 
was replaced with a PGK neo cassette. This resulted in a truncated protein that lacks DNA 
binding, dimerization, nuclear transport and transcriptional transactivation (Köntgen et al., 
1995). In contrast our C-REL
KO 
mice lack the exon encoding amino acids 102-130 which 
encodes the Rel-homology domain (RHD) only, thereby leaving an intact transactivation 
domain (Liou et al., 1999). The RHD contains sequences required for DNA binding, 
dimerization, association with IκB family members and the nuclear localisation sequence 
(Perkins, 2007). Carrasco et al (1998) produced a mouse lacking only the transcriptional 
activation domain of C-REL. This mouse exhibited more severe defects than mice lacking the 
entire C-REL protein, possibly due to decreased compensation from other family members 
(Carrasco et al., 1998). 
 
 
Responding B blasts downregulate CD62L normally and upregulate CD86, yet CD69 
induction is reduced. CD69 is upregulated within four hours of stimulation in B cells (Arvå 
and Andersson, 1999) and has been shown to possess a negative regulatory role in T cells (la 
Fuente et al., 2012). Upregulation of CD69 has been reported following interaction with latent 
membrane protein-1 (LMP-1) of Epstein-Barr virus (EBV) and this required signalling via the 
NFκB  family(Ishikawa  and  Mori,  2013).  CD69  was  required  for  downregulation  of 
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sphingosine 1-phosphate receptor -1 (S1P1) following activation of B cells with IFN-α/β and 
this prevented lymphocyte egress from lymphoid organs thereby retaining lymphocytes at the 
site of activation (Shiow et al., 2006). Therefore C-REL
KO 
B cells may demonstrate impaired 
retention within the spleen following activation. Indeed we observed reduced numbers of 
activated B cells following immunisation. This would need to be tested by measuring the 
number of antigen-specific B cells in the blood following immunisation, as within 6 h of 
immunisation antigen-specific lymphocyte numbers in the blood and lymph decrease when 
CD69 is normally upregulated (Shiow et al., 2006). 
 
 
C-REL has an important role in a number of cell types. In DCs this signalling molecule was 
required for the efficient production of IFN-γ and IL-4, and thereby the efficient activation of 
T cells (Boffa et al., 2003). C-REL
KO 
mice were defective in their production of cytokines 
such as Il-2, IL-3 and granulocyte macrophage colony stimulating factor (Köntgen et al., 
1995; Liou et al., 1999). In addition C-REL absence can lead to lymphoid hyperplasia 
(Carrasco et al., 1998). Due to the diverse roles of C-REL in numerous cell types, we tested 
the differentiation of C-REL
KO 
B cells in a wild-type environment. Following normal 
upregulation of IRF4 protein and mRNA 2 h post-activation we find that AID protein levels 
by FC and in situ differentiating B blasts are normal. However plasma cells and germinal 
centre differentiation are inhibited. Defects in plasma-cell differentiation are B-cell intrinsic 
but not due to a failure to upregulate Prdm1 levels. Furthermore, the few plasma cells which 
successfully differentiate express normal levels of IRF4 protein. Whilst antibody titres 
produced by CREL
KO 
B cells are reduced, Ig CSR is not. . Furthermore the induction of both 
IgG3 germline switch transcripts and the induction of post-switched Iµ-Cγ3 transcripts are 
normal indicating that the heavy chain locus is accessible and CSR occurs normally to IgG3. 
 7.8 Summary NFκB family members in B-cell activation 
 
The active subunit of NFκB1 is p50. This is processed from a larger 105KDa subunit. 
Homodimers of p50 are transcriptional repressors as p50 contains a DNA binding domain but 
not a transactivation domain. Expression of p50 may therefore be required for the down- 
regulation of IRF4 in germinal centre cells. p50 can also form heterodimers with RelA, RelB 
and C-REL. As these binding partners contain a transactivation domain, they are capable of 
acting as transcriptional activators. Neither NFκB1 or C-REL are required for intermediate 
level IRF4 expression in the first hours following immunisation. However high level IRF4 
expression associated with plasma-cell differentiation is blocked when NFκB is absent 
(Figure 7.1). Expression of intermediation level IRF4 is sufficient for AID upregulation and 
Ig class switching, even in the absence of plasma-cell differentiation. To test the factors which 
regulate intermediate level IRF4 induction, IF staining for NFκB family members could be 
performed to test which members are located within the nucleus immediately after activation 
via the BCR. In addition, gene silencing via small interfering RNA (siRNA) could be utilised 
to test each NFκB member separately. To test a wide range of signaling molecules at the RNA 
level, gene arrays could be utilised on sorted activated QM B cells. 
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Figure 7 1 Signalling leading to IRF4 intermediate and IRF4 high expression 
 
 
Following BCR stimulation, IKK phosphorylates IκBα and targets it for degradation leading 
to the release of NFκB family members. These translocate to the nucleus where they induce 
IRF4 protein. High levels of which lead to BLIMP1 expression and plasma-cell 
differentiation. Signals mediating the upregulation of intermediate level IRF4 are currently 
unknown. 
 
Naive B cells expressed p50, C-REL, p52 and RelB. All of these were detected by 
electrophoretic mobility shift assay (EMSA) 2 hours after BCR stimulation, or following 
CD40L treatment. In addition, p65 was detected after activation, but not in resting B cells 
(Francis et al., 1998). This contradicts an earlier study which shows that pre-B cells and naïve 
B cells expressed p65 (Grumont and Gerondakis, 1994). This indicates that all these family 
members are part of DNA-binding complexes. There may be redundant roles for different NF- 
kappaB family members in IRF4 induction following stimulation through the BCR (Francis et 
al., 1998) and redundancy within the NF-kappaB family has been observed for NFκB1/p50 
and NFκB2/p52 (Franzoso et al., 1997). Interestingly 24h after stimulation RelB activity was 
undetectable (Figure 7.2). Other studies have shown that p50/CREL heterodimers were the 
main complexes formed in activated B cells (Grumont and Gerondakis, 1994). NFκB1/p50KO 
mice did not increase their levels of other NF-κB family members in a compensatory manner 
(Sha et al., 1995), in fact levels of Rel, RelB and p65 but not p52 were found to be lower in 
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mice lacking p50. However the frequency of different NF-κB complexes in the absence of 
p50 may still have a role in compensatory functions (Sha et al., 1995). 
 
 
 
 
 
 
Figure 7 2 NFκB family members involved in initial B-cell activation and differentiation 
 
 
Resting B cells express p50, C-REL, p52, RELB and possibly p65. In the first hours 
following activation expression of NFκB family members are similar whereas 24 hours 
following stimulation expression of RELB is lost. 
 
 
 
7.9 Overexpression of miR-125b leads to expansion of the splenic red pulp largely due to 
an increase in NK and CD11c+-cell numbers. 
miR-125b was found to be highly expressed within haematopoietic stem cells (O'Connell et 
al., 2010a; Ooi et al., 2010) and its role in these cells is controversial. Ooi et al (2010) found 
that myeloid cells were expanded when miR-125b was over-expressed. In contrast O’Connell 
et al (2010) found an expansion in the lymphoid compartment, specifically CD8
+ 
T cells. We 
found that numbers of immature B cells within the bone marrow are reduced, however this 
experiment would need to be repeated to confirm the result and numbers of splenic B cells are 
similar whether mice were infected with control cells or cells over-expressing miR-125b. In 
addition, there is no increase in T-cell numbers in spleens from miR-125b infected mice. 
However there are significantly more CD11c
+ 
and NK cells in the spleens of mice that 
overexpress miR-125b, this represents an increase in both the lymphoid and myeloid 
compartment. Contradictory reports on the effect of miR-125b overexpression within 
haematopoietic stem cells may be due to the different expression systems used in each study. 
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The study by O’Connell et al used a murine stem-cell virus to transfect haematopoetic cells 
whereas Ooi et al (2010) used a lentivirus expression vector, which resulted in overexpression 
by 35 fold. O’Connell et al (2010) also found that the myeloproliferative disorder was miR- 
125b dose dependent. 
7.10 Overexpression of miR-125b leads to expanded GC volume later during the 
response and decreased plasma-cell differentiation 
Within eight days of immunisation, GCs in mice overexpressing miR-125b are significantly 
larger. As miR-125b has been shown to be highly expressed within centroblasts in the 
germinal centre (Gururajan et al., 2010) and IRF4 and BLIMP1 are targets of this micro- 
RNA, this may be due to a failure of plasma cells to exit the germinal centre (Gururajan et al., 
2010; Malumbres et al., 2009). In addition, germinal centre cells may be less sensitive to 
apoptosis. It has been shown that miR-125b had a role in apoptosis via blockage of caspase 
activation (Puissegur et al., 2012) and inhibition of the pro-apoptotic gene Trp53inp1 
(Enomoto et al., 2011). 
 
 
Extrafollicular plasma-cell numbers are reduced four and five days after immunisation, 
however, 8 d after immunisation, plasma-cell numbers have normalised despite miR-125b 
overexpression. During the splenic antibody response, extrafollicular plasmablasts proliferate 
for about four days (Sze et al., 2000). After this plasmablasts differentiate into plasma cells 
that stop further proliferation. In responses where large numbers of plasma cells develop, 
most plasma cells will die via apoptosis within the next day, until numbers sustainable by the 
niches available in the red pulp have been reached (Sze et al., 2000). The fact that WT and 
miR-125b overexpressing B cells yield similar numbers of plasma cells 8 d post 
immunisation, although plasmablasts proliferation and differentiation are seriously affected, 
shows that plasma-cell survival and the ability to be accommodated by survival niches is not 
dependent on IRF4. 
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7.11 Blocking intermediate level IRF4 leads to a defect in AID protein and mRNA and 
Ig CSR 
A luciferase reporter assay was used to test whether IRF4 is a direct binding target of miR- 
125b. We found that IRF4 protein levels were reduced by miR-125a, miR-125b-1 and miR- 
125b-2 overexpression. MiR-125-1 and miR-125b-2 are located on different chromosomes 
and possess different pre-miRNA sequences, however following processing by DICER, the 
mature sequences are identical (O'Connell et al., 2010a). 
 
 
To confirm this effect in vivo within murine cells, we tested expression of IRF4 mRNA two 
days after immunisation in control B cells and miR-125b overexpressing B cells. miR-125b 
overexpressing B cells were found to express significantly less IRF4 mRNA and this leads to 
a decrease in translation to IRF4 protein. IRF4 protein levels were found to be further 
supressed four days after immunisation in mice overexpressing miR-125b. Repression of 
IRF4 by miR-125b has been reported previously (Gururajan et al., 2010; Malumbres et al., 
2009). 
 
 
 
Reduced intermediate level IRF4 expression in B cells overexpressing miR-125b lead to 
decreased levels of Aicda mRNA and AID protein. This resulted in reduced Ig class switched 
antibodies and reduced Ig class switching in situ within the extrafollicular foci of the splenic 
red pulp. 
 
 
In contrast, miR-125b overexpressing B cells formed AID
+ 
germinal centres within B-cell 
follicles and these expressed normal levels of AID protein. AID is also required for somatic 
hypermutation and Ig CSR within GC B cells that do not express IRF4. As miR-125b is 
highly expressed in centroblasts (Gururajan et al., 2010), this may explain why GC cells do 
204  
not express IRF4 protein. Therefore it is likely that AID is regulated differently within the 
GC. One candidate for this regulation with the GC is IRF8. IRF8 is highly expressed by 
centroblasts within the dark zone. Using small interfering RNA knockdowns of IRF8 
expression, the targets of this transcription factor were found to be Aicda and Bcl6. In mouse 
and human cells, both genes demonstrated binding to IRF8 at their 5’ sequences following 
chromatin immunoprecipitation (CHIP) assay (Lee et al., 2006).  In addition, mice lacking 
IRF8 had poorly defined GC structures that expressed reduced Aicda and Bcl6 transcripts. 
However another study (Feng et al., 2011) showed that CD19-cre IRF8
KO 
mice seem to have 
no defect in antibody production following immunisation, however they do exhibit increased 
numbers of marginal zone and follicular B cells. A higher frequency of responding cells may 
therefore compensate for reduced CSR. 
 
7.12 miR-125b overexpressing B cells locate to the marginal zone of the spleen eight days 
after immunisation 
We found that eight days after immunisation miR-125b overexpressing B cells accumulated 
in the marginal zone of the spleen in significantly higher numbers. Memory B cells locate to 
this region during the TD response (Anderson et al., 2007). We found that these cells are IgD
−
 
and IgM
+ 
which is typical for marginal zone cells. To test whether this increase in marginal 
 
zone B cells reflects stronger splenic differentiation towards memory cells we tested the 
expression of memory-cell markers in blood five and eight days after immunisation. Memory 
B cells can be detected in the blood as early as one week after immunisation (Blink et al., 
2005) and they express higher protein levels of FAS, CD80 and CD62L. We detected GFP+ 
NP-binding cells in the blood of mice which had received control infected or miR-125b 
infected B cells at five days after immunisation. These cells expressed higher levels of CD80, 
FAS and CD62L than non-antigen specific B cells in the blood. However there was no 
difference in the expression of CD80 or CD62L between control infected B cells and miR- 
125b overexpressing B cells.  However, expression of FAS was significantly higher in mice 
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over-expressing miR-125b. Signalling events leading to the production of memory cells 
remain elusive. Whilst memory cells do express IRF4 (Cattoretti et al., 2006), IRF4 does not 
appear to be required for the generation of memory cells (Klein et al., 2006). However it may 
be required for their maintenance and subsequent differentiation to plasma cells (Klein et al., 
2006). Repressing IRF4 protein in our system may drive cells which should have 
differentiated into plasma cells into alternative cell fate decisions. 
 
 
 
7.13 Micro-RNA regulation of genes 
 
micro-RNAs can regulate protein levels via different mechanisms: miRNAs not only lead to 
degradation of the messenger RNA of the target protein but binding of micro-RNA to the 
messenger sequence can also block translation. Indeed in some cases, mRNA levels can be 
increased whilst protein levels are decreased in an apparently compensatory mechanism 
(Malumbres et al., 2009). We found that overexpression of miR-125b did lead to a reduction 
in both mRNA transcripts and protein levels of IRF4.  IRF4 has been shown previously to be 
a direct target of miR-125b (Gururajan et al., 2010; Malumbres et al., 2009). This also occurs 
in macrophages where miR-125b is highly expressed and represses IRF4, this potentiates 
macrophage activation with increased macrophage responsiveness to IFN-γ and higher levels 
of CD80 expressed (Chaudhuri et al., 2011). However, it is possible that the phenotype 
observed may be due to effects on other genes, as micro-RNAs can regulate many genes 
(Vigorito et al., 2007). miR-125b has also been shown to target BLIMP-1 in addition to IRF4 
(Gururajan et al., 2010; Malumbres et al., 2009). Defects in plasma-cell generation may 
therefore be due to repression of BLIMP-1. 
 
 
Ig class switching by extrafollicular plasma blasts – the main focus of this study – is initiated 
within two days of immunisation (Marshall et al., 2011). AID induction in T zone B blasts 
two days after immunisation is long before high levels of IRF4 and Blimp1 are appearing in 
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emerging plasmablasts, or before GC B cells appear. Therefore we propose that the effects of 
mir125b on Ig CSR are due to repression of intermediate levels of IRF4 and extrafollicular 
AID and not on the following downstream differentiation events. 
 
 
 
7.14 General discussion 
 
We have provided evidence that intermediate levels of IRF4 are expressed rapidly after 
activation, and that these are required for extrafollicular AID protein expression and Ig class 
switch recombination within extrafollicular B blasts. This is a question that has been difficult 
to test experimentally. Although this does not appear to be a direct effect as an earlier CHIP- 
PCR experiments found no IRF4 binding in the Aicda gene (Sciammas et al., 2006). 
However, this study tested only small parts of the Aicda gene for IRF4 binding. Therefore, it 
is possible that IRF4 binding was missed. More recent genome wide CHIP experiments found 
evidence of at least three IRF4 binding sites in the Aicda gene (Kent et al., 2002) 
Alternatively, IRF4 may form complexes with other transcription factors (Shindo et al., 2011) 
and may regulate a gene/genes which regulates AID. 
 
 
AID is likely to be differently regulated within GC B cells, as most do not express IRF4 and a 
number of factors have been proposed to have a role here. AID facilitates DNA cleavage and 
deregulation of AID is implicated in malignancies (Feldhahn et al., 2007). Therefore AID 
expression and function is a tightly regulated process. 
 
 
 
 
 
7.15 Conclusion 
 
 
In summary, many different cross-interacting mechanisms of AID regulation exist, and 
dependent at the differentiation stage of the B-cell, different mechanisms may be active. We 
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have mainly focused on regulation of extrafollicular Ig class switching. This showed that 
intermediate level expression of IRF4, which has been implied to regulate AID expression 
and Ig class switching in the GC (Sciammas et al., 2013), correlate with and is essential for 
extrafollicular Ig class switching. However, although this was not the focus of this study, it 
seems that IRF4, although expressed in some GC centrocytes, does not regulate follicular 
CSR in the GC. 
 
 
We have correlated IRF4 expression with different phases of B blast differentiation. 
Furthermore we have shown evidence of the role of the graded expression of IRF4 in Ig class 
switching via the induction of AID protein. This data complements research from other 
groups which have used knock-out models (Klein et al., 2006; Ochiai et al., 2013) and in vitro 
methodology (Sciammas et al., 2006; 2011) to test this relationship. 
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